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Gliomas are highly malignant brain tumours characterised by extensive areas of hypoxia 
which significantly contribute to therapy-resistance and reduced survival. Therapies that 
address the hypoxic microenvironment are therefore likely to significantly improve patient 
outcomes. Hypoxic regulation of Yes-associated protein (YAP) and its paralog TAZ – 
transcriptional co-activators whose increased activity enhance tumour survival – was 
investigated and observed to increase both YAP/TAZ expression and transactivation 
activity in glioma. Furthermore, YAP/TAZ were identified to be important for glutamine 
metabolism – an interesting finding since glutamine is heavily relied upon in hypoxic 
tumour cells to sustain anabolic growth. Suppressing YAP/TAZ activity could represent a 
novel means of targeting hypoxic gliomas and thus the effect of YAP inhibitor, verteporfin 
was investigated. Treatment of primary and immortalised glioma cell lines with 
verteporfin resulted in cell death but strikingly only under hypoxic conditions (1% O2). 
This investigation discovered that cell death occurs through a YAP-independent 
mechanism, predominately involving binding of free iron and production of reactive 
oxygen species. This results in disruption of normal cellular processes and death in cells 
already under oxidative stress – such as those in hypoxia. Overall, this study suggests 
that repurposing verteporfin represents a novel means of treating highly therapy-
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1.1.1. The burden of cancer 
Cancer is a highly complex disease characterised by the malignant transformation of 
cells. Currently, over 200 different types of cancer have been identified, each with its own 
aetiology, cellular identity and therapeutic regimes which renders designing successful 
cancer treatments a significant challenge for scientists and clinicians1. Cancer is one of 
the leading causes of mortality in the UK, equating to around 28% of all deaths in 20162. 
Brain and central nervous system (CNS) tumours comprise around 3% of all newly 
diagnosed cancers in the UK, although despite this relatively low incidence, are one of 
the most deadly with a five-year survival rate of just 19%3. The most common type of 
brain and CNS tumour in adults is glioma, a class of diffuse tumours derived from glial 
cells that account for around 34% of all brain neoplasms3. Gliomas are locally invasive 
tumours, which makes effective treatment extremely difficult given that one of the most 
significant determinants of overall survival is extent of surgical resection4,5. It is therefore 
not surprising that gliomas are incurable, with patients suffering from high-grade gliomas 
(HGG; grade IV) having an extremely poor prognosis – average overall survival without 
treatment being less than one year post-diagnosis which is extended to approximately 
15-18 months upon addition of multimodal treatment6,7. Despite the wealth of glioma 
research conducted over the years, there has been little progress in providing effective 
treatment options and thus more research is desperately warranted in order to uncover 





1.2.1. Glioma classification 
Gliomas are initially histologically and immunocytochemically categorised as either being 
an astrocytoma or oligodendroglioma, which are subsequently classified according to the 
morphology of the suspected glial cell of origin8. Gliomas are then graded using a set of 
parameters outlined by the World Health Organisation (WHO)9. The tumour specimen is 
analysed for histological features such as the number of mitoses present, microvascular 
proliferation, nuclear atypia and the presence of necrosis10. Like all tumour grading 
systems, this means of stratifying patients is based on a subjective assessment of the 
tumour, which then affects the clinical management of the patient9. To improve 
diagnostic objectivity, the WHO classification of tumours of the CNS was recently revised 
to include some of the signature genetic markers which should now be combined with 
histological analysis to provide a more accurate diagnosis11. 
 
Low-grade gliomas (LGG) are classified as grade I or II and considered to be less 
aggressive due to their slower-growth rate. Grade I tumours exhibit a low proliferation 
potential and thought by many to be biologically benign8,9. Gliomas of a grade II nature, 
despite exhibiting low proliferative potential, are well-differentiated tumours with a 
diffusely infiltrative phenotype concomitant with cytological atypia10,12. Despite often 
occupying significant space within the cranium, they exhibit little to no contrast-
enhancement on magnetic resonance imaging (MRI) scans, indicating these tumours 
have an intact blood-brain barrier (BBB) and a lack of tumour necrosis13. Variations in 
survival outcome has been noted between the two types of grade II glioma, with 
oligodendrogliomas demonstrating the best prognosis, compared with diffuse 
astrocytomas, which have the worst prognosis14. Patients who present with LGG are 
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generally younger in age (median age of 41 years) and survive for an average of seven 
years post-diagnosis, however unfortunately almost all grade II tumours eventually 
progress to a higher malignancy grade9,12,15. 
 
Once tumours have progressed to grade III or IV, they are considered HGG. Grade III 
lesions typically show anaplasia, nuclear atypia, increased mitotic activity and a more 
invasive and proliferative phenotype compared to grade II tumours9. Reduced overall 
survival is also observed in patients diagnosed with grade III tumours, with survival on 
average between two and three years9. Grade III neoplasms show continuous growth 
and can rapidly progress to the most malignant grade, IV. Compared with lower grades, 
grade IV tumours are cytologically malignant with high mitotic activity, microvascular 
proliferation and a highly-accelerated growth rate9,13. In addition, grade IV tumours are 
also seen to exhibit a large degree of necrosis9. Histologically, these tumours are highly 
invasive and widely disseminate into the surrounding brain tissue meaning that despite 
gross total resections regularly being achieved, the tumour can never entirely be 
removed and thus have a fatal outcome9. Grade IV astrocytomas are known as 
glioblastoma (GBM) and account for 82% of malignant gliomas with median survival of 
less than one year post-diagnosis16. When a patient presents clinically with a GBM, it is 
seen to have one of two aetiologies; either as primary GBM which arise de novo, without 
any clinical or histological evidence of tumour progression from a preceding lower grade, 
or as secondary GBM, which show evidence of tumour progression from a less 
malignant lesion12,17,18 (Figure 1.1). Around 90% of malignant gliomas are primary GBMs 
and often occur within older patients, with the average age of diagnosis being 62 years17. 





Figure 1.1 Simplified schematic depicting the classification of gliomas and the 
common mutations associated with each category. Image based upon Oghaki and 
Kleihues17. 
 
1.2.2. Glioma heterogeneity and genetic profiling 
Over the past decade, genetic profiling of glial tumours has been used to attempt to 
better understand the underlying biology and heterogeneous behaviour of these 
tumours. Tumour heterogeneity is particularly important to consider in cancer treatment 
as tumours are not solely comprised of homotypic cells but rather a collective of diverse 
cell phenotypes that differ in their genetic landscape and/or microenvironment, ultimately 
leading to differential treatment sensitivity, invasiveness and survival outcome19. Cells 
obtained from different regions within the same tumour have been shown to exhibit 
diverse genetic profiles and even confer a different malignancy grade20. 
 
Advancements in next-generation sequencing (NGS) technologies have led to the 
identification of key mutations associated with the different histological subtypes. Many 
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genetic hallmarks have been identified within LGG and are distinguishable between 
morphological classes. Co-deletion of chromosomal arms 1p and 19q are associated 
with tumours of an oligodendroglial origin and are commonly observed in around 80% of 
grade II oligodendrogliomas14,21. Co-deletion of 1p/19q has been shown, independent of 
tumour grade, to be a significant predictor of increased survival in oligodendrogliomas, 
although the nature of the molecular driver of this phenotype is unclear14. 
 
Other mutations which have been uncovered in genomic characterisation of LGGs 
include mutations in IDH1/2 (isocitrate dehydrogenase 1/2), CIC (capicua transcriptional 
repressor), FUBP1 (far upstream element-binding protein 1) and ARTX (ATP-Dependent 
Helicase ATRX)22. HGG, predominately GBM, however have been shown to exhibit 
many additional mutations which are not apparent in LGGs. In 2010, The Cancer 
Genome Atlas (TCGA) research network outlined four genetic subtypes based on gene 
expression signature, according to the Verhaak classification system, which allowed for 
subsequent identification of different histological subtypes of GBM; proneural, classical, 
mesenchymal and neural7,23,24 (Figure 1.2). The proneural subclass of GBM tumours is 
typically characterised by alterations in PDGFRA (platelet derived growth factor receptor 
alpha) and point mutations in IDH1, although the latter is highly observed in secondary 
GBM but rarely in primary GBM suggesting that these tumours may be the product of a 
different mechanism of pathogenesis25-27. Mutations in TP53 (tumour protein p53; p53) 
are also a frequent occurrence in this class24. The classical subclass is predominantly 
defined by amplification or mutation (EGFRvIII truncation) of the epidermal growth factor 
receptor (EGFR) gene, which is apparent in approximately 40-50% of primary GBMs and 
a small fraction of secondary GBMs18,28. TP53 mutations are rare in this class however 
homozygous deletion of CDKN2A (cyclin dependent kinase inhibitor 2A) is significantly 
 
7 
associated with the classical subtype24. Homozygous mutations or deletions in the 
neurofibromin 1 (NF1) gene typically defines the mesenchymal subclass of GBM, 
alongside other mesenchymal markers which classically correspond to a higher degree 
of necrosis and inflammation, which is generally observed within this class of tumours24. 
Alterations in PTEN (phosphatase and tensin homolog), MET (met proto-oncogene), and 
RB1 (retinoblastoma 1) also occur more commonly in the mesenchymal subtype24. 
Finally, the neural subclass is generally classified by the expression of neuronal markers 
such as neurofilament light polypeptide (NEFL) and gamma-aminobutyric acid receptor 1 
(GABRA1) and is most similar to normal neuronal tissue24. 
 
 
Figure 1.2 Genetic mutations defining primary GBM subtypes. Schematic showing four 
subtypes of GBM as defined by the Verhaak classification system and the corresponding 
gene amplifications, deletions, mutations and expression that characterise these subtypes. 
Secondary GBM are believed to arise from a pre-existing lesion of a lower malignancy grade 




The development of the Verhaak classification system of GBMs has allowed for objective 
molecular classification and therefore helped to overcome the limitations of 
morphological diagnosis. However, as previously mentioned, tumours are known to 
exhibit high intratumour heterogeneity, with cells from different areas in the tumour 
portraying diverse genetic profiles30. Interestingly, a study that collected multiple biopsies 
from spatially different areas within the same tumour showed that in 6 out of 10 tumours 
analysed, biopsies were classified into at least two different Verhaak subgroups31. 
Typically, molecular analysis is based upon a single tissue biopsy of the patient’s tumour 
and is therefore likely to significantly underestimate the full genetic landscape of the 
tumour and potentially provide a misleading diagnosis20,31. Furthermore, different GBM 
subtypes have shown to respond differently to chemotherapy which may result in some 
areas of the tumour responding to treatment but other areas of the tumour being 
resistant and therefore perpetuating tumour growth24. As such, GBM treatment is yet to 
be stratified based upon Verhaak classification. 
 
Despite the vast array of genetic markers identified, the only one of significant prognostic 
interest is the IDH1 gene as heterozygous mutations have been strongly associated with 
increased patient survival from an average of 11.3 months to 27.1 months after 
combined surgery and radiotherapy, independent of the 1p/19q co-deletion25,32. A large-
scale genomic study conducted by Parsons et al., showed that IDH1 mutations were 
evolutionarily conserved at a key residue in the substrate-binding site at residue 132, 
where arginine (R) is converted to histidine (H; R132H), and was observed in around 80-
90% of low-grade and secondary GBMs that possessed mutant-IDH133. LGG that did not 
possess an IDH1 mutation were occasionally observed to possess a mutation in the 
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analogous residue, R172, of mitochondrial IDH2; although these mutations were only 
seen in around 3% of diffuse gliomas34. 
 
Physiologically, IDH1/2 isozymes are involved in a number of metabolic processes 
associated with lipid synthesis and the tricarboxylic acid (TCA) cycle, where IDH1 
catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG)35. Mutant 
IDH1 however loses the ability to catalyse this conversion but instead acquires a gain-of-
function, converting α-KG to the (R)-enantiomer of 2-hydroxyglutarate (2-HG), which has 
since been described as an ‘oncometabolite’36 (Figure 1.3). This oncometabolite may 
influence gliomagenesis since excessive 2-HG production has been shown to increase 
risk of brain tumour formation in individuals who have mutations in 2-HG metabolism21,37. 
 
 
Figure 1.3 Cellular functions of IDH enzymes. In the cytosol, IDH1 catalyses the oxidative 
decarboxylation of isocitrate to α-KG, which is used within the TCA cycle. IDH1 (R132H) and 
IDH2 (R172K) mutant enzymes however gain neomorphic enzymatic activity, producing 2-
HG from α-KG. Increased 2-HG production inhibits α-KG dependent reactions and has been 




1.2.3. Glioma treatment strategies 
Management of glioma are particularly problematic due to the tumour’s extensive 
infiltration into surrounding healthy parenchyma meaning that complete surgical 
resection is not possible without significant damage to healthy brain tissue39. Dandy and 
Gardener, pioneers of neurosurgery in the early twentieth century, noted that even 
complete hemispherectomies of glioma patients were not sufficient for patients to be 
cured40. This concept has more recently been supported by research conducted using 
patient-derived xenograft models, demonstrating that primary GBM cells are capable of 
invading significantly into the contralateral hemisphere41. 
 
Tumour resection is however still the first line of treatment for gliomas wherever possible. 
Previously, there has been a lack of consensus as to the optimum treatment strategy, 
with some surgeons adopting a ‘watch and wait’ policy for the management of LGG. 
However, it has since been strongly argued due to the high percentage of LGGs that 
rapidly progress in malignancy, that these tumours should not be managed as a ‘GBM in 
waiting’22,42. Therefore, in order to standardise glioma treatment across the UK, the 
National Institute of Health and Care Excellence (NICE) have recently published a set of 
guidelines (NICE guideline NG99) for healthcare professionals now advocating complete 
tumour resection (wherever possible) as part of initial management, with the assistance 
of the imaging agent, 5-aminolevulinic acid (5-ALA), to maximise total resection in 
HGG43. 5-ALA is an endogenous porphyrin based molecule which is metabolised within 
the cell to form haem44. As 5-ALA is metabolised, the photoactive precursor molecule 
protoporphyrin IX (PPIX) is produced and when light activated, is capable of exhibiting 
fluorescence in the red end of the visible spectrum44. Previous studies have indicated 
that tumours exhibit a selective uptake and accumulation of PPIX in the range of 50:1 for 
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malignant brain tissue compared with normal tissue45. As such, surgeons have exploited 
this biological pathway by orally administering exogenous 5-ALA to patients, which is 
then subsequently converted to PPIX and photo-activated during surgery, thereby 
allowing the surgeon to more accurately visually identify the brain-tumour interface as 
well as improving the extent of resection44. Consequently, trials have shown that 
fluorescence-guided surgery with 5-ALA significantly improved 6-month progression-free 
survival of glioma patients to 41% versus 21% when surgery was performed under white-
light alone45,46. 
 
In addition to surgical intervention, radiotherapy remains the cornerstone of treatment for 
glioma, aiming to improve local control of the tumour as well as helping to preserve brain 
function and increase overall survival through destruction of residual tumour cells 
following tumour resection47,48. Historically, clinical trials have demonstrated a significant 
benefit of post-operative radiotherapy over supportive care, extending GBM patient 
survival by 3-6 months, as well as significantly improving quality of life49-51. This small, 
but significant increase in patient survival is further improved upon the addition of 
concurrent and adjuvant chemotherapy, extending median GBM patient survival to 14.6 
months when compared to 12.1 months with radiotherapy alone and as such, become 
the standard of care for newly diagnosed GBM6,52. Over the past few decades, there 
have been significant advancements in radiotherapy treatment and imaging 
technologies, such as stereotactic fractionated radiotherapy, which allow for more 
precise delineation of treatment volumes as well as the ability to deliver conformal 
radiation doses. This thereby maximises treatment efficacy while restricting toxicity to 
adjacent normal tissue, which is particularly pertinent in the brain, and is likely to further 
contribute towards extending overall patient survival and improving quality of life47,52. 
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Conventional radiotherapy doses and schedules for treatment of glioma are typically 
determined by patient diagnosis as well as prognostic factors such as age, Karnofsky 
performance status (KPS) and the extent of surgical resection47. As such, for 
radiotherapy treatment of LGG a standard dose of 50.4 Gy in 28 fractions of 1.8 Gy over 
six weeks is accepted practice in both the UK and internationally53. The standard 
radiotherapy dosage and schedule adopted for GBM patients who are perceived to have 
a better prognosis and are under 70 years old with a KPS of >70, is 60 Gy delivered in 
30 fractions (1.8-2 Gy per fraction) over six weeks47,52. For management of GBM in 
elderly patients (>70 years old), it has recently been proposed that despite one of the 
significant negative prognostic factors for GBM being increased age, there is a significant 
benefit of treating elderly patients who have a higher KPS (>70) with radiotherapy, 
increasing median overall survival to 29.1 weeks compared to patients who received 
supportive care post-surgery, who had a median survival of 16.9 weeks52,54. 
Furthermore, it has also been suggested that for elderly GBM patients who exhibit a poor 
KPS and are considered unsuitable for chemoradiation treatment, a course of 
hypofractionated radiotherapy (30 Gy in six fractions over two weeks) may be an option 
for palliative treatment53.  
 
As previously mentioned, radiotherapy is now combined with successive rounds of 
chemotherapy, where tolerable by the patient. The current chemotherapy reagent of 
choice is the alkylating agent Temozolomide (TMZ), which is typically administered 
concomitantly during radiotherapy at 75 mg/m2 per day followed by up to six cycles of 
adjuvant TMZ which consists of 150-200 mg/m2 for 5 days during each 28 day cycle6. 
Although this can be successful in some tumours, unfortunately others can have 
resistance mechanisms against TMZ-induced cell destruction. Repair of the TMZ-
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induced DNA adducts can be achieved by expression of the DNA repair enzyme O6-
methylguanine DNA methyltransferase (MGMT)55. However, epigenetic silencing of the 
MGMT gene promoter by methylation has been documented in between 45-50% of 
GBMs, successively restoring TMZ sensitivity in tumour cells and therefore increasing 
overall survival of those patients56-58. 
 
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor 
(VEGF), is one of the four treatments alongside alkylating agent TMZ and the nitrogen 
mustards carmustine and lomustine, that are systemically administered for GBM59. 
However, while effective at controlling oedema in GBM patients, it has unfortunately 
shown no overall impact on patient survival for newly diagnosed GBM patients59-61. 
Erlotinib, a small molecule inhibitor of EGFR and EGFRvIII, has been effective in some 
cancers such as non-small cell lung cancer (NSCLC), but was again less effective in 
glioma patients, exhibiting limited clinical efficacy62,63. Some recent developments have 
changed tactics and employed different strategies such as electrical stimulation. Tumour 
treating fields (TTF) uses alternating electric fields set at specific frequencies to disrupt 
mitosis in dividing cancerous cells, leading to mitotic arrest64. Whilst clinical trials have 
shown some benefit to overall survival when combined with TMZ treatment (20.5 months 
compared to 15.6 months with TMZ alone), TTFs can cost in excessive of £18,000 per 
month and therefore based on a cost-benefit analysis, NICE do not currently advocate 
TTF for HGG treatment in the UK43,64. 
 
It is well known that tumours actively influence the host’s immune system to avoid 
detection, of which gliomas are no exception65. The CNS was once believed to be 
immune privileged due to the presence of the BBB and absence of conventional 
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lymphatic drainage65,66. However, current evidence suggests that the CNS in fact exhibits 
its own form of immune surveillance different to that of other tissues, and is as such now 
identified as an immunologically specialised area67. The success of immunotherapy in 
the treatment of a wide range of cancers has thereby provided some hope in the search 
for effective therapeutics for glioma. GBM are known to induce a highly 
immunosuppressive microenvironment through secretion of immunosuppressive 
cytokines which can suppress natural killer cell activity, inhibit T-cell activation and 
growth, downregulate major histocompatibility complex expression and induce regulatory 
T-cells65,67. As such, current research has focused on discovering ways to modulate the 
glioma tumour microenvironment to prevent immune escape or to prime immune cells to 
target tumour-specific antigens65. Currently, only two phase III clinical trials have been 
completed – the EGFRvIII targeted vaccine rindopepimut and the checkpoint inhibitor 
nivolumab – however unfortunately neither have shown any benefit in extending patient 
survival65. Further clinical trials are being conducted investigating the effect of checkpoint 
inhibitors, adoptive T-cell therapies such as CAR-T, oncolytic viruses and dendritic cell 
vaccines65-67. Although many of these trials are still ongoing, early interim reports have 
been mixed but overall largely encouraging65,68. Future treatments are however, likely to 
require combination therapies in order to address the full complexity of the tumour-
immune system interaction. 
 
Novel therapies for glioma are therefore continually being sought after due to their high-
therapy resistance and complications with drug delivery due to the BBB. The BBB is 
known to be highly disrupted or ‘leaky’ in GBM allowing some therapeutic access to the 
tumour. However, the BBB can remain intact across significant proportions of the tumour, 
resorting in large areas not receiving adequate therapy69. Studies are therefore being 
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conducted investigating methods of manipulating the BBB to allow efficient drug 
delivery60. Further investigations should also be conducted into how the tumour 
microenvironment, as well as the tumour metabolism, can be influenced as these also 
play a crucial role in the generation of therapy-resistance. 
 
1.3. Tumour hypoxia 
The significant demand for biomass production required to sustain the rapid and 
uncontrolled proliferation of cancer cells often leaves tumour cells in challenging 
environments. Proliferating cells are known to consume oxygen up to five times faster 
than quiescent cells and so the tumour avidly exhausts nutrients and oxygen from the 
surrounding vasculature, quickly resulting in cells being forced to survive under low 
oxygen conditions known as hypoxia70. As a biological consequence, pro-angiogenic 
factors are upregulated, stimulating neovascularisation of the tumour. However these 
newer vessels are often both structurally and functionally abnormal71,72, leading to 
perpetuation of tumour hypoxia throughout the mass, with resulting mild to severe 
oxygen and nutrient deprivation71. To adapt to the surrounding hostile environment, 
physiological mechanisms are quickly instigated to maintain cell survival, many of which 
are mediated through the family of hypoxia-inducible factors (HIFs)72. 
 
1.3.1. Hypoxia inducible transcription factors 
HIFs are a family of heterodimeric transcription factors comprised of a constitutively 
expressed β subunit (encoded by the aryl hydrocarbon receptor nuclear translocator, 
ARNT) and one of three oxygen-regulated subunits, HIF-1α, HIF-2α or HIF-3α. In the 
presence of oxygen, HIF-α subunits are targeted for degradation via hydroxylation of two 
prolyl residues situated in the oxygen-dependent degradation domain (ODDD) by a 
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family of dioxygenases, the prolyl hydroxylases (PHDs)73-75. PHDs require both oxygen 
and α-KG for their function; using one oxygen atom to hydroxylate the prolyl residue, with 
the other used to oxidatively decarboxylate α-KG to succinate and CO2 for subsequent 
use in the TCA cycle73. Increased prolyl hydroxylation permits binding of the α subunit to 
the von Hippau-Lindau protein (pVHL), which is part of an E3 ubiquitin ligase complex 
that polyubiquitinylates and targets the subunit for proteasomal degradation76 (Figure 
1.4). HIF activity is further controlled through the oxygen-dependent factor inhibiting HIF-
1 (FIH), which hydroxylates a specific asparaginyl residue in the C-terminal 
transactivation domain (C-TAD), consequently blocking interaction with p300; a co-
activator required for HIF to exhibit full transcriptional activity72,77,78. Intriguingly, FIH has 
a considerably lower oxygen affinity compared to the PHDs, thereby permitting a graded 
response to hypoxia and ability to fine-tune the HIF transcriptional response by allowing 
differential expression of target genes at varying levels of hypoxia71,79. 
 
Reduced availability of oxygen consequently inactivates both PHDs and FIH, stabilising 
the α subunit which consequently relocates to the nucleus to form a heterodimer with the 
HIF β subunit80. This heterodimerisation subsequently triggers association with p300 and 
initiates transcription through binding to hypoxia response elements (HREs) – which 
contain the core sequence 5’-RCGTG-3’ – in HIF-target genes73,81 (Figure 1.4). Both 
HIF-1α and -2α can recognise the same HRE sequence although they can elicit different 
transcriptional responses, most likely dependent on tissue context; HIF-1α is ubiquitously 
expressed, while HIF-2α has a more restricted expression profile limited to certain cell 
types such as vascular endothelial cells and liver parenchymal cells82. Little is known 
about the influence of HIF-3α on the biological response to hypoxia as it lacks a C-TAD, 
but it is thought it might have a negative regulatory function76. Hundreds of HIF-regulated 
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genes have been identified, with genome-wide analysis uncovering over 600 binding 
sites of HIF-1α, HIF-2α or both factors83. Some of the main HIF targets are heavily 
involved in processes such as angiogenesis, cell survival, migration and metastasis, as 
well as mediating the switch from oxidative to glycolytic metabolism71-73, which will be 
discussed in further detail in section 1.6. 
 
 
Figure 1.4 HIF-1α regulation by hydroxylation. (A) In the presence of oxygen, iron, 2-
oxoglutarate (2-OG) and ascorbate, PHDs hydroxylate HIF-1α subunits subsequently 
permitting binding of pVHL. Part of an E3 ubiquitin ligase complex, pVHL assists in the 
polyubiquitination of HIF-1α subunits, thereby targeting subunits for degradation. (B) Under 
hypoxic conditions, PHDs are inactive allowing HIF-1α to accumulate and translocate to the 
nucleus where it dimerises with HIF-1β subunits. This triggers association with p300, 
initiating transcription of HIF-1 target genes which are implicated in a wide variety of 
biological processes. Image from Carroll and Ashcroft84. 
 
1.3.2. HIF and cancer 
Tumours that exhibit high levels of hypoxia (intratumoural partial oxygen pressure 
(pO2)<10 mmHg) have been associated with an increased risk of mortality, independent 
of prognostic factors such as malignancy grade, histology, nodal status and size of the 
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tumour71. Primary tumour biopsies from numerous cancers such as breast, lung, skin, 
pancreas, stomach, bladder and colon have all shown high expression levels of HIF-1α 
or HIF-2α71,85,86. Both animal and clinical models have shown that increased HIF 
expression correlates with increased tumour vascularisation, invasion and promotes 
epithelial-mesenchymal transition (EMT), therefore increasing the risk of metastasis and 
mortality87,88. Furthermore, xenograft studies have indicated that loss of HIF expression 
can result in a reduction in overall tumour mass, in VEGF expression and also tumour 
growth rate, thus providing evidence that HIF activity is crucial for cancer progression89-
91. 
 
In addition to intratumoural hypoxia, there are other factors that can regulate HIF 
expression and activity such as loss of VHL, as reported in clear cell renal cell carcinoma 
(ccRCC), which results in constitutive HIF-α activity92,93. Additionally, HIF activity can be 
increased by oncogenes such as p53 and v-myc avian myelocytomatosis viral oncogene 
homology (MYC) which also influences cell metabolism71. Furthermore, mutations in the 
genes encoding the TCA enzymes succinate dehydrogenase (SDH) and fumarate 
hydratase (FH) can also affect HIF stability. Loss of enzymatic function blocks TCA cycle 
activity resulting in accumulation of either succinate or fumarate respectively, which can 
competitively inhibit PHD activity and result in stabilised HIF expression94. Interestingly, 
these mechanisms can all influence HIF stability independent of oxygen availability; a 
phenomenon known as pseudohypoxia, which is observed in many cancers94,95. 
 
1.3.3. Tumour hypoxia and glioma 
Gliomas are highly hypoxic tumours as a result of both a rapid growth rate outstripping 
the bloody supply and the extensive cerebral oedema exhibited through breakdown of 
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the BBB. Intratumoural oxygen measurements recorded in vivo by Rampling et al., in the 
1990’s characterised the extent of hypoxia in gliomas, with tumours exhibiting a median 
pO2 of a 7.4 mmHg (1% O2). Tumour oxygen levels were observed to be highly 
heterogeneous, with some HGG also exhibiting areas under 2.5 mmHg O2 (0.3% O2), 
which is in stark contrast to normal brain tissue which has a pO2 of around 35 mmHg 
(4.6% O2)96,97. As mentioned above, elevated HIF expression has been associated with 
increased tumour progression. A substantial factor contributing to this is that poorly 
oxygenated/hypoxic tumour cells are highly resistant to both chemotherapy and 
radiotherapy (both dependent and independent of HIF)97. Intratumoural oxygen content 
is particularly important for radiotherapy since oxygen is a potent radiosensitiser98. 
Molecular oxygen has a particularly high affinity for electrons and following absorption of 
energy from ionising radiation, participates in chemical reactions that lead to generation 
of reactive oxygen species (ROS), which cause subsequent DNA and cellular damage99. 
As such, radiosensitivity rapidly declines when tumour pO2 is <25-35 mmHg100. 
Furthermore, HIF-1 mediated upregulation of downstream pathways involved in cell 
survival, proliferation, angiogenesis and metabolism also significantly contribute towards 
chemo- and radioresistance under hypoxic conditions100. As a result of this oxygen-
enhancement effect, the dose of ionising radiation necessary to attain the equivalent cell 
survival fraction is 2-3 times higher in hypoxia than compared with normoxia97. 
Furthermore, hypoxia can also support the development and survival of both neural and 
glioma stem cells, which have been characterised to exhibit high drug resistance as well 
as a high tumorigenic potential101. This well-established association between hypoxia 
(increased HIF expression) and therapy resistance has resulted in the search for 
therapeutics that act to either reduce or exploit tumour hypoxia. An extensive number of 
treatments have been investigated including inhibitors targeting HIF expression and 
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stability, approaches to normalise tumour vasculature as well as therapeutics to induce 
radiosensitisation72,88. Despite these efforts, drugs targeting the tumour hypoxia such as 
bevacizumab have shown limited clinical efficacy in GBM, which may be due aspects of 
clinical trial design (use of single-agents rather than rational combinations), inefficiency 
at completely inhibiting HIF activity or unacceptable off-target effects72. Further 
investigations into targeting the hypoxic microenvironment as well as identifying hypoxia-
interacting signalling pathways which contribute towards promoting tumour progression 
and therapy resistance are critically warranted in the hope to identify novel glioma 
therapeutics. 
 
1.4. The Hippo pathway as a therapeutic target 
1.4.1. Origins and physiological function 
A pathway that has stimulated interest in the search for new glioma therapeutics is the 
Hippo pathway. First elucidated from genetic mosaic screens and loss-of-function studies 
in Drosophila melanogaster, this core pathway has emerged to regulate many cellular 
processes underpinning tissue homeostasis and regulation of organ size such as cell 
proliferation, survival and differentiation102,103. These studies identified a set of four core 
genes – Hippo, Warts, Salvador and Mats – which when mutated, caused organomegly 
resulting in a ‘hippopotamus-like’ phenotype characterised by increased cell proliferation 
and decreased cell apoptosis102,104,105. The core components of pathway were 
subsequently shown to be highly conserved in mammals; MST1/2 (mammalian Ste2-like 
kinases), LATS 1/2 (large tumour suppressor kinase 1/2), SAV1 (salvador homolog 1) 
and MOB1A/1B (MOB kinase activator 1A/1B) are orthologs of Hippo, Warts, Salvador 
and Mats respectively106. Downstream targets of this cascade – the transcriptional co-
activator Yes-associated protein (YAP; ortholog of Yorkie) and its close paralog TAZ 
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(transcriptional co-activator with PDZ-binding motif; also known as WWTR1) – were also 
identified and found to be the dynamic effectors of this pathway as they orchestrate 
binding to various different transcription factors to initiate transcription of various 
downstream target genes involved in cell growth and survival103,107,108. 
 
1.4.2. Mechanism of YAP and TAZ 
YAP is a highly evolutionarily conserved 65 kDa protein expressed in all mammalian 
cells, with the exception of leukocytes109. The human YAP1 gene is located on 
chromosome 11 at position q22.1 and can be alternatively spliced into 11 different splice 
variants, nine of which are protein coding110. YAP1 splice variants are subsequently 
divided into 2 main categories, YAP1-1 or YAP1-2 (also referred to as YAP2), depending 
on whether the variant contains one or two WW domains respectively104. 
Characterisation of YAP isoforms has also determined the presence of an N-terminal 
TEA domain (TEAD)-interacting motif which is followed by either one or two WW 
domains, whose function is to mediate protein complexes containing a PPxY motif104,111. 
Within the C-terminal domain of YAP resides a PDZ-binding domain that has been 
proposed to orchestrate YAP cellular localisation112. YAP paralog TAZ, has been found 
to have 46% amino acid sequence homology, although TAZ has only been discovered in 
vertebrates and much less is known about this protein104. 
 
The core mechanism of the mammalian Hippo cascade is instigated through activation of 
the serine/threonine kinases MST1/2 by homodimerisation, triggered by various 
upstream regulators113. Once activated, MST1/2 function to phosphorylate the 
downstream kinase LATS1/2. Scaffold protein SAV1 acts to facilitate this interaction by 
forming a complex with MST1/2, bringing MST1/2 and LATS1/2 into close spatial 
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proximity in the cell114. Activation of LATS1/2, whose kinase activity is enhanced by 
forming a complex with the adaptor protein MOB1A/1B, subsequently continues the 
cascade and phosphorylates the downstream targets YAP and TAZ, which become 
inactivated upon phosphorylation at serine 127 and serine 89 respectively106,114,115. This 
inactivation of YAP/TAZ inhibits their function as transcriptional co-activators thus 
preventing transcription of various downstream targets involved in cell proliferation and 
survival. These inactive proteins are sequestered by 14-3-3 binding proteins and retained 
in the cytoplasm where they are subsequently degraded by ubiquitin proteasomes, 
therefore preventing cell proliferation and tissue growth102. Conversely, upon inactivation 
of the Hippo pathway, the kinase cascade is inhibited which results in YAP protein 
remaining un-phosphorylated and able to freely translocate to the nucleus, thereby co-
activating transcription of its target genes114. 
 
In mammalian cells, YAP protein acts as a transcriptional co-activator but despite 
possessing strong transcriptional activity within the C-terminus, YAP does not possess 
DNA binding ability. Transactivation of downstream genes therefore requires a 
transcriptional binding partner, of which the most well-described are the TEAD family of 
transcription factors (TEADs 1-4)114,116. These transcription factors individually are not 
able to activate transcription of target genes, but when YAP is nuclear localised, a 
heterodimer is formed with a TEAD family protein117,118. Once forming this complex, 
YAP-TEAD can then activate expression of direct downstream genes such as connective 
tissue growth factor (CTGF), cysteine-rich angiogenic inducer 61 (CYR61) and 
amphiregulin (AREG), which have been implicated in cellular migration, proliferation and 




Interestingly, additional transcription factors have been identified to interact with the WW 
domains of YAP/TAZ proteins such as Smad1 (mothers against decapentaplegic 
homolog 1), RUNX1/2 (runt-related transcription factor 1/2), and p73 (tumour protein 73), 
which exhibit pro-apoptotic effects in cells – an outcome seemingly at odds with the well-
defined role of YAP supporting proliferation and survival of cells107,114. As a result, there 
has been much debate over the true role of YAP within the Hippo pathway, and whether 
it is a bona fide tumour suppressor or potential oncogene. It is currently believed that 
YAP has a dual function exhibiting pro- or anti-apoptotic downstream effects depending 
on the cell and tissue context, supporting its physiological function in the precise 
regulation of organ size119,120.  
 
Since signalling pathways are arranged more as networks than linear cascades, it 
implies that these pathways are dynamic and can alter depending on cellular context and 
differential regulation of the upstream components121 (Figure 1.5). This is likely the case 
for YAP, as it has been shown that activation of the pathway through different upstream 
regulators leads to diverse downstream effects. It has been shown that activation of the 
Hippo pathway through the Ras association domain-containing protein 1A (RASSF1A), 
promotes association of YAP1 with pro-apoptotic protein p73 and limited association with 
TEAD transcription factors, therefore exerting an overall tumour suppressor effect122. 
This was further investigated by knocking down RUNX2 expression, which functions as a 
tumour suppressor gene. The reduction in RUNX2 expression consequently caused an 
enhanced association of YAP1 and TEAD transcription factors demonstrating that 
competition may exist between these factors depending on availability and/or upstream 
regulation122. It is therefore important to further investigate and fully understand the 
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differential upstream regulation of the Hippo pathway and how this contributes to YAP 
function in a variety of cell contexts. 
 
 
Figure 1.5 Overview of Hippo pathway regulation and regulation of transcription by 
YAP/TAZ transcriptional co-activators. Upstream activation of the Hippo pathway results 
in phosphorylation of downstream mediators YAP/TAZ. This phosphorylation inhibits their 
function as transcriptional co-activators thus preventing transcription of various downstream 
targets. Upon inactivation of the Hippo pathway or direct activation of YAP/TAZ, the co-
activators remain un-phosphorylated and are consequently able to freely translocate to the 
nucleus, thereby co-activating transcription of its target genes involved in cell proliferation, 




1.4.3. Regulation of YAP/TAZ activity 
Regulation of YAP/TAZ activity can be either achieved through exerting direct effects on 
YAP/TAZ proteins or through indirect mechanisms that mediate the activity of the 
upstream Hippo pathway (Figure 1.5). Consistent with the distinct role of Hippo and YAP 
in regulating organ size, the majority of established regulators discovered were 
mechanical and physical cues involved in controlling tissue architecture. Cell-cell contact 
in particular has been prominently implicated in the direct and indirect regulation of 
YAP/TAZ, with high cell density inactivating YAP/TAZ activity124. The cadherin α-catenin, 
an important sensor of cell density which functions to integrate signals from neighbouring 
cells through the construction of adherens junctions, has been shown to interact directly 
with YAP by forming a complex with 14-3-3 proteins, thereby inhibiting YAP activation 
through sequestration at the plasma membrane125. This consequently prevents YAP 
dephosphorylation, thus blocking its nuclear translocation and subsequent activation of 
downstream transcription targets126. Other structural components that have been 
identified to influence YAP/TAZ activity include filamentous (F-) actin, which is important 
for a variety of cell functions such as cell mobility, division, establishment of cell junctions 
as well as integrating various mechanical and hormonal cues from neighbouring cells 
and the extracellular matrix (ECM)102,127. Actin destabilising proteins such as F-actin 
capping and severing protein cofilin, have been observed to directly assist in the 
cytoplasmic retention and therefore inactivation of YAP/TAZ, whereas stabilisation of F-
actin instigates downstream activation of YAP/TAZ proteins112,128. Actin cytoskeleton 
dynamics are known to be influenced by a family of GTPases, the Rho GTPases, which 
transduce upstream cues from G-coupled protein receptors (GPCRs), and are 
consequently another important upstream regulator of the Hippo pathway112. As GPCRs 
are the largest family of cell surface molecules involved in signal transduction, it 
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highlights the huge amount of potential cross-talk between various hormonal signalling 
pathways, in addition to mechanical regulatory pathways, and YAP/TAZ to directly or 
indirectly influence their activity129. 
 
Since the Hippo pathway is not regulated by a specific and unique receptor/ligand 
interaction, it heavily relies on integration with other signalling networks to both regulate 
its own activity as well as influencing the downstream function of the interacting 
pathway130. Consequently, significant reciprocal cross-talk between Hippo/YAP/TAZ 
signalling and Wingless (Wnt), Notch, Hedgehog (Hh) and bone morphogenic protein 
(BMP) signalling pathways have already been identified124,130. Furthermore, 
microenvironmental cues have been recognised to be extremely important in regulating 
the output of YAP/TAZ signalling network, with stress responses such as AMP-activated 
protein kinase (AMPK) activation, DNA damage and hypoxia also being identified to 
influence Hippo/YAP/TAZ signalling activity130.  
 
The relationship between hypoxia and regulation of YAP/TAZ activity has been recently 
exposed in a handful of investigations, partially uncovering some of the complex 
interactions that mediate the pro-survival response to such hostile conditions. Previous 
research has demonstrated in MDA-MB-231 breast cancer cells, that hypoxia can 
negatively regulate the Hippo pathway through the ubiquitin E3 ligase, SIAH2 (seven in 
absentia homolog 2)131. SIAH2 is recognised as an essential component of the hypoxia 
response pathway as it targets PHDs for degradation via the ubiquitin-proteasome 
pathway thereby resulting in increased HIF-1α stabilisation and activity in hypoxia132. 
Additionally, SIAH2 was previously identified to directly interact with LATS2, instigating 
its proteasomal degradation and thus reducing LATS2-mediated YAP S127 
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phosphorylation131. As a result, enhanced YAP nuclear localisation was observed 
alongside increased protein and messenger RNA (mRNA) expression of the direct YAP 
target genes, CYR61 and CTGF131. Furthermore, direct interaction between YAP and 
HIF-1α was confirmed and shown to be significantly enhanced under hypoxic conditions, 
again implicating that the potential purpose of integrating these signalling networks is to 
ensure continuous cell growth and survival under hypoxic conditions131. 
 
This hypothesis was further corroborated by research showing that hypoxic induction of 
HIF-1α, but not 2α, was able to mediate both increased TAZ expression as well as 
nuclear localisation, inducing the breast cancer stem cell phenotype133. It was found that 
HIF-1α and TAZ acted as reciprocal co-activators, with the bi-directional crosstalk 
synergistically driving the expression of downstream target genes under hypoxic 
conditions134. This pro-survival hypoxic-YAP/TAZ regulation was also shown to 
perpetuate treatment resistance as hypoxia-induced YAP activity in hepatocellular 
carcinoma (HCC) cells was suggested to contribute towards chemoresistance against 
Topoisomerase I inhibitor SN38135. Interestingly, this study also demonstrated hypoxia-
induced YAP activity in HCC cells to be HIF-1α independent as depletion of HIF-1α was 
insufficient to impair nuclear translocation of YAP135. This again highlights the complex 
nature of YAP under different cellular and tissue contexts and indicates that additional 
hypoxia-responsive regulatory mechanisms other than HIF-1α activity can also play a 
role in influencing YAP/TAZ activity. Hypoxic regulation of YAP/TAZ therefore warrants 
further investigation, and could be of particular interest within gliomas since they exhibit 




1.4.4. Dysregulation of YAP/TAZ activity 
1.4.4.1. Association with cancer 
Strict control of the Hippo pathway is imperative to healthy tissue development and it is 
therefore of no surprise that dysregulation of YAP/TAZ signalling has been strongly 
linked with tumorigenesis136. Despite this, naturally occurring mutations in Hippo pathway 
core components are extremely rare with only 0.2% of cancer tissue sections exhibiting 
homozygous deletion of YAP1137. Additionally, it has been presented that knockout of 
YAP results in embryonic lethality in mice137. Amplification and epigenetic silencing of 
Hippo pathway components however are more common and frequently observed within 
human cancers115,116. YAP/TAZ amplification and increased transcriptional activity has 
been observed in numerous cancers (reviewed in Zanconato et al.,138) and is detected in 
as high as 85% of colorectal tumours, 60-70% of astrocytomas and around 20% of 
breast neoplasms104,116,139. A wealth of studies have since demonstrated that increased 
YAP/TAZ expression and sustained activation can significantly promote aberrant tumour 
growth, induce EMT as well as enhance tumour migration, invasiveness and 
metastasis104,138. Supporting this, experiments using mouse xenograft models have 
shown that in vivo knockdown of YAP1 can significantly suppress tumour growth of 
cancers in organs including the oesophagus, lung and bone140-142. Nevertheless, in some 
breast cancer models, tumour growth of mouse mammary glands cannot be solely 
induced by YAP overexpression, suggesting that under some circumstances additional 
lesions are required to assist in the oncogenic transformation of these cells114. The status 
of YAP as a true oncogenic driver remains under debate since research has also shown 
YAP to act as a tumour suppressor in several haematological cancers such as multiple 
myeloma (MM), lymphoma and leukaemia136. It has been suggested that in these 
cancers YAP could induce expression of pro-apoptotic genes through interaction with the 
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transcription factor p73, thereby suppressing cancer formation143. These observations 
provide further evidence that YAP/TAZ signalling is incredibly complex and the functional 
output is heavily dependent upon the cell and tissue context. 
 
Enhanced YAP/TAZ activation has also been identified as a prognostic indicator for 
patient survival in cancers in which YAP drives oncogenesis114. A recent meta-analysis 
has shown both YAP amplification and increased nuclear localisation to be statistically 
associated with both decreased overall survival (OS) and disease-free survival (DFS)144. 
Furthermore, additional studies have also highlighted the strong association between 
increased YAP/TAZ expression and both higher tumour malignancy grade and 
progression in several cancers114,145,146. Interestingly, a novel subclass of ovarian 
cancers have been identified that exhibit an independent prognostic gene signature 
reflecting YAP1 activation147. This expression signature corresponded with a poorer 
prognosis and was able to predict response to taxane-based treatment, stratifying 
patients who were likely to benefit from this therapy147. This provides new means of 
identifying tumours with high YAP activity through a defined gene signature and may 
prove to represent a novel method of stratifying patients for treatment. 
 
In addition to influencing tumour growth and survival, increased YAP/TAZ activity has 
been demonstrated to confer chemoresistant properties on cancer cells104. In normal 
physiology, YAP/TAZ signalling has been associated with the maintenance and function 
of stem and progenitor cells, inducing the expression of genes such as OCT4 (octamer-
binding transcription factor 4), Nanog (Nanog homeobox), and Sox2/9 (sex determining 
region Y box 2)102. Unsurprisingly, associations between aberrant YAP/TAZ signalling 
and regulation of cancer stem cells (CSCs) during tumorigenesis have been observed, 
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including that of high YAP and TEAD expression in CSCs of medulloblastomas102. CSCs 
are known to exhibit high chemoresistance and tumorigenic potential and are thought to 
be largely responsible for cancer initiation as well as recurrence and metastasis102. 
Interestingly, research has identified YAP1 to be a major determinant of bestowing CSC 
properties in both non-tumorigenic and oesophageal cancer cells through direct 
upregulation of Sox9148. Through genetic and pharmacological inhibition of YAP1, it was 
also shown that reduced YAP1 expression and activity significantly attenuated CSC 
tumorigenicity in vivo and tumoursphere formation in vitro148. Suppression of YAP/TAZ 
signalling may therefore be of inherent interest in the search for novel cancer therapies, 
as well as invaluable in overcoming therapy resistance to existing treatments. 
 
1.4.4.2. YAP/TAZ in glioma 
Despite the strong association between aberrant Hippo signalling and tumorigenesis, 
only a small number of studies have thus far focused their attention on elucidating the 
role of YAP/TAZ signalling in gliomas. YAP1 nuclear expression has been 
immunohistochemically characterised in both normal brain tissue and tissue from 198 
glial tumours of varying WHO grades149. Non-neoplastic tissue was seen to exhibit YAP1 
immunoreactivity exclusively in areas of the brain which were enriched with proliferating 
neural stem and progenitor cells, consistent with the established role of YAP/TAZ 
signalling in development149. Strikingly, nuclear YAP1 expression was also readily 
detected in 80-100% of grade II-IV glial tumours, although was considerably lower in 
grade I pilocytic astrocytomas (30%)149. These observations were corroborated in an 
additional glioma cohort, which showed significant amplification of both YAP/TAZ mRNA 
and protein expression to be associated with increasing malignancy grade150. Analysis of 
data from 564 gliomas from TCGA dataset also showed that amplified YAP/TAZ 
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expression positively correlated with a worse OS in glioma patients150. Expression levels 
of direct YAP target genes, CYR61 and CTGF which are known to stimulate cell 
proliferation and migration as well as ECM formation, were also observed to be 
prognostic for both glioma progression and overall patient survival151. CYR61 and CTGF 
expression were analysed in tissue from 66 primary gliomas and observed to be 
significantly overexpressed in 48% and 58% of samples respectively when normalised to 
samples taken from normal brain tissue151. Furthermore, a significant association 
between increased tumour grade and worse OS with high CYR61 and CTGF expression 
was identified, again highlighting increased YAP/TAZ signalling to be associated with the 
advanced, more malignant stage of disease151. 
 
To date, only a few studies have investigated the molecular effect of YAP on glioma 
biology. Following the identification that nuclear YAP expression was significantly 
amplified in glial tumours, research demonstrated that by reducing YAP1 expression in 
GBM lines U87, U373 and neurosphere line HSR-GBM1, cell growth could be 
significantly attenuated149. In addition, it was recently demonstrated in established GBM 
lines (U251 and U87) and primary glioma cells, that YAP1 downregulation significantly 
impeded both cell migration and invasion whereas YAP overexpression significantly 
promoted these malignant phenotypes152. Together, these studies highlight the 
importance of aberrant YAP/TAZ signalling in glioma and how understanding this 




1.5. Therapeutic targeting of YAP/TAZ signalling 
1.5.1. Discovery of verteporfin as a YAP inhibitor 
The idea of suppressing aberrant YAP/TAZ signalling to reduce malignant growth and 
cancer progression sparked the search for therapeutics which could directly or indirectly 
manipulate YAP/TAZ activity. Since the direct interaction between YAP and TEAD leads 
to transcription of pro-proliferative target genes, disrupting the YAP-TEAD complex could 
therefore provide an ideal drug target to selectively suppress YAP-induced 
tumorigenesis. Consequently, a previous study conducted a pharmacological drug 
screen of over 3300 small molecules contained in the John Hopkins Drug Library, with 
the hope of identifying YAP-TEAD interactors153. Three compounds that stood out 
amongst the top hits were interestingly all members of the porphyrin family; 
hematoporphyrin (HP), PPIX and verteporfin (VP)153. Further experimentation showed 
VP to be the most potent inhibitor of the YAP-TEAD interaction, with PPIX exhibiting 
much weaker activity and HP causing minimal effects at a concentration of 10 µM153. VP 
was shown to selectively bind YAP and alter its structural confirmation which as a result, 
abolished its ability to interact with TEADs153. However, it was unclear whether VP was 
able to inhibit the oncogenic ability of YAP in vivo. Using transgenic mouse models, it 
was observed that VP was able to suppress liver overgrowth induced by either YAP 
overexpression or increased activation, independently of light activation of the compound 
(see below). These data provided evidence to suggest that pharmacologically inhibiting 





1.5.2. Clinical use of VP 
VP is a benzoporphyrin derivative currently used in the clinic to treat age-related macular 
degeneration (AMD); a severe degenerative eye disease which is the leading cause of 
blindness in adults aged 65-74 years in Western countries154,155 (Figure 1.6). Clinically-
approved by the USA Food and Drug Administration (FDA), VP (trade name Visudyne) is 
commonly used as a photosensitiser in the application of photodynamic therapy 
(PDT)155. During PDT, VP is intravenously injected and activated using low-intensity light 
of between 685-690nm targeted at the area of interest to induce localised production of 
cytotoxic free radicals155. These radicals can subsequently inflict damage to the 
surrounding area and in the case of AMD, lead to thrombus formation and vascular 
occlusion which can improve or maintain visual acuity155. A major challenge when 
designing effect treatments is being able to precisely and specifically target the area of 
interest without damaging normal cell function and viability. Fortunately, VP is known to 
be selectively taken up by neovascular endothelial or malignant tumour cells via low-
density lipoprotein receptors (LDLs) and is thus designed as a liposomal formulation155. 
Due to the strong preferential uptake in tumour cells, a few phase I/II clinical trials have 
examined VP efficacy in the use of PDT treatment in cancer such as in locally advanced 
pancreatic cancer156. Multiple applications of VP at a clinical dose of 6-12 mg/m2 has 
been shown to be well-tolerated within patients causing minimal local and systemic side-






Figure 1.6 Chemical structure and absorption spectra of VP. VP is a benzoporphyrin 
derivative and characteristically strongly absorbs light. In addition to an absorption maximum 
in the UVA range (~430 nm; Purple/blue), VP offers an absorption peak between 685–690 
nm (orange/red) which is used in the application of PDT. Image adapted from Ratkay et al157. 
 
Following the discovery that VP can also attenuate aberrant YAP-mediated signalling 
independent of light-activation, studies have recently focused their attention on the 
possibility of repurposing VP as a cancer therapeutic without the need for PDT. 
 
1.5.3. Effect of VP as a YAP inhibitor on cancer growth 
Several studies have previously demonstrated VP to significantly attenuate both tumour 
growth and proliferation in cancers such as retinoblastoma, pancreatic and ovarian 
through suppression of YAP-TEAD signalling158-160. More recently, VP has also shown to 
inhibit growth of LN229 and SNB19 glioma cell lines, again highlighting the importance of 
investigating YAP signalling in glioma161. Within these studies, VP was observed to 
directly reduce YAP expression as well as its direct targets CYR61, CTGF, survivin, axl 
and OCT4. Interestingly, VP has been shown to induce apoptosis and autophagy as a 
result of YAP-TEAD disruption however the mechanisms underlying how VP reduces 
tumour growth and progression remain elusive since some studies demonstrate VP to 
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reduce tumour mass through strict inhibition of cell proliferation and not through induction 
of cell death mechanisms158-160. 
 
A functional genomics screen previously identified YAP1 as a key determinant to 
overcome treatment resistance in lung cancer cells and it was consequently shown that 
treatment with VP was able to significantly sensitise PC9 cells to cisplatin, radiation and 
erlotinib treatment162. Research has also shown the ability of VP to both reverse YAP-
induced paclitaxel resistance in colon cancer cells and overcome BRAF inhibitor 
resistance in melanoma respectively163,164. These studies provide further evidence that 
targeting aberrant YAP/TAZ signalling could be a valuable opportunity in the 
development of effective cancer therapeutics as well as in sensitising cancer cells to pre-
existing treatments. 
 
Despite pre-clinical studies highlighting the huge potential of YAP suppression by VP to 
attenuate tumour growth, research has also uncovered that under some circumstances 
VP can exhibit tumour suppressor activity independently of YAP. Two recent 
investigations have both demonstrated that despite significant YAP1 depletion, VP 
retains its ability to induce a significant reduction in both tumour cell proliferation and 
viability165,166. The tumour suppressive characteristics of VP are therefore complex and 
further investigation is warranted into the potential for repurposing VP as a new cancer 




1.6. Metabolic-rewiring in cancer  
1.6.1. Introduction to cancer metabolism 
Sustaining the high rates of cell proliferation in tumours requires cells to regularly 
duplicate their entire cellular contents including nucleotides, proteins, lipids and other 
macromolecules. This therefore places a significant energy demand on the cell, requiring 
increased uptake and use of key nutrients, production of adenosine triphosphate (ATP), 
as well as challenges in continuing to maintain cellular redox homeostasis. In the recent 
update to their seminal work in 2000 positing six hallmarks of cancer, Hanahan and 
Weinberg extended it to include two further emerging hallmarks: avoidance of immune 
destruction and deregulation of cellular bioenergetics167. This reprogramming can arise 
as a direct consequence of activation of various oncogenes (e.g., MYC, RAS) or 
mutations in tumour suppressors (e.g., TP53)71,168. Additionally, tumour metabolism can 
also be influenced by the surrounding microenvironment such as hypoxia, which as 
previously described, often leads to a more malignant phenotype168. 
 
Alterations in tumour metabolism were first identified almost a century ago in the 1920’s, 
by Otto Warburg169. He discovered that unlike differentiated cells, which preferentially 
utilise mitochondrial oxidative phosphorylation for energy production, rapidly proliferating 
cancer cells significantly increase their rate of glycolysis to favour production of lactate 
from pyruvate169,170. This phenomenon termed ‘the Warburg effect’ (also referred to as 
aerobic glycolysis), at first seems counterintuitive since metabolising glucose to pyruvate 
and then lactate is far less efficient at producing ATP (per unit of glucose metabolised; 
~2 moles ATP/mole glucose) as opposed to complete glucose catabolism through 
oxidative phosphorylation (~36-38 moles ATP/mole glucose)171. However, tumour cells 
have been observed to significantly increase their glucose uptake, predominately 
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through upregulation of cellular glucose transporters (GLUTs), to increase and sustain 
glycolytic rates which have been documented in some instances, to exceed ATP 
production from oxidative phosphorylation172-175. Although a specific functional rationale 
for this increased glycolysis and subsequent decrease in glucose oxidation remains 
elusive, a plausible justification could be for the cell to accumulate glycolytic 
intermediates such as 3-phosphoglycerate (3-PG), which can be diverted into various 
biosynthetic pathways to generate nucleotides and amino acids which are crucially 
required to facilitate sustained proliferation176 (Figure 1.7). 
 
 
Figure 1.7 Cancer cells alter their metabolism to support anabolic growth.. Schematic 
highlighting some of the key metabolic pathways in central carbon metabolism which are 
heavily relied upon or altered in cancer to sustain uncontrolled proliferation and maintain 
cellular redox. Image adapted from DeBerardinis and Chandel177. 
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1.6.2. Glucose metabolism in cancer 
It has long been known that cancer cells rapidly consume glucose, demonstrating 
elevated rates of glycolysis. This phenotype is harnessed in the clinic through the use of 
18F-deoxyglucose-positron emission tomography (FDG-PET), the signal from which can 
be used to identify small, otherwise undetectable metastases and has been shown to 
significantly negatively correlate with patient survival in many cancers172. The plasma 
membrane is impermeable to glucose and thus glucose is mainly imported into the cell 
through the use of a family of plasma membrane transporters (GLUTs; SLC2A). Once 
imported, glucose is phosphorylated by hexokinase to produce glucose 6-phosphate 
(G6P). G6P can then be oxidatively used in glycolysis to produce ATP, culminating in 
generation of the end-product of glycolysis, pyruvate. Additionally, G6P can be diverted 
away from glycolysis into the oxidative arm of the pentose phosphate pathway (PPP) to 
generate reduced nicotinamide adenine dinucleotide phosphate (NADPH) and activated 
pentose units such as ribose 5-phosphate (R5P), for nucleotide synthesis178. Similarly, 
downstream glycolytic intermediate 3-PG can be shunted into the serine synthesis 
pathway (SSP) for de novo production of non-essential amino acids (NEAAs) serine and 
glycine which are utilised in biosynthetic production of nucleic acids, proteins and 
lipids178. 
 
Pyruvate has many metabolic fates within the cell, although in aerobic glycolysis a 
significant proportion is converted to lactate through lactate dehydrogenase (LDH). LDH 
is a ubiquitously expressed enzyme which reversibly catalyses the reduction of pyruvate 
to lactate coupled with the oxidation of reduced nicotinamide dinucleotide (NADH) to 
oxidised nicotinamide dinucleotide (NAD+)179. This reaction is particularly important as 
the NAD+ produced is critical for the continued activity of the glycolytic enzyme 
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glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to facilitate ATP production and 
maintain glycolytic flux179. In addition to lactate production, pyruvate can also be 
transaminated by the enzyme alanine transaminase (ALT) to produce alanine for use in 
protein synthesis179. 
 
Once imported into the mitochondria through the mitochondrial pyruvate carrier (MPC), 
pyruvate can enter the TCA cycle to support ATP production through subsequent 
oxidative phosphorylation179. Pyruvate is first oxidatively carboxylated via pyruvate 
dehydrogenase (PDH) to form acetyl Coenzyme A (CoA), which subsequently 
condenses with oxaloacetate (OAA) to form citrate. Citrate is either isomerised to 
isocitrate and oxidatively decarboxylated via IDH enzymes to form α-KG for continued 
use in TCA cycle or exported to the cytoplasm where it is converted back to acetyl CoA 
via ATP citrate lyase (ACLY) for de novo lipid synthesis. Additionally, pyruvate 
carboxylase (PC), an enzyme traditionally associated with gluconeogenesis, can support 
alternative pyruvate entry into the TCA cycle through carboxylation of pyruvate to OAA. 
PC has been shown to be important for cancer cell proliferation in glutamine-deprived 
and hypoxic conditions, where PDH activity is reduced, through carboxylation of pyruvate 
to OAA supplying carbon for TCA intermediates as well as citrate for lipid synthesis71,180. 
OAA can also be transaminated to form aspartate, which has consequently been shown 
to be essential for tumour growth181,182. 
 
1.6.3. Glutamine metabolism in cancer 
Since increased conversion of pyruvate to lactate in aerobic glycolysis is concomitant 
with decreased availability of pyruvate for oxidation in the mitochondria, cancer cells are 
known to become increasing reliant on glutamine both as a carbon and nitrogen source 
 
40 
for generation of TCA cycle intermediates and subsequent ATP production. In fact, some 
cancer cells cannot survive in the absence of exogenous glutamine and are described to 
be ‘glutamine addicted’183. 
 
As with glucose, glutamine must first be imported into the cell through membrane 
transporters such as neutral amino acid transporter alanine-serine-cysteine-threonine 
transporter 2 (ASCT2/SLC1A5)184. Following its import, glutamine can either be directed 
towards use in nucleotide and protein synthesis or converted to glutamate through 
glutaminase enzymes (GLS). Glutamate has many uses within the cell including as an 
amino donor for nucleotide and NEAA synthesis, such as proline biosynthesis, as well as 
a crucial contributor towards glutathione (GSH) synthesis- a tripeptide produced from 
amino acids cysteine, glycine and glutamate, which acts as an essential endogenous 
antioxidant to reduce cellular damage incurred through cellular reactive oxygen species 
(ROS)185,186. Glutamate can also supply carbons into the TCA cycle for the production of 
anabolic substrates and reducing potential to generate ATP through its conversion to α-
KG via glutamate dehydrogenase (GLDH) or transaminase activity. 
 
1.6.4. Role of YAP/TAZ signalling in cancer metabolism 
Aberrant YAP/TAZ signalling, as previously described, can induce tumour proliferation 
and survival and so it is possible that YAP/TAZ could directly regulate the metabolic 
pathways required to support this uncontrolled proliferation. Little is currently known 
about this emerging relationship, although it was recently shown that aerobic glycolysis 
could fine tune YAP/TAZ transcriptional activity in breast cancer187. When glucose 
metabolism was inhibited or diverted away from glycolysis in MDA-MB-231 and MCF10A 
cells, YAP/TAZ transcriptional activity was impaired, consequently attenuating cell 
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proliferation and clonogenic abilities187. Mechanistically, the authors showed that 
phosphofructokinase 1 (PFK1), an important regulatory enzyme in glycolysis, directly 
interacts with TEAD cofactors to stabilise their interaction with YAP/TAZ, thereby 
promoting increased transcriptional activity when glucose is being metabolised187. 
 
Further to the notion that metabolic pathways can exhibit cross-talk with YAP/TAZ 
signalling to support uncontrolled tumour growth, it has been demonstrated that 
YAP/TAZ can directly regulate expression of enzymes crucial for deoxyribonucleotide 
triphosphate (dNTP) biosynthesis188. This directly impacts dNTP metabolism as well as 
the pool of dNTP precursors available for DNA replication, consequently influencing cell 
proliferation. This was similarly demonstrated in a transgenic zebrafish model, where 
YAP was observed to directly induce expression and activity of glutamine synthetase 
(GLUL) to enhance glutamine production and thus increase steady-state glutamine 
levels189. This elevated glutamine was shown to enhance de novo nucleotide 
biosynthesis to fulfil the anabolic demands of rapid cell proliferation189. 
 
Finally, two recent studies have identified the importance of YAP/TAZ signalling in 
regulating glutaminolysis to drive both pulmonary hypertension and liver fibrosis190,191. 
Both studies came to the conclusion that YAP/TAZ activation regulated expression of 
metabolic enzyme GLS1, and was therefore crucial for replenishment of carbon 
intermediates in the TCA cycle to support biosynthesis of amino acids, such as 
aspartate, to continue cell proliferation190,191. It would therefore be of interest to 
investigate this relationship between YAP/TAZ signalling and glutaminolysis in cancer, 




1.6.5. Hypoxia-induced alterations to cancer metabolism 
Cancer cells are known to modify their metabolism in response to hostile conditions, 
such as hypoxia, to switch towards oxygen-independent ATP production and maintain 
tumour cell proliferation and survival. Increased HIF-1 activity is believed to be the 
primary mediator of this response, enforcing increased glycolysis for ATP production in 
the face of reduced oxygen availability and consequent attenuated oxidative 
phosphorylation86,192. HIF-1 is known to directly stimulate increased transcription of 
glucose transporters GLUT1 and 3 to increase glucose uptake, as well as increasing the 
expression of nearly all glycolytic enzymes192,193. HIF-1 is also known to enhance 
expression of LDHA, increasing the pyruvate to lactate conversion rate in hypoxia to 
support continued glycolytic flux through regeneration of NAD+ as well as maintaining the 
NADH/NAD+ ratio in the absence of efficient mitochondrial oxidative phosphorylation81. 
Lactate must be rapidly excreted from the cell to prevent inhibition of glycolysis through 
lactate accumulation, which is supported by the HIF-1-dependent upregulation of 
monocarboxylate lactate transporters (MCTs)194. Not only does this prevent intracellular 
acidosis (which inhibits glycolysis), but it also acidifies the tumour microenvironment, 
which has been shown to be beneficial for the tumour by promoting tumour cell invasion 
and metastasis as well as immune evasion71,179. 
 
Another function of increased lactate production in hypoxia is to divert pyruvate away 
from undergoing oxidative phosphorylation in the absence of oxygen as the final electron 
acceptor in the mitochondrial electron transport chain (ETC), thereby limiting ROS 
accumulation. HIF-1 also mediates mitochondrial metabolic remodelling to limit carbon 
entry into the TCA cycle through transactivation of the gene encoding pyruvate 
dehydrogenase kinase1 (PDK1)195. PDK1 phosphorylates the E1α subunit of the PDH 
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enzyme complex, inactivating PDH and therefore the production of mitochondrial acetyl 
CoA from glucose195,196. This hypoxia-induced metabolic switch thereby supports 
increased glycolysis for ATP production as well as limiting inefficient mitochondrial 
pyruvate oxidation and ROS production195. However, this reduction in carbon entry into 
the TCA cycle alters the carbon incorporation intro citrate, thereby reducing the citrate to 
α-KG ratio. This reduction is believed to trigger altered glutamine metabolism as an 
alternative means to support production of citrate, which is required to generate acetyl 
CoA for fatty acid synthesis197. It was consequently demonstrated that cells under 
hypoxia almost exclusively rely on reductive carboxylation of glutamine-derived α-KG, 
mediated through IDH and aconitase (ACO) enzymes, to support de novo lipogenesis198. 
This mechanism additionally allows conservation of glucose for use in other biosynthetic 
pathways such as the PPP and SSP to generate molecules such as ribose and serine, 
thereby sustaining continued cell growth in conditions where nutrients are limiting, such 






Figure 1.8 Hypoxia-induced changes in cancer metabolism. Hypoxia is known to 
enhance glycolytic flux through upregulation of glucose transporters GLUT1/3 as well as 
other glycolytic enzymes (green). As a result high levels of pyruvate are generated and 
converted to lactate by LDHA, which is also upregulated in hypoxia. Hypoxia is also known to 
decrease fatty acid oxidation and reduce glucose oxidation through the TCA cycle (grey). 
Glutamine oxidation is also reduced, diverting glutamine to reductive glutamine metabolism 
to produce citrate which is used to generate acetyl CoA for increased fatty acid (FA) 
synthesis (purple). Image from Wong et al199. 
 
1.6.6. Oxidative and endoplasmic reticulum stress in cancer 
Metabolic rewiring not only acts to sustain tumour growth, it also prevents oxidative 
stress inflicted through toxic accumulation of ROS, which ultimately can result in cell 
death. Oxidative stress occurs when there are perturbations in the oxidant-antioxidant 
balance, in favour of excessive production of oxidants (ROS) alongside attenuated 
protective antioxidant mechanisms200,201. Tight regulation of cellular stress is therefore 
crucial for maintaining both healthy and malignant cell survival. 
 
Under physiological conditions, ROS are a natural by-product of aerobic metabolism and 
at low levels, can act as signalling molecules stimulating and regulating various biological 
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processes in response to environmental changes, known as redox-signalling202. 
However, major and prolonged disturbances in this balance results in excessive ROS 
production causing subsequent destructive damage to the cell. The largest contributor to 
ROS production is through continuous leakage of electrons to oxygen from the 
mitochondrial ETC during ATP synthesis and it is believed that between 1-5% of oxygen 
consumed during aerobic metabolism gives rise to superoxide anions (O2-)200. ROS are 
subsequently known to be significantly increased in both cancer and under hypoxia, 
where the reduced availability of O2 as an electron acceptor in the final stage of electron 
transport extends the time each electron spends in the chain, exacerbating their leak and 
therefore the generation of O2-203,204. ROS are also known to increase stabilisation and 
activity of HIF-1α, thereby perpetuating the malignant phenotype200. 
 
In a ploy to maintain cancer cell survival in the face of ROS production, enzymatic and 
non-enzymatic antioxidant mechanisms are employed to detoxify these reactive 
molecules such as superoxide dismutases (SODs), that convert superoxide anions to 
hydrogen peroxide, which is then further reduced to water by catalase and glutathione 
peroxidase203. Non-enzymatic molecules such as ascorbate, carotenoids and flavonoids 
also act to counteract the harmful effects of free radicals on the cell203. However, when 
the fine balance between oxidants and antioxidants is severely disrupted, H2O2 is a 
potent oxidising agent, capable of reacting with metal ions, such as ferrous iron (Fe2+), to 
generate hydroxyl radicals (OH); another highly reactive form of ROS species 
generated through Fenton chemistry202,203,205: 
 
𝐹𝑒𝑛𝑡𝑜𝑛 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛: 𝐹𝑒2+ + 𝐻2𝑂2  → 𝐹𝑒




In addition to mitochondrial oxidative stress, the endoplasmic reticulum (ER) is also a 
large source of ROS due to the highly oxidised environment which is essential for 
successful oxidative protein folding and is strictly regulated by the redox state of the 
microenvironment. Hypoxia and nutrient deprivation are known to disrupt this, inflicting 
ER stress through impaired protein folding in the ER205. Accumulation of misfolded 
proteins consequently activates the unfolded protein response (UPR) in an attempt to 
resolve this defect. However, multiple attempts at correctly refolding proteins is a process 
known to increase ROS production since H2O2 is generated as a by-product of constant 
cycles of disulphide bond breakage and formation206. This increased ROS production is 
known to further exacerbate ER stress causing calcium release and a rise in cytosolic 
calcium concentration, which results in calcium-mediated calcium release from the 
second largest intracellular calcium store – the mitochondria. This, in turn, continues the 
feed-forward effect, further increasing mitochondrial ROS production206. This potent loop 
accentuates both ER and oxidative stress resulting in potentially catastrophic ROS levels 
in the cell206. All of the highly reactive ROS species, but particularly the OH•, can 
consequently attack and cause oxidation of DNA, protein and lipids, causing irreparable 
damage and ultimately induction of cell death mechanisms, such as apoptosis, necrosis 




Figure 1.9 Interplay between oxidative stress and ER stress. Intracellular stresses such 
as hypoxia can generate ROS which can in turn disrupt protein folding in the ER. Protein 
misfolding can then produce ROS as H2O2 is generated as a by-product of protein refolding. 
This exacerbates ER stress causing Ca2+ release which ultimately results in Ca2+ release 
from the mitochondria, further increasing ROS production. ER stress is also known to 
activate CHOP expression which may lead to a further increase in ROS. This potent loop 
accentuates both ER and oxidative stress eventually resulting in cell death. Image adapted 




1.7. Thesis aims 
Despite recent technological and surgical advancements, glioma patient survival remains 
incredibly poor. A large contributing factor to this abysmal survival is the severely hypoxic 
nature of gliomas, which bestows a highly aggressive and therapy-resistant phenotype. It 
is therefore imperative that pathways involved in gliomagenesis, as well as those that 
encompass the tumour microenvironment, are identified in the hope to discover more 
effective therapies to dramatically increase patient survival. 
 
One signalling pathway of interest is YAP/TAZ signalling, with increased activity 
associated with enhanced cancer growth, invasion, metastasis and chemoresistance. 
Regulation of YAP/TAZ is incredibly complex, although hypoxia has recently been 
identified to influence signalling activity in breast cancer and could therefore potentially 
be observed in other cancers. This thesis therefore aims to investigate this potential 
hypoxic regulation of YAP/TAZ signalling in an established in vitro model of GBM. The 
challenging nature of the hypoxic tumour microenvironment is also known to contribute 
towards metabolic reprogramming in order to sustain uncontrolled proliferation and 
survival in this hostile environment. Integration of both hypoxic metabolism and YAP/TAZ 
signalling could potentially support this adaptation and so this thesis aims to investigate 
this potential relationship. Suppression of aberrant YAP/TAZ signalling has become an 
attractive target to develop novel cancer therapies. As such, the final objective of this 
thesis is to investigate the repurposing potential of VP – a recently identified YAP 











2.1. Cell culture  
2.1.1. Immortalised cell lines 
Table 2.1 shows an outline of the four immortalised human glioma cell lines selected for 
this investigation. 
 
Table 2.1 Glioma cell line characteristics.Four main glioma cell lines were used 
throughout this investigation. U343 cells are known to exhibit amplified EGFR expression 
which is representative of the classical GBM subtype, as outlined by the Verhaak 
classification system24. The HOG cells have been engineered to express either wild-type 
(WT) or mutant (MUT; R132H) IDH1 enzyme. 
 
U87 (300367) and U343 (300365) cell lines were obtained from CLS Cell Lines Service 
GmbH (Germany). U343 cells were known to have high EGFR expression, which is 
typical of the classical subtype of GBM (Figure 2.1A). The HOG (Human 
OligodendroGlioma) cells, kindly donated by Professor Hai Yan, were derived from a 
grade III human oligodendroglioma and infected with a lentivirus to stably express either 
wild-type (WT) or mutated (MUT) IDH1 (R132H)208. The cells were routinely assessed 
via western blotting to ensure stable expression of mutant IDH1 (Figure 2.1B). 
 
Cell line U87 U343 HOG IDH1 Wild-type (WT) 
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Figure 2.1 Expression of EGFR and IDH1 R132H in glioma cell lines. 
 
Additional glioma lines U87 WT and MUT IDH1 (R132H), LN18 WT and MUT IDH1 
(R132H) and LN18 WT and MUT IDH2 (R172K) were previously derived as outlined in 
Hollinshead et al209. Melanoma cell line, A375 (ATCC® CRL-1619™) was obtained from 
ATCC. 
 
All cell lines were cultured under standard conditions (37°C, 5% CO2) using Dulbecco's 
Modified Eagle Medium High Glucose with L-Glutamine (DMEM; Sigma Aldrich, D5796) 
supplemented with 10% Foetal Bovine Serum (FBS; Hyclone Thermo Scientific, 
SV30160.03). Cells were subject to routine mycoplasma testing using the EZ-PCR 
Mycoplasma Test Kit (Geneflow, K1-0210) to ensure no contamination. 
 
For hypoxia studies, cells were cultured at 21% O2 and then for each experiment 
transferred to the Whitley H35 Hypoxystations (Don Whitley Scientific) set to 1% and 
0.3% O2 for the stated amount of time, unless otherwise identified. 
 
It should be noted that cell density is an important and defined regulator of YAP/TAZ, 
with high cell densities causing inactivation of YAP/TAZ activity124. As such, the in vitro 
cell densities used throughout this investigation were determined so that the cells were 
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approximately 50-70% confluent at the time of use, in order to minimise the risk of under- 
or over-stimulating YAP/TAZ activity during experiments. 
 
2.1.2. Cell lines derived from patient tumours 
2.1.2.1. Patient information 
GBM cell lines, T1 and T2, were derived from a single surgical specimen excised in 
November 2014 from a 32 year old male diagnosed with GBM at the Queen Elizabeth 
Hospital Birmingham (QEHB) NHS Foundation Trust. The patient had previously 
undergone a right temporal craniotomy in March 2014 followed by cranial radiotherapy 
over 6 weeks to 54 Gy in 30 fractions with continuous oral TMZ. This was followed by a 
course of 5/30 adjuvant TMZ in July 2014. Immediate ‘post-op’ imaging showed two 
distinct areas/foci of residual tumour medial and lateral in the right temporal lobe (Figure 
2.2). Follow-up MRI imaging in October 2014 showed that one area (labelled ‘A’; from 
which T1 was derived) had increased in size, while the other (labelled ‘B’; from which T2 
was derived) was around the same size as when previously imaged suggesting a 
therapeutic response in one area but not the other. During reoperation in November 
2014 samples were removed from sites ‘A’ and ‘B’ for derivation of cell lines – T1 






Figure 2.2 MRI scans from GBM patient showing progression of therapy-resistant foci 
A but not of therapy-responsive foci B. Images courtesy of Prof. G. Cruickshank. 
 
The use of patient material was approved by the Human Biomaterials Resource Centre 
(HBRC) at the University of Birmingham (UoB; research project number 13-165) and the 
reference committee for ethical approval 15/NW/0079 (NRES Committee North West-
Haydock). All patients provided full, informed, written consent as per the Declaration of 
Helsinki. Histopathological analysis of the tumour biopsy was conducted by the 
pathology department at QEHB and consequently given a tumour grade in accordance 
with the 2007 WHO classification system9. Following grading, the biopsies were 
processed and anonymised at the HBRC after which a piece of the biopsy was flash 
frozen. Primary cell lines were derived from the remaining biopsy through mechanical 
and enzymatic dissociation of the solid piece. 
 
2.1.2.2. Primary cell line generation 
Firstly, under sterile conditions, the tumour piece was placed into a petri dish and 
washed three times using 1x sterile phosphate buffered saline (PBS). Following washing, 
the tumour was dissected using a scalpel. The dissected pieces were transferred into a 
50 ml Falcon tube, washed again with 1x PBS and then centrifuged (230 x g, 5 min) in 5 
ml 1x PBS at room temperature (RT). The PBS was then carefully removed, ensuring 
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that the pieces were not disrupted, after which the washing and centrifugation was 
repeated. For enzymatic digestion, 5 ml of TrypLE TM Express (Gibco; 12605-10) was 
incubated with the pieces at 37°C for 10 min. Following digestion, the trypsin was 
neutralised with 10 ml of DMEM High Glucose with L-Glutamine (Sigma-Aldrich; D5796) 
and then centrifuged at 230 x g for 5 min at RT. The media was removed and the pieces 
were resuspended in 15 ml of DMEM with added antibiotics and fungicide (1% 
Penicillin/Streptomycin, 0.1% Gentamycin and 1% Amphotericin B; Sigma-Aldrich). The 
tumour pieces were mechanically dissociated by repeated pipetting until a homogenous 
solution was achieved. This cell suspension was then seeded onto flasks and cultured at 
the required oxygen tensions. 
 
2.1.3. Spheroid culture 
In addition to culturing the cells as adherent monolayers, U87 and U343 cells were 
grown in spontaneous cellular aggregates known as spheroids. This 3D culture method 
allows spatial and temporal organisation of cell growth, creating a metabolite, nutrient 
and oxygen gradient across the spheroid similar to that witnessed in in vivo tumours.  
 
Spheroids were cultured on 0.5% agarose coated plates using the liquid-overlay 
method210. Firstly, 6-well plates were coated with a layer of 0.5% low-melting point 
agarose (Promega, V2111) in DMEM, which had been pre-heated to 60°C. Of this 
solution, 2 ml was added to each well of a 6-well plate and left to solidify at 4°C. 
Following plate preparation, 1.8x105 cells were seeded onto each well with a total media 
volume of 2 ml, creating the aqueous overlay in which the spheroids formed. The plates 




2.1.3.1. VP treatment of spheroids (Chapter 4) 
To establish the effect of VP on spheroid formation and growth, spheroids were treated 
with vehicle (0.2% DMSO), 1, 3, 5 and 10 µM VP 2 h following cell seeding. The 
spheroids were left for 24 and 48 h undisturbed in the incubator. Images were then taken 
after the stated incubation time using the Leica DFC290 HD camera (20x objective). For 
quantitative analysis, spheroid images were imported into Image J (NIH) and two 
perpendicular diameters were measured and a mean diameter recorded for each 
complete, singular spheroid. It should be noted that an assumption has been made in the 
analysis that the spheroids were perfectly circular therefore two perpendicular diameters 
were recorded taking into consideration the smallest and widest parts of the spheroid. 
Any aggregated spheroids were excluded from analysis. 
 
To assess long-term VP treatment, spheroids were also imaged following 1-10 µM VP 
treatment for 7 days. To investigate the effect of VP on fully formed spheroids, cells were 
seeded onto the agarose coated plates and left for 7 days to form, after which the 
spheres were treated with 5 µM VP and incubated for 24-168 h. Images were taken 
periodically every 24 h to assess spheroid morphology. 
 
2.2. Chemicals 
Unless otherwise stated, the following treatment conditions used during this investigation 
are summarised in Table 2.2. Drug concentrations were determined based upon dose-




Drug Abbreviation Concentration Product Information 
ALLN N/A 10 µM VWR International, 208719 
Chloroquine CQ 10 µM Sigma-Aldrich, C6628 
Cyclosporin A CsA 15 µM Cayman Chemical, 12088  
Dimethyloxalylglycine DMOG 1 mM Cayman Chemical, 71210 
Dimethyl Sulfoxide DMSO Vehicle Fisher, BP231-1 
Eeyarestatin-1 Eer1 1 and 3 µM Tocris Bioscience, 3922 
Ferric Chloride 
Hexahydrate FeCl3/Fe
3+ 3-500 µM Sigma-Aldrich, F-2877 
Hydrogen Peroxide H2O2 50 and 100 µM Sigma-Aldrich, 31642 
Iron (II) Chloride 
Tetrahydrate (Ferrous 
Chloride) 
FeCl2/Fe2+ 3-500 µM 
Honeywell Fluka, 
44939 
Magnesium Chloride MgCl2/Mg2+ 3-500 µM Fisher, BP214-500 
Methanol MeOH Vehicle VWR Chemicals, 20847.307 
Necrostatin-1 Nec-1 50 µM Cayman Chemical, CAY11658-5 
Pifithrin-α PFT-α 30 µM Tocris Bioscience, 1267 
Protoporphyrin IX PPIX 5 µM Sigma-Aldrich, 258385 
Verteporfin VP 1-30 µM Tocris Bioscience, 5305 
Zinc Chloride ZnCl2/Zn2+ 3-500 µM Alfa Aesar, A16281 





Z-VAD-FMK/Z-VAD 20 µM Sigma-Aldrich, V116 
2’,7’-Dichlorofluorescin 
Diacetate DCFDA 20 µM Sigma-Aldrich, D6883 
4-Hydroxy-TEMPO TEMPOL/TPL 3 mM Sigma-Aldrich, 176141 
Table 2.2 Details of reagents used in this investigation. 
 




2.3. Sulforhodamine B assay  
Cells were fixed by adding 20% (v/v) ice-cold trichloroacetic acid (final concentration 
25%; Sigma-Aldrich, T0699) directly to the media and incubated at 4°C for 30 min. The 
solution was then carefully removed and plates were washed three times with dH2O and 
left to air-dry. Once dry, the intracellular protein was stained with 0.4% (w/v) 
sulforhodamine B (SRB; Sigma-Aldrich, 230162) in 1% acetic acid for 10 min at RT. SRB 
solution was removed and wells were washed three times with 1% acetic acid to reduce 
any non-specific staining. After drying at RT, SRB was dissolved using 50 mM Tris/HCL 
pH 8.8 and 100 µl per well was aliquoted into a 96-well plate. The absorbance was then 
quantified at 495 nm on FLUOstar OMEGA microplate reader (BMG LabTech). 
Absorbance values were corrected for background absorbance using 50 mM Tris/HCL 
pH 8.8 as a blank. Unless otherwise stated, final values were then normalised in each 
experiment to the vehicle for each oxygen tension. 
 
2.3.1. Cell proliferation assay (Chapter 3) 
U87 and U343 cells were seeded at 3x104 cells on 24-well plates and left to settle 
overnight under standard conditions. The following day, the plates were either kept at 
21% O2 or moved to 1% or 0.3% O2 and cultured for a further 24, 48 and 72 h. At each 
time point cells were fixed for SRB analyses. A time-zero plate was fixed when the plates 
were transferred into hypoxia to use as the control for all conditions. Data was 
normalised to the time-zero control plate. 
 
2.3.2. Determining VP dosage and treatment time (Chapter 4)  
For determining the dosage and treatment time of VP, U87 and U343 cells were seeded 
at 3x104 cells on 24-well plates and left to adhere overnight under standard conditions. 
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The following day, cells were treated with either vehicle (control; 0.2% DMSO) or 1, 3, 5 
and 10 µM VP and incubated under standard conditions. Cells were then fixed and 
processed via SRB assay 24, 48 and 72 h post VP-treatment. Cell number was recorded 
and normalised to the vehicle control for each time point. 
 
For hypoxic cell viability, cells were seeded and treated as aforementioned before being 
incubated in 21% and 1% O2 for 24 h. Cell viability was then measured via SRB and 
normalised to the vehicle control for each oxygen tension. Representative images were 
taken using the Leica DFC290 HD camera (20x objective). 
 
2.3.3. Cell viability following treatment with porphyrins (Chapter 4) 
To compare cell viability following VP treatment to other members of the porphyrin 
family, U87, U343 and A375 cells were seeded at 3x104 cells on 24-well plates and left 
to adhere overnight under standard conditions. Cells were treated the next day with 
either vehicle (control; 0.1% DMSO) or 5 µM VP, PPIX or ZnPP in both 21% and 1% O2 
for 24 h. Primary GBM cell lines T1 and T2, HOG IDH1 WT and MUT, and LN18 IDH1 
and IDH2 WT and MUT cells were also seeded onto 24-well plates at 3x104 cells/well 
and treated with 5 µM VP for 24 h in 21% and 1% O2. Cell viability was recorded using 
SRB assay. Data was normalised to vehicle control for each oxygen tension. For IDH1 
and IDH2 WT and MUT cell lines, data was also normalised to the normoxic WT control. 
 
2.3.4. Cell viability following VP treatment when exposed to light (Chapter 4) 
U87 and U343 cells were seeded at 3x104 cells on 24-well plates and left to adhere 
overnight under standard conditions. Cells were treated the next day with either vehicle 
(control; 0.1% DMSO) or 5 µM VP for 4 or 24 h in both 21% and 1% O2. In the 4 h VP 
 
59 
condition, the media was removed and replaced with fresh DMEM for the remaining 20 h. 
For cells in the dark condition, the plates were kept obscured from ambient light as best 
possible during media replacement, whereas cells in the light condition were exposed to 
ambient light while the media was changed. Viability was measured using SRB assay. 
 
2.3.5. Cell viability following VP and DMOG treatment (Chapter 4) 
U87 and U343 cells were seeded at 3x104 cells on 24-well plates and left to adhere for 
up to 8 h before being treated with 1 mM DMOG overnight under standard conditions. 
The following morning, cells were treated with either vehicle (control; 0.1% DMSO) or 5 
µM VP for 4 h in both 21% and 1% O2 before cell viability measured via SRB. 
 
2.3.6. Cell viability following treatment with VP and cell death inhibitors 
(Chapter 4) 
U87 and U343 cells were seeded at 3x104 cells on 24-well plates and left to adhere 
overnight under standard conditions. Cells were treated the next day with either vehicle 
(control; 0.1% DMSO), 5 µM VP or 5 µM VP in combination with either 20 µM Z-VAD-
FMK, 10 µM ALLN, 15 µM CsA, 50 µM Nec-1, 30 µM PFT-α, 10 µM CQ or 1 and 3 µM 
Eer1 for 24 h in both 21% and 1% O2. Cells were also treated with inhibitor alone. Cells 
were pre-treated with the inhibitors for 1 h prior to VP addition. Cell viability was 
measured via SRB as aforementioned. 
 
2.3.7. Cell viability following VP and anti-oxidant treatment (Chapter 4) 
U87 and U343 cells were seeded at 3x104 cells per 24-well plate and left to adhere 
overnight under standard conditions. The following day, cells were pre-treated with 3 mM 
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4-hydroxy-TEMPO (TEMPOL) for 2 h before being treated with 5 µM VP for 24 h in both 
21% and 1% O2. Cell viability was then measured via SRB. 
 
2.4. Cell proliferation assay (Chapter 4) 
U87 and U343 cells were seeded at 3x104 cells in 24-well plates and left to settle for 4 h 
under standard conditions. VP (1-10 µM) was then added and the cells were cultured for 
up to 96 h. Cells were trypsinised (10 min, 37C) and manually counted using chamber 
slides 24, 48, 72 and 96 h post VP-treatment. An average was taken from two cell counts 
for each VP concentration recorded at each time-point. Representative images were 
taken using the Leica DFC290 HD camera (20x objective).  
 
2.5. Quantitative polymerase chain reaction (qPCR) 
RNA was extracted using the RNeasy Mini Kit in accordance with the manufacturer’s 
protocol (Qiagen, UK; 74104). A total of 1 μg RNA was transcribed using the Reverse 
Transcription System kit (Promega, UK; A3500). qPCR was performed on AB 7500 Real 
Time PCR System using the TaqMan® gene expression master mix (Applied 
Biosystems, UK). The following probes were used: BBC3 (HS00248075_m1), BNIP3 
(HS00969291_m1), CTGF (HS01026927_g1), CYR61 (HS00998500_g1), SLC2A1 
(GLUT1; HS00892681_m1), VEGF-A (HS00900055_m1) and YAP1 (HS00902712_g1) 
(Thermo Fisher Scientific, UK). Gene expression levels were normalised to ACTB (Actin; 
HS01060665_g1). Relative expression levels were calculated using the 2-ΔΔCT method 




2.6. Protein analysis of cells under hypoxia (Chapter 3) 
U87 and U343 cells were seeded at 2x105 cells per 6-well and left to settle overnight 
under standard conditions. The following day, the cells were transferred to 1% or 0.3% 
O2 for up to 24 h. Cells were lysed at the time-points 2, 4, 6, 8 and 24 h into 100 µl 1x 
Laemmli buffer (Sigma-Aldrich, S3401-1VL). Cells cultured under 21% O2 for 24 h were 
used as a control. Samples were then stored at -20C for western blotting. 
 
To analyse TAZ expression under hypoxia, U87 and U343 cells were seeded at 6x104 
cells on 12-well plates and left to settle overnight. The following morning cells were either 
left under 21% O2 or transferred to 1% O2 for 24 h, after which cells were harvested for 
western blotting. 
 
For analysis of protein expression of phosphorylated YAP (p-YAP) and YAP1 in T1 and 
T2 primary cells, protein was extracted from cells that had been cultured long-term under 
hypoxic conditions for four passages. Cells were seeded under hypoxic conditions at 
3x105 cells onto 10 cm plates and harvested 48 h later. 
 
2.7. Western blotting 
2.7.1. Protein preparation 
To prepare samples for western blotting, cells were washed with 1x PBS and scraped 





2.7.2. SDS-PAGE gel electrophoresis, protein transfer and antibody 
incubation 
Extracted protein was heated to 95-100°C for 10 min and then placed on ice prior to 
loading on a polyacrylamide gel for sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Proteins were resolved under reducing denaturing 
conditions at 120-150 V using the mini-PROTEAN Tetra System (BIO-RAD). Proteins 
were then transferred to 0.1 µm nitrocellulose membrane (GE Healthcare, 10600000) 
using either wet transfer at 100 V for 1.5 h or via dry transfer using the iBlot® gel transfer 
system (Invitrogen) and iBlot® gel transfer nitrocellulose stacks (Invitrogen, IB301001) 
for 7 min. Membranes were then blocked in 5% non-fat skimmed dried milk powder 
(Marvel) in 1x PBS-0.05% Tween (PBS-T) for 1 h at RT. All antibodies (Table 2.3) were 
diluted in either 5% milk PBS-T or 5% bovine serum albumin (BSA; Sigma-Aldrich, 
A7906) -PBS-T depending on antibody specification. Membranes were cut and incubated 
with the appropriate primary antibody overnight at 4°C (except for Anti-Actin which was 
incubated for 1.5 h at RT). Following incubation, membranes were washed three times 
with PBS-T and incubated with the appropriate Horseradish peroxidase (HRP)-
conjugated secondary antibody for 1 h at RT (Table 2.4). The membranes were then 
washed three times for 15-30 min and developed using the EZ-ECL enhanced 
chemiluminescence detection kit (BI, 20-500-120). Proteins were visualised on High 
Performance Chemiluninescence Hyperfilm™ (Amersham, 28906836) using the Ecomax 
X-Ray film processor (Protec, 1186-3-4000). 
 
2.7.2.1. Western blot antibodies 




Antibody Dilution Molecular Weight (kDa) Species 
Product 
Information 
Anti-Actin 1:4000 42 Mouse Sigma-Aldrich, A4700 















1:1000 ~55, 48 Rabbit Abcam, ab7260 
Anti-Glutaminase 1 
(GLS1) 1:1000 ~76 Rabbit 
Abcam 
ab156876 







1:500 47  Mouse Dianova, DIA H09 
Anti-phosphorylated 
YAP (S127) 1:1000/1:2000 ~65-75 Rabbit 
Cell Signaling, 
#4911 
Anti-YAP1 1:1000 ~65-75 Mouse Abcam, ab56701 
Anti-YAP1 
(EP1674Y) 1:25,000 ~70 Rabbit 
Abcam, 
ab52771 




Table 2.3 Primary antibodies used for western blotting. 
 
The following secondary antibodies outlined in Table 2.4 were also used. 
 
Table 2.4 Secondary antibodies used for western blotting. 
 
Densitometry was performed using Fiji software211. Samples were normalised within 
each biological experiment and expressed as a percentage of the control. 
 
Antibody Dilution Molecular Weight (kDa) Species Product Information 
Anti-mouse IgG HRP-Linked 
Secondary 1:4000 - Mouse Cell Signaling, #7076 
Anti-rabbit IgG HRP-linked 
Secondary 1:4000 - Rabbit Cell Signaling, #7074 
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2.8. Co-immunoprecipitation  
2.8.1. Preparing cell lysates 
U343 cells were seeded at 4x106 cells/15 cm dish and cultured overnight. The following 
day, cells were treated with either vehicle (0.1% DMSO) or 5 µM VP in both 21% and 1% 
O2 for 4 h. After treatment, the media was removed and cells were washed twice with 
ice-cold 1x PBS. The PBS was removed and 1 ml of immunoprecipitation (IP) buffer (50 
mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1% IGEPAL and 1x protease 
inhibitor cocktail (Sigma-Aldrich, P8340)) was added. Cells were then scraped into an 
Eppendorf before being placed on ice for 20 min and then centrifuged for 20 min at 
13,000 RPM, 4°C. The supernatant was then aliquoted into a fresh tube and protein 
concentration was determined using a bicinchoninic assay (BCA) following the 
manufacturer’s protocol (Thermo Fisher Scientific, 23227). 
 
2.8.2. Co-immunoprecipitation 
Primary antibody (YAP1, ab52771; 1:70 dilution) was added to 200 µg cell lysate per 
condition into an Eppendorf and incubated with rotation overnight at 4C. A sample of the 
undiluted cell lysate was kept aside as the whole cell input for western blotting. Volumes 
were kept consistent between samples with addition of IP buffer. 
 
Following overnight incubation, 30 µl of the 50% Protein G agarose bead slurry (Cell 
Signaling, #37478) was added to the lysate-antibody mix and incubated for 3 h under 
rotation at 4C. Afterwards, samples were microcentrifuged for 30 sec followed by 
removal of the supernatant, which was kept in case of future use. The bead pellet was 
then washed five times on ice with 500 µl of IP buffer to remove any non-specific binding. 
Following washing, the bead pellet was resuspended in 20 µl of 2x Laemmli buffer and 
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heated to 95-100C for 5 min before centrifugation for 1 min at 14,000 x g. Samples were 
then subjected to western blotting, as described previously, and probed for the protein of 
interest. 
 
2.9. Immunocytochemistry (ICC) 
Post treatment, cells were immediately fixed with 4% paraformaldehyde (PFA) for 15 
min, followed by quenching with 0.1 M glycine-PBS for 5 min. Cells were then washed 
twice with 1x PBS and permeabilised with 0.1% Triton-X-100 for 5 min. Cells were then 
incubated with primary antibody (Table 2.5) for 1.5-2 h. Following incubation, cells were 
washed twice and incubated with secondary antibody (Table 2.6) for 1 h at 4°C. 
Afterwards, cells were washed twice and incubated with Hoechst 33342 for 20 min at RT 
to stain the nuclei. Cells were then washed and fixed onto microscope slides using 
Mowiol (Sigma, 81381). Images were then taken using a ZEISS LSM 780 confocal 
microscope using the Plan-Apochromat 100x/1.4 Oil DIC objective (1024 x 1024 pixels; 
8-bit). The pinhole was set at 100 µm and the gain was adjusted for each cell line using 
the range indicator on the brightest sample for each channel. These parameters were 
then kept consistent across all samples and experiments using that antibody. Pseudo-
colouring was applied to images using Zen 2012 SP1 software (ZEISS; black-edition, 
version 8.1): UV channel (blue), 488 channel (green) and 633 channel (red). 
 
2.9.1. Immunochemistry antibodies 
Table 2.5 lists the primary antibody and dilution used in this investigation. All primary and 




Antibody Dilution Species Production Information 
Anti-Calreticulin (CRT) 1:100 Rabbit Cell Signaling, 12238 
Anti-p73 
(EPR18409(T)(MIX)) 1:100 Rabbit Abcam, ab189896 
Anti-SQSTM1/Anti-p62 1:100 Rabbit Abcam, ab91526 
Anti-YAP1 1:100 Mouse Abcam, ab56701 
Anti-YAP1 (EP1674Y) 1:100 Rabbit Abcam, ab52771 
Anti-YAP1 1:100 Mouse Abcam,ab56701 
Anti-8OHdG 1:100 Rabbit Abcam, ab62623 
Table 2.5 Details of primary antibodies used for ICC. 
 
The following secondary antibodies and additional stains used in this investigation are 
listed in Table 2.6. 
Table 2.6 Secondary antibody and additional stains used for ICC. 
 
2.9.2. Hypoxic YAP expression (Chapter 3) 
U87 and U343 cells were seeded at a density of 1.5x105 per coverslip and left to settle 
overnight under standard conditions. Cells were then incubated the following day at 












1:100 Mouse 488 ExMax- 500 EmMax- 520 





1:100 Rabbit 488 ExMax- 500 EmMax- 520 






































either 21% or 1% O2 for 4 and 8 h. Cells were then fixed for ICC and stained for YAP1 
expression. 
 
2.9.3. VP timecourse (Chapter 4) 
U87 and U343 cells were seeded at a density of 1.5x105 per coverslip and left to settle 
overnight under standard conditions. Cells were then treated the following day with either 
vehicle (0.1% DMSO) or 5 µM VP and incubated at either 21% or 1% O2 for 1, 2, 4, 6 
and 8 h. Cells were then fixed for ICC and stained for YAP1 expression. Cells were also 
co-stained for p73 expression 4 and 8 h post VP-treatment. 
 
2.9.4. p62 (Chapter 4) 
U87 and U343 cells were seeded at a density of 1.5x105 per coverslip and left to settle 
overnight under standard conditions. Cells were then treated the following day with 
vehicle (0.1% DMSO) or 5 µM VP for 4 h in both 21% and 1% O2. Cells were then dual 
stained for both YAP1 and p62 expression. 
 
2.9.5. Z-VAD-FMK (Chapter 4) 
U87 and U343 cells were seeded at a density of 1.5x105 per coverslip and left to settle 
overnight under standard conditions. Cells were then treated the following day with 
vehicle (0.1% DMSO), 5 µM VP, 5 µM VP and 20 µM Z-VAD-FMK or 20 µM Z-VAD-FMK 
only for 8 h in both 21% and 1% O2. Cells were initially pre-treated with Z-VAD-FMK for 2 





2.9.6. Calreticulin (CRT)(Chapter 4) 
U87 and U343 cells were seeded at a density of 1.5x105 per coverslip and left to settle 
overnight under standard conditions. Cells were then treated the following day with 
vehicle (0.1% DMSO) and 5 µM VP for 2 h at either 21% or 1% O2. After treatment, cells 
were dual-stained as described above for YAP1 (mouse) and CRT for 1.5-2 h. Cells were 
then imaged using confocal microscopy as aforementioned. 
 
2.9.7. Eeyarestatin-1 (Eer1)(Chapter 4) 
U87 cells were seeded at a density of 1.5x105 per coverslip and left to settle overnight 
under standard conditions. Cells were then treated the following day with vehicle (0.1% 
DMSO), 5 µM VP, 5 µM VP and 1 µM Eer1 or 1 µM Eer1 only for 4 h at either 21% or 1% 
O2. Cells were pre-treated with Eer1 for 1 h prior to VP addition. Following treatment, 
cells were processed for ICC and stained for YAP1 expression. 
 
2.9.8. 8-OHdG (Chapter 4) 
U87 and U343 cells were seeded at a density of 2x105 per coverslip and left to settle 
overnight under standard conditions. Cells were then treated the following day with 
vehicle (0.1% DMSO), 5 µM VP or 100 µM H2O2 for 2 h at either 21% or 1% O2. 
Following treatment, cells were stained with Anti-8-hydroxydeoxyguanosine (8-OHdG) 
and imaged according to previously aforementioned. 
 
2.9.9. Analysis of nuclear fluorescence  
To analyse YAP1 nuclear expression, confocal images were imported into Image J 
(NIH). Using the freeform line tool, an outline was drawn around the nucleus and the 
following measurements taken; AREA, INTEGRATED DENSITY and MEAN GRAY 
 
69 
VALUE. Background fluorescence measurements were taken the same way by selecting 
three areas surrounding the cell. The following formula was then used to determine the 
corrected total nuclear fluorescence (CTNF) for each cell212: 
 
CTNF= Integrated Density – (Area of selected cell X Mean fluorescence of 
background) 
 
The integrated density determines the sum of all the pixels within a region to give a total 
fluorescence value, as opposed to an average fluorescence intensity. The CTNF further 
takes into account the area of the nucleus as smaller nuclei may appear to have higher 
levels of staining compared to a larger nucleus however this could be just down to its 
smaller size. To remove bias during cell imaging, areas of cells were selected at random 
using the Hoechst 33342 channel to discourage selecting for cells with the brightest 
YAP1 expression. During image analysis, only cells with complete nuclei present in each 
image were analysed for nuclear fluorescence. 
 
2.10. Gene Silencing  
2.10.1. Knockdown of YAP and TAZ 
For experiments investigating the effect of knockdown of Hippo pathway genes YAP and 
TAZ, cells were seeded onto 12-well plates – U87 cells were seeded at a total density of 
3x104 and U343 at 4x104 cells per well. Cells were cultured overnight under standard 
conditions and the following day were transfected with small-interfering RNA (siRNA). 
According to manufacturer’s instructions, ON-TARGETplus SMARTpool human non-
targeting RNA (siNT; Dharmacon, D-001810-10) and siRNA targeting YAP (siYAP; 
Dharmacon, L-012200-00), TAZ (siTAZ/siWWTR1; Dharmacon, L-016083-00) and both 
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YAP and TAZ together (siYAP/TAZ) were transfected at 25 nM using DharmaFECT 1 
transfection reagent (Thermo Fisher Scientific, T2001). Target sequences for YAP1 and 
TAZ can be viewed in Appendix 1. The amount of DharmaFECT 1 reagent used per well 
had been optimised at 2 µl/ 12-well and 4 µl/ 6-well. Cells were then incubated at either 
21% or 1% O2 for 72 h post-transfection and subsequently processed for western blotting 
to assess protein knockdown and SRB analysis to assess cell proliferation.  
 
2.10.2. Knockdown of YAP and TAZ for metabolic analysis (Chapter 3) 
U343 cells were seeded at 2.5x105 cells per 6-well and left to settle overnight under 
standard conditions. The following day, cells were transfected with siNT, siYAP, siTAZ 
and siYAP/TAZ as described above. Cells were left for 48 h before being used for 
metabolic tracing analysis. 
 
2.10.3. VP treatment following YAP/TAZ knockdown (Chapter 4) 
For experiments investigating the effect of VP on cell viability following YAP and TAZ 
knockdown, cells were seeded onto a 6-well plate (U87 at 3x105 cells/well and U343 at 
3.5x105 cells/well) and cultured for 24 h. Cells were then transfected with siRNA as 
previously described and cultured under standard conditions. 24 h post-transfection, cells 
were re-plated onto 24-well plates at a density of 3x104 cells per well and cultured for a 
further 24 h under standard conditions. The following day cells were treated with either 
vehicle (0.1% DMSO) or 5 µM VP and incubated at either 21% or 1% O2 for 24 h. Post-




2.10.4. Knockdown of HIF-1α (Chapter 4) 
For knockdown of HIF-1α, cells were seeded at 3x104 cells/12-well and left to settle 
overnight. The following day, cells were transfected with 25 nM siNT or siHIF-1α 
(Dharmacon, L-004018-00) according to manufacturer’s instructions. Cells were then 
cultured for 48 h before being treated with either vehicle (0.1% DMSO) or 5 µM VP and 
incubated at either 21% or 1% O2 for 24 h. Post-treatment period, cells were then fixed 
and analysed using the SRB method.  
 
In all biological experiments, protein was harvested to ensure proper gene silencing. 
 
2.11. Protein over-expression 
Overexpression of a triple mutant form of HIF-1α (HIF1αTM)213 was used which confers 
HIF-1α stabilisation under normoxic conditions, when the protein would normally be 
rapidly degraded. U87 cells were seeded at 4x104 cells on 24-well plates and left to 
adhere. Cells were then transfected 24 h post-seeding with 3 µg of HIF1αTM plasmid 
using DharmaFECT kb transfection reagent (Dharmacon, T-2006-01) according to the 
manufacturer’s protocol. Cells were then treated with 5 µM VP 24 h post-transfection for 
4 h in 21% O2. Cells were analysed 28 h post-transfection via SRB assay. Protein was 
also harvested to confirm HIF-1α expression in normoxia. 
 
2.12. Metabolic tracing analysis 
Metabolite labelling using stable isotope tracers is an effective technique to assess 
changes in metabolic pathway activity. 13C-enriched tracers such as glucose and 
glutamine are added to the culture medium for a set period of time until isotopic steady 
state has been reached. For glycolysis this can typically be achieved in ~10 minutes, 
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TCA metabolites ~2-3 hours and nucleotides ~24 hours214. When a labelled substrate is 
metabolised by the cell, enzymatic reactions result in the rearrangement of carbon atoms 
incorporated in the downstream metabolites, resulting in a distinctive labelling pattern 
which can be used to infer the relative activity of metabolic pathways215. Analytical 
techniques such as gas chromatography-mass spectrometry (GC-MS), can determine 
the metabolite isotopomer distribution (MID) in each metabolite, which refers to the shift 
in mass of a metabolite as a result of the incorporation of 13C isotopes. Typically, these 
are defined as M+0, M+1, M+2 to M+n, where M is the base mass of an ion fragment 
and the following number 0 to n refers to the mass shift from M as a result of the number 
of 13C carbon atoms incorporated216. Consequently, the sum of all the fractions from M+0 
to M+n is 100%217. For accurate labelling determination from 13C isotopic tracers, the 
MIDs must also be corrected for natural isotope abundance. 
 
2.12.1. Addition of tracer 
Following transfection with siNT, siYAP, siTAZ and siYAP/TAZ for 48 h (outlined in 
section 2.10.2), the media was changed to basic formulation DMEM (Sigma-Aldrich 
D5030) containing 10% FBS and supplemented with the appropriate tracer; 10 mM 
uniformly labelled glucose ([U-13C6]-glucose; Sigma-Aldrich, 389373) or 2 mM uniformly 
labelled glutamine ([U-13C5]-glutamine; Sigma-Aldrich, 605166) and incubated at 21% or 
1% O2 for 24 h. Either unlabelled glucose (Sigma-Aldrich, G7021; 10 mM) or unlabelled 
glutamine (Sigma-Aldrich, G7513; 2mM) was supplemented to the media – depending on 





2.12.2. Metabolite extraction 
Following 24 h labelling, the media was quickly removed and the cells washed twice with 
500 µl ice-cold 0.9% saline solution. The plate was then transferred onto dry-ice and 500 
µl ice-cold methanol (HPLC grade; Fisher Scientific, 10093880) was added to rapidly 
quench cell metabolism. The cells were then scraped and transferred to a pre-chilled 
safe-lock Eppendorf tube where 500 µl ice-cold 1 µg/ml D6-glutaric acid in dH2O (C/D/N 
Isotopes Inc, D-5227) was added. Afterwards, 500 µl ice-cold chloroform (Sigma-Aldrich, 
650498) was added and the tubes were rocked at full speed on ice for 15 min. Samples 
were then centrifuged at 14,000 RPM for 15 min at 4C, after which 800 µl of the upper 
fraction containing the polar metabolites was aliquoted into a clean safe-lock Eppendorf 
and dried by speed vacuum at 45C for 2-3 h. Once completely dried, samples were 
stored at -80C until processing for GC-MS analysis. 
 
2.12.3. GC-MS (in collaboration with Dr. A. Thakkar, UoB) 
2.12.3.1. Sample derivatisation 
For metabolite derivatisation for GC-MS analysis, the dried samples were first incubated 
at 95C to remove any residual moisture. Next, the dried extracts were solubilised using 
40 µl 2% methoxyamine hydrochloride (Sigma-Aldrich, 226904) dissolved in pyridine 
(Sigma-Aldrich, 270970) and incubated for 1 h at 60C. Following incubation, 60 µl N-
tertbutyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) with 1% (w/v) 
tertbutyldimethyl-chlorosilane (TBDMSCI; Sigma-Aldrich, 375934) derivatisation agent 
was added and incubated for 1 h at 60C. Finally, samples were centrifuged (13,000 
RPM, 5 min) and the supernatant transferred to a chromatography vial with glass insert 




2.12.3.2. GC-MS analysis  
Derivatised polar extracts were analysed using an Agilent 7890B GC/MSD gas 
chromatograph equipped with a polydimethylsiloxane GC column (DB35MS; 30 m x 0.25 
mm x 0.25 µm film thickness) coupled to an Agilent 5977A mass spectrometer (Agilent 
Technologies). 1 μl of sample was injected into the GC-MS in splitless mode with helium 
carrier gas at a rate of 1 ml/min. The inlet liner containing glass wool was set at 270°C 
and oven temperature at 100°C for 1 min before ramping to 280°C at a rate of 5°C/min. 
Temperature was further ramped to 320°C at a rate of 10°C/min held at 320°C for 5 min. 
Compound detection was carried out in full scan mode in the mass range 50 to 650 m/z, 
with 2-4 scans/sec and a source temperature of 250°C, a transfer line temperature of 
280°C and a solvent delay time of 6.5 min. Before data was recorded, the injector needle 
was cleaned with acetonitrile three times as well as three times following every 
measurement thereafter. 
 
Raw GC-MS data was converted to common data format using the acquisition software. 
Further data processing, including correcting for natural isotope abundance and MID 
determination was conducted using MetaboliteDetector software218. Metabolite ion 
counts were normalised to the internal standard D6-glutaric acid and cell counts for each 
condition to account for any variation in derivatization and metabolite concentrations 
respectively. MID analysis and total carbon contribution from glucose and glutamine for 




2.13. Flow Cytometry  
2.13.1. Cell treatment 
U87 and U343 cells were seeded 2x105 onto 6-well plates and left to adhere overnight 
under standard conditions. The following day, cells were treated with vehicle (0.1% 
DMSO), 5 µM VP, 5 µM VP and 20 µM Z-VAD-FMK, or 20 µM Z-VAD-FMK alone in both 
21% and 1% O2 for 4 and 8 h. Cells were pre-treated with Z-VAD-FMK for 1 h prior to VP 
treatment. 
 
2.13.2. Annexin V/ Propidium Iodide viability assay 
After treatment, the cell media was collected separately for each condition following end 
of treatment. Cells were PBS washed, trypsinised and added to the appropriate collected 
media. Cell suspensions were then left for 20 min to allow for re-stabilisation of 
phosphatidylserine (PS) expression. Cells were centrifuged (230 x g, 5 min) and washed 
before the cell pellet was resuspended in 1x Annexin V binding buffer (BD Biosciences, 
556454). Cells were then stained with FITC Annexin V (BD Biosciences, 556419; 5 µl 
per sample, Ex/Em 490/525 nm) and propidium iodide (PI; Life Technologies, V13242; 1 
µl of 0.1 mg/ml solution, Ex/Em 535/617 nm) for 10 min at RT. Cells were then analysed 
on the BD LSRFortessa X-20 cell analyser (BD Biosciences) using BD FACSDiva 
Software. Forward scatter, side scatter and FITC and PE (laser channel to measure PI) 
signal intensities were recorded. The laser intensities for both channels were determined 
using the unstained control sample and set at 103. To check there was no signal bleed 
through across the channels, single stained cells were provided as a control (Figure 2.3). 
H2O2 treated cells was used as a positive control for both stains. 10,000 cells were 
analysed per sample and data was processed using FlowJo software (version 8.7.3, 




Figure 2.3 Examples of single and double stain controls for flow cytometry. 
Firstly, FITC Annexin V signal was plotted against PI signal intensity for the vehicle 
control sample and gates were applied surrounding the viable population of cells. These 
gates were then kept consistent across the rest of the samples being analysed. From the 
gating, four different populations of cells can be determined (Figure 2.4). 
 
 
Figure 2.4 Simplified schematic depicting distinct cell populations generated through 
intensity of Annexin V and PI staining.  
 
When cells are undergoing apoptosis, cells expose the membrane phospholipid PS on 
the outside of the plasma membrane. Annexin V can irreversibly bind to these residues 
and can therefore provide an estimation of cell apoptosis. During necrosis however, the 
plasma membrane integrity is disrupted allowing uptake of the cell-impermeable dye PI. 
Using these dyes in conjugation can therefore make a distinction between modes of cell 
death219. Consequently, the viable cell population is denoted by cells that are negative 
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for both Annexin V and PI staining (bottom left quarter). Cells which are undergoing early 
apoptosis generally have higher Annexin V but low PI staining (bottom right quarter). 
Late stage apoptosis is commonly represented by cells that stain highly for both Annexin 
V and PI (top right quarter) and finally, cells deemed to be necrotic largely have high 
levels of PI but low levels of Annexin V staining (top left quarter). To assess changes in 
viability upon VP treatment, the viable cell population for each sample was recorded. 
 
2.14. DCFDA assay  
2’,7’-Dichlorofluorescin Diacetate (DCFDA) is a cell-permeable fluorogenic compound 
which is deacetylated by cellular esterases into a non-fluorescent intermediate which can 
subsequently be oxidised in the presence of ROS into the highly fluorescent compound 
DCF220. The fluorescence can then be measured using a plate reader (Excitation 485 
nm, Emission 520 nm) and is directly proportional to the amount of oxidised DCFDA by 
hydroxyl, peroxyl and other ROS species220. 
 
U87, U343 and GBM T1 and T2 cells were seeded at 2.5x104 cells per 96-well plate and 
left to adhere overnight under standard conditions. The following morning, to assess 
ROS, cells were treated with 5 µM VP or 5 µM PPIX (2 h, standard conditions) followed 
by overlay of 2x DCFDA (20 μM final concentration; Sigma-Aldrich, D6883) for the last 
45 min of VP treatment. Wells were then washed with PBS and measured at 485 nm 
using the FLUOstar OMEGA microplate reader. To investigate whether VP-induced ROS 
production could be reduced, cells were co-treated with VP and free radical scavenger 
TEMPOL (TPL; 2 h pre-treatment, Sigma-Aldrich, 176141) and ROS levels assessed via 
DCFDA assay. H2O2 (50 µM) was used as a positive control. Fluorescence values were 
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corrected to the untreated cells for each experiment. For hypoxic measurements, the 
assay was conducted as described but in 1% O2 before measurements read in normoxia. 
 
2.15. Binding Assays 
2.15.1. VP absorption spectra 
VP was diluted to 75 µM in both dH2O and methanol. The absorption spectra was then 
measured in the UV/Visible range (300-800 nm) using the FLUOstar OMEGA microplate 
reader. 
 
2.15.2. Metal cation binding 
To assess whether VP could bind metal ions, 3-500 µM of ferric chloride hexahydrate 
(FeCl3/Fe3+; Sigma-Aldrich, F-2877) Iron (II) chloride tetrahydrate (FeCl2/Fe2+; Honeywell 
Fluka, 44939), magnesium chloride (MgCl2/Mg2+; Fisher, BP214-500) and zinc chloride 
(ZnCl2/Zn2+; Alfa Aesar, A16281) was added to 30 µM VP diluted in methanol. The 
absorbance spectra were measured between 300-800 nm using the FLUOstar OMEGA 
microplate reader. For hypoxic measurements, 100 µM FeCl3 was left under 21% or 1% 
O2 for 4 h before 30 µM VP was added and absorbance read at 300-800 nm.  
 
VP is activated during PDT around 685-690 nm (VP activation point). A shift in the VP 
absorption spectra from 686 nm towards 670 nm was seen upon addition of some of the 
metal cations indicating that the compounds could bind VP through altering the structure, 
inducing this shift. To determine binding therefore, first order binding kinetic graphs were 
generated by calculating the ratio of absorbance at 670/686 nm for all the metal chloride 
compounds. Absorbance values were read 1 min following addition of metal chloride to 
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VP (time-zero), and after 8 and 24 h. A specific binding nonlinear line of best fit was 
drawn for each metal chloride. 
 
2.15.3. Mass Spectrometry (in collaboration with Prof. J.H.R. Tucker, UoB)  
FeCl3, FeCl2, MgCl2 and ZnCl2 was added in excess to VP and dissolved using 99.8% 
methanol (extra-dry over molecular sieve; ThermoFisher, 10649492). Samples were then 
subject to low-resolution MALDI-TOF LD+ mass spectrometry using the service provided 
by The Centre for Chemical and Materials Analysis in the School of Chemistry at UoB. 
Samples were prepared and analysed by E. Wilkinson from Prof. J.H.R Tucker’s 
research group. 
 
2.16. Statistical analysis 
All statistical analysis was performed using GraphPad Prism v7 (GraphPad Software, La 
Jolla California, USA). Data is presented as mean  standard error of the mean (S.E.M) 
or mean ± standard deviation (S.D) where stated. An unpaired T-test with Welch’s 
correction (2 samples), one-way ANOVA (> 2 samples) or two-way ANOVA (>2 samples 
and oxygen conditions) with multiple comparisons post-hoc tests (Bonferroni and Tukey) 
were conducted as appropriate. A Shapiro-Wilk normality test was conducted where 
appropriate. Statistical significance was assigned at * p<0.05, ** p<0.01 and *** p<0.001. 





Investigating the hypoxic regulation of 






Hippo signalling, in particular the main effectors YAP and its paralog TAZ, are known to 
be highly dysregulated in various cancers such as lung, breast, colorectal and liver to 
name a few138. Amplified expression and hyper-activated transactivational activity of YAP 
and TAZ have been strongly associated with the induction of a CSC phenotype, 
increased tumour growth and chemoresistance as well as increased metastases, as 
previously described. Studies conducted by Orr et al.,149 and Zhang et al.,150 have also 
highlighted the role of YAP and TAZ in glioma pathology, with amplified YAP expression 
observed in glioma tissues. In addition, YAP expression was seen to increase with 
histological grade in glioma, with the highest expression associated with grade IV 
(GBM)149,150. Patient prognosis is therefore also correlated with YAP1 expression, with 
high expression associated with a worse OS when compared with low expression, 
across all glioma grades149,150. Investigations into the underlying mechanisms as to how 
aberrant YAP1 expression influences tumour survival and therapy-resistance revealed a 
mechanistic relationship between hypoxia and aberrant Hippo/YAP signalling. It has 
previously been discovered that hypoxia influenced YAP activity in MDA-MB-231 breast 
cancer cells by deactivating upstream Hippo signalling which consequently led to 
increased YAP nuclear localisation and a concomitant increase in protein and mRNA 
expression of well-established YAP targets, CYR61 and CTGF, contributing to a pro-
survival role in hypoxic tumours131. Furthermore, these observations have been 
corroborated in breast cancer and HCC respectively, although this relationship has yet to 
be defined in glioma133,135. 
 
It is well known that cancer cells demonstrate an abnormal cellular metabolism, resulting 
in an altered, often increased requirement for nutrients to aid uncontrolled and 
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inappropriate cell proliferation221. Rapidly proliferating cells must accumulate biomass 
such as nucleotides, proteins, lipids and other cellular building blocks in order to 
generate new cells. The activity through the biosynthetic pathways underlying these 
processes has therefore been observed to be considerably altered in cancer. The 
challenging nature of the tumour microenvironment, which often includes hypoxia, also 
contributes to the metabolic reprogramming observed. Indeed, these alterations can 
support enhanced cell survival and proliferation, often resulting in a more malignant 
phenotype80. Despite many studies highlighting the oncogenic roles of YAP/TAZ in 
various cancers, little is known about how YAP/TAZ can potentially influence metabolism 
to support the increased cell proliferation observed with amplified YAP/TAZ expression 
and transactivational activity. 
 
This chapter therefore aims to investigate the potential hypoxic regulation of YAP/TAZ in 
gliomas. Due to their complex hypoxic nature, aberrant YAP/TAZ activity is likely to be 
induced, which could ultimately contribute towards increased glioma growth and tumour 
progression. Furthermore, the metabolic implications of YAP/TAZ activity will be 
investigated using metabolic tracer-based analysis to assess whether YAP/TAZ can 
influence glioma metabolism, particularly under hypoxia, and whether YAP/TAZ could 




3.2. Results  
3.2.1. Glioma cell lines exhibit differential sensitivity to hypoxia 
Gliomas are known to be extremely hypoxic tumours due to their excessive growth and 
presence of oedema, as previously described. To assess whether hypoxia could 
influence the growth of the in vitro glioma cell lines used in this investigation, U87 and 
U343, cell proliferation was evaluated over a 72 hour period of hypoxia. Proliferation was 
seen to be significantly attenuated in the U87 cells after 48 hours in 1% and 0.3% O2 
when compared to cells grown under normoxia (21% O2; Figure 3.1A). Conversely, 
proliferation of the U343 cell line was unaffected when the cells were cultured under 
hypoxic conditions (Figure 3.1B), indicating that these cells may harbour a specific 




Figure 3.1 Glioma cells exhibit differential sensitivity to hypoxia. U87 (A) and U343 (B) 
cells were grown under normoxic (21% O2) or hypoxic (1% and 0.3% O2) conditions for up to 
72 h. Cell growth was determined via SRB analyses every 24 h and normalised to the time-
zero control. Although both cell lines proliferated under hypoxic conditions, growth was 
significantly reduced after 48 h in U87 cells whereas U343 cells remained unaffected. Data 
was performed in technical quadruplicate in 3 independent experiments. Error bars represent 





3.2.2. YAP1 and YAP1-target gene transcription is increased under hypoxic 
conditions 
YAP has been previously associated with increased growth and progression in numerous 
different tumour types including GBM, and thus its aberrant regulation in cancer must be 
deeper investigated. Due to tumours exhibiting a high degree of hypoxia, studies have 
now begun to focus on the potential relationship between hypoxia and YAP, however this 
association has yet to be characterised in glioma. Therefore, YAP1 mRNA expression 
was assessed in U87 and U343 (Figure 3.2A, E) as well HOG IDH1 WT and MUT 
(Figure 3.3A, E) glioma cell lines following 8 hours of hypoxia (1% O2). At a 
transcriptional level, hypoxia was seen to increase YAP1 gene expression as well as 
amplifying YAP1 activity, which is implied through a concomitant increase in expression 
of YAP1-target genes CYR61, CTGF and BBC3 (BCL2 binding component 3) due to 






Figure 3.2 Hypoxia increases YAP1 and YAP1-target gene expression in U87 and U343 
cell lines. Quantitative PCR was carried out on RNA harvested from U87 (A-D) and U343 
(E-H) cells following 8 h in 21% or 1% O2. YAP1 gene expression was seen to significantly 
increase under hypoxia in both cell lines compared to the 21% O2 control (A and E). YAP1 
activity was analysed through YAP1-target gene (CYR61 (B and F), CTGF (C and G) and 
BBC3 (D and H)) expression which suggested that hypoxia increased YAP1 activity due to 
increased expression of YAP1 target genes compared to the normoxic control. Samples 
were run in technical duplicate in 3 independent experiments. Error bars represent ± S.E.M. 




Figure 3.3 Mutation in IDH1 does not influence hypoxia-induced YAP1 and YAP1-
proliferative gene expression. Quantitative PCR was carried out on RNA harvested from 
HOG IDH1 WT (A-D) and HOG IDH1 MUT (E-H) cells following 8 h in 21% or 1% O2. YAP1 
gene expression was seen to increase under hypoxia in both cell lines compared to the 21% 
O2 control but was only significant in the WT cells (A and E). Expression of YAP1-target 
genes CYR61 (B and F), CTGF (C and G) and BBC3 (D and H) were also analysed and 
observed to be increased under hypoxic conditions. Gene expression of the HOG IDH1 MUT 
cells was normalised to the HOG IDH1 WT normoxic cells to observe the influence of the 
IDH1 R132H mutation (I-L). No significant differences in gene expression were seen 
between WT and MUT cells except in the expression of BBC3. HOG MUT cells were seen to 
have a significantly higher basal level of BBC3 compared to the 21% O2 WT control which 
was also significantly increased under hypoxia when compared to hypoxic WT cells. 
Samples were run in technical duplicate in 3-5 independent experiments. Error bars 





To confirm cells were hypoxic, HIF-1α target genes BNIP3 (BCL2 interacting protein 3), 
VEGF-A and SLC2A1 (otherwise known as GLUT1) were analysed across all cell lines 
and indeed found to be increased upon exposure to 1% O2 (Figure 3.4 and 3.5). 
 
 
Figure 3.4 Hypoxia induces expression of HIF-1 target genes in U87 and U343 cell 
lines. To ensure glioma cells were hypoxic during gene analysis experiments, RNA was 
harvested from U87 (A-C) and U343 (D-F) cells following 8 h in 21% or 1% O2. HIF-1 target 
genes BNIP3 (A and D), VEGF-A (B and E) and GLUT1 (C and F) were assessed via qPCR 
and were seen to increase under hypoxic conditions, with B, D and E deemed statistically 
significant. Samples were run in technical duplicate in 3 independent experiments. Error bars 
represent ± S.E.M. Significance determined using Welch’s unpaired t-test . * p<0.05, ** 
p<0.01. 
 
To assess the whether the presence of the R132H IDH1 mutation influenced YAP1 and 
YAP1-target gene expression, gene expression data from the HOG IDH1 MUT cells was 
normalised to their WT counterparts (Figure 3.3I-L and 3.5G-I). No significant differences 
were observed upon IDH1 mutation except in the expression of YAP1-target gene, 
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BBC3, in which a significant increase in mRNA expression was apparent under normoxic 
and hypoxic conditions (Figure 3.3L). 
 
 
Figure 3.5 Hypoxia induces expression of HIF-1 target genes in HOG IDH1 WT and 
MUT cell lines. To ensure glioma cells were hypoxic during gene analysis experiments, RNA 
was harvested from HOG IDH1 WT (A-C) and HOG IDH1 MUT (D-F) cells following 8 h in 
21% or 1% O2. HIF-1 target genes BNIP3 (A and D), VEGF-A (B and E) and GLUT1 (C and 
F) were assessed via qPCR and were seen to increase under hypoxic conditions, with B, C, 
E and F deemed statistically significant. Gene expression of HOG IDH1 MUT cells was then 
compared to IDH1 WT cells (G-I), however no significant differences were observed between 
the two cell lines. HOG IDH1 MUT cells were seen to have a higher basal level of GLUT1 
compared to WT cells however this was non-significant. Samples were run in technical 
duplicate in 2-5 independent experiments. Error bars represent ± S.E.M. Significance 
determined using Welch’s unpaired t-test . * p<0.05, ** p<0.01. 
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3.2.3. YAP1 protein expression is increased under hypoxic conditions 
To assess whether hypoxia could also increase YAP1 protein expression, U87 and U343 
cells were exposed to hypoxia for 2-24 hours (Figure 3.6). While 1% O2 was sufficient to 
induce a strong increase in YAP1 mRNA, only a minimal increase in YAP1 protein 
expression was apparent in the U87 and U343 cells after 8 hours hypoxia when 
compared to the normoxic control (Figure 3.6B, E). In fact, a lower oxygen tension of 
0.3% O2 was required to significantly increase YAP1 protein expression in the U87 cells 
(Figure 3.6B), whilst only a small difference was apparent in the U343 cell line (Figure 
3.6E). Hypoxia was also able to induce a significant increase in YAP1 protein expression 
in the HOG IDH1 WT and MUT cells however only after exposure to the lower oxygen 





Figure 3.6 YAP1 protein expression is increased under hypoxic conditions. (A) Protein 
was harvested from U87 cells which had been under 1% and 0.3% O2 for 2-24 h or 21% O2 
(C) for 24 h. HIF-1α (~120 kDa), phosphorylated-YAP (p-YAP, S127; ~65-70 kDa) and YAP1 
(~65-70 kDa) expression was analysed through western blotting. As expected, HIF-1α 
expression was increased in hypoxic conditions, although was seen to reduce after 24 h. p-
YAP and YAP1 expression increased however only under 0.3% O2. (B) Densitometry 
analysis showed that YAP1 expression significantly increased under 0.3% O2 for 8 h when 
compared to the control cells. Data is normalised to actin expression and expressed as a 
percentage of the control. (C) YAP1 activity was calculated as a ratio of the inactive p-YAP to 
the total YAP1 present. A reduction in p-YAP was observed under hypoxic conditions 
suggesting increased YAP1 activity. (D) Protein was harvested from U343 cells which had 
been under 1% and 0.3% O2 for 2-24 h or 21% O2 (C) for 24 h. Expression of p-YAP and 
YAP1 was seen to increase under 8 h hypoxia although was not significant from 
densitometry analysis (E). YAP1 activity was also increased under 0.3% O2 (F), however was 
again non-significant. Actin (42 kDa) was used as a loading control. Data is from 3 (U343) 
and 4 (U87) independent experiments. Error bars represent ± S.E.M. Significance 






Figure 3.7 Hypoxia induces YAP1 protein expression in the HOG cells. (A) Protein was 
harvested from HOG IDH1 WT cells following 2-24 h under 1% and 0.3% O2. Compared with 
the 21% O2 control (C), p-YAP and YAP1 were induced under hypoxic conditions. 
Expression of HIF-1α was increased during hypoxic conditions, although undetected 
following 24 h. (B) Densitometry analysis showed a significant increase in YAP1 expression 
following 8 h 0.3% O2. (C) A trend increased in YAP1 activity following 8 h hypoxia was 
observed from a decreased p-YAP/YAP1 ratio however was non-significant compared to the 
21% O2 control. (D) Protein was harvested from HOG IDH1 MUT cells following 2-24 h in 1% 
and 0.3% O2. HIF-1α protein was seen to increase over time under hypoxic conditions. 
Expression of p-YAP was increased under hypoxic conditions compared to the 21% O2 
control cells. YAP1 expression also significantly increased but only under 0.3% O2 which was 
confirmed by densitometry analysis (E). A trend decrease in p-YAP/YAP1 ratio was also 
observed suggesting increased YAP1 activity under hypoxic conditions, although was non-
significant. Actin was used as a loading control. Data is from 2-5 independent experiments. 
Error bars represent ± S.E.M. Significance determined using Welch’s unpaired t-test. * 
p<0.05, ** p<0.01. 
 
YAP1 activity can also be inferred from determining the expression of phosphorylated 
YAP (p-YAP) compared to the total YAP1 expression. As previously described, YAP 
phosphorylation via upstream kinases renders the protein unable to enter the nucleus, 
thereby interfering with YAP’s nuclear function as a transcriptional co-activator. Hence if 
less p-YAP is present in the cell, it can be suggested that more of the YAP present is 
 
92 
nuclear and thereby able to influence downstream target-gene transcription. YAP1 
activity was thereby determined by calculating the ratio of p-YAP to total YAP1 protein in 
all four glioma cell lines and was seen to decrease upon exposure to hypoxia (Figure 3.6 
and 3.7). Although a trend decrease in p-YAP/YAP1 ratio was apparent across all cell 
lines suggesting increased YAP1 activity in hypoxia, only 0.3% O2 was able to induce a 
significant reduction in the U87 cell line when compared to the normoxic control (Figure 
3.6C). 
 
To further assess whether hypoxia influenced YAP1 transcriptional activity in addition to 
its expression, protein expression of YAP1-target gene CTGF was analysed and seen to 
be increased upon 6 hours of hypoxia, providing further evidence to suggest that hypoxia 
can amplify YAP1 transactivational activity (Figure 3.8A). In addition to YAP1, hypoxia 
elicited a strong upregulation in protein expression of its close paralog TAZ in both U87 
and U343 cells following 24 hour exposure to 1% O2 (Figure 3.8B). To confirm whether 
this response was also true in a more physiologically relevant model, p-YAP and YAP1 
expression was analysed in two novel GBM cell lines, T1 and T2, which had been 
derived in-house from a single GBM patient biopsy (Figure 3.8C). Interestingly, the T1 
cell line originated from an area of residual tumour which had progressed following the 
patient’s initial craniotomy and chemoradiation treatment and thus deemed to be 
therapy-resistant due to its recurrent growth. The T2 cell line, on the other hand, was 
believed to be therapy-responsive as this area of the tumour did not increase in size over 
the follow-up period. From initial western blotting experiments, it was clear that both p-
YAP and YAP1 expression were distinctly increased in the T1 therapy-resistant cell line 
(Figure 3.8C). Furthermore, culturing cells under hypoxia was able to induce a significant 
increase in YAP1 expression in both the T1 and T2 cell line when compared to their 
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normoxic counterparts, with the relative increase more exaggerated in the T2 line (Figure 
3.8D). However, the initial YAP expression was lower in the T2 line, which may have 
resulted in the system being more sensitive to upregulation by hypoxia. The p-YAP/YAP1 
ratio was calculated and small decrease was apparent in hypoxia suggesting potential 
increased YAP transcriptional co-activation activity (Figure 3.8E). In addition to 
differences in total YAP1 expression, distinct morphological differences were also 
apparent between the two cell lines (Figure 3.8F). Additionally, glial fibrillary acidic 
protein (GFAP) expression was assessed to confirm that the cell lines were derived from 





Figure 3.8 Hypoxia increases YAP/TAZ expression and transcriptional co-activator 
activity in established and primary GBM cell lines. (A) YAP1 target gene CTGF, 
expression was analysed via western blotting following 6 h under 1% and 0.3% O2. 
Compared to control cells (21% O2), hypoxia was seen to increase CTGF expression (38 
kDa, upper band) in all four glioma cell lines. (B) Protein expression of YAP1 paralog TAZ 
(~50 kDa) was also analysed and seen to dramatically increase in 1% O2 for 24 h when 
compared to normoxia. (C) Protein was harvested from cell lines T1 and T2, which were 
derived from a single GBM biopsy, in 21% and 1% O2. p-YAP and YAP1 expression was 
seen to increase in the T2 therapy-sensitive line under hypoxic conditions however only a 
slight increase was observed in the T1 therapy-resistant cell line. (D) Densitometry analysis 
shows increased YAP1 expression in hypoxic conditions in both T1 and T2 cells compared to 
the normoxic control. (E) A slight decrease was observed in p-YAP/YAP1 ratio in both T1 
and T2 cells indicating increased YAP1 activity when compared to the normoxic control. (F) 
Images showing the difference in cell morphology between the GBM T1 and T2 cell lines. 
Objective 32x. (G) Glial fibrillary acidic protein (GFAP; ~55, 48 kDa) expression confirms that 
T1 and T2 cells are of glial origin. Actin was used as a loading control. 
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3.2.4. Increased YAP1 nuclear localisation suggests hypoxia amplifies YAP1 
activity in glioma cells 
Cellular localisation of YAP is crucial for its function as a transcriptional co-activator as 
previously mentioned, and so YAP1 nuclear localisation was assessed by determining 
the CTNF for each cell, as outlined in section 2.2.9, upon exposure to hypoxia (Figure 
3.9). Quantitative analysis of YAP1 nuclear staining showed that exposure to 1% O2 for 4 
hours significantly enhanced fluorescence indicating an increased presence of YAP1 in 
the nucleus and thus potentially increased transcriptional co-activator activity (Figure 
3.9B, C). This nuclear enhancement was also present after 8 hours under 1% O2 in the 
U87 cells although was not apparent in the U343 cells suggesting differential responses 





Figure 3.9 YAP1 nuclear localisation is increased under hypoxic conditions. (A) U87 
and U343 cells were cultured under 21% and 1% O2 for 4 and 8 h before being processed 
via ICC to visualise YAP1 localisation. Analysis of the nuclear YAP1 fluorescence was 
conducted and was seen to significantly increase following 4 h in 1% O2 in the U87 (B) and 
U343 (C) cell lines when normalised to the normoxic control. Interestingly, YAP1 nuclear 
localisation was only seen to increase in the U87 and not the U343 cells following 8 h 
hypoxia. Scale bar represents 10 μm. All experiments were conducted in biological triplicate 
(except U343 4 h in biological duplicate). 2-4 images were analysed per condition, per 
experiment. Error bars represent ± S.E.M. Significance determined using one-way ANOVA, 





3.2.5. Knockdown of YAP/TAZ reduces glioma cell proliferation  
Since enhanced YAP expression and activity have been associated with increased 
tumour progression and survival, it was questioned whether knockdown of YAP/TAZ 
would affect glioma cell survival; particularly under hypoxic conditions where YAP and 
TAZ expression were shown to be increased. Knockdown of YAP and TAZ using 
targeted siRNA was first validated in both U87 and U343 cell lines over a 96 hour time 
period (Figure 3.10A, B). Cell proliferation was then assessed in both normoxic (21% O2) 
and hypoxic (1% O2) conditions in both glioma cell lines following 72 hour knockdown of 
YAP, TAZ and YAP and TAZ together – to account for any potential compensation of the 
two proteins – compared to non-targeting siRNA control. Upon knockdown, cell 
proliferation was significantly reduced in the U87 cells, which was further increased 
under hypoxia (Figure 3.10C, E). On the other hand, only siTAZ and knockdown of both 
YAP and TAZ together was able to significantly reduce cell growth of the U343 cells and 
no additional reduction in cell growth under hypoxia was apparent (Figure 3.10D, E). To 
confirm that knockdown of YAP and TAZ was affecting the cell proliferation and not 
inducing cell death, images were taken showing that both cell lines were still viable upon 






Figure 3.10 Knockdown of YAP1 and TAZ significantly reduces glioma cell growth. 
siRNA knockdown of YAP1 (A) and TAZ (B) was conducted over a 96 h time-course in both 
the U87 and U343 cell lines. 72 h post-transfection was subsequently chosen for all following 
experiments as this time point achieved the best knockdown for both proteins in both of the 
cell lines. (C and D) YAP, TAZ and both YAP and TAZ together were subjected to siRNA 
knockdown in the U87 and U343 cell lines. Cells were cultured under 21% and 1% O2 for 72 
h post-transfection and fixed for SRB analysis. Knockdown was seen to significantly reduce 
cell number in both cell lines in both normoxia and hypoxia however siYAP did not induce 
any significant reduction in growth of the U343 cell line. (E) Representative western blots 
confirming successful protein knockdown in the cell proliferation experiments. (F) Images 
showing that knockdown of YAP, TAZ and YAP/TAZ reduced U87 and U343 cell proliferation 
and was not a result of induced cell death. Actin was used as loading control. Scale bar 100 
µm. Data is from 3 biological experiments, conducted in technical triplicate. Error bars 
represent ± S.E.M. Significance determined using two-way ANOVA, with Tukey post-hoc 





3.2.6. Investigating the importance of YAP/TAZ in cancer cell metabolism 
Since cell metabolism is extensively altered in cancer to support increased tumour 
proliferation and survival in the often hostile microenvironment and as YAP/TAZ can play 
a significant role in these tumour phenotypes, it was investigated whether YAP/TAZ 
could influence aspects of metabolism. U343 glioma cells were incubated for 24 hours 
with either uniformly 13C labelled glucose ([U-13C6]-glucose) or glutamine ([U-13C5]-
glutamine) in normoxic (21% O2) and hypoxic (1% O2) conditions following siRNA 
knockdown of YAP, TAZ and YAP and TAZ together. The MIDs for each metabolite was 
conducted using GC-MS, and refers to the shift in mass of a metabolite as a result of the 
incorporation of 13C isotopes. Typically, these are defined as M+0, M+1, M+2 to M+n, 
where M is the base mass of an ion fragment and the following number 0 to n refers to 
the mass shift from M as a result of the number of 13C carbon atoms incorporated216. 
Consequently, the sum of all the fractions from M+0 to M+n is 100%217. 
 
3.2.6.1. YAP/TAZ support de novo serine synthesis 
The NEAA serine is known to provide precursors for a variety of biosynthetic pathways 
which are vital for cell proliferation and survival222. Serine can either be imported from 
extracellular sources or synthesised de novo from a branch in glycolysis (Figure 3.11A). 
Importantly, serine can be converted into glycine via serine hydroxymethyltransferase 1/2 
(SHMT1/2) to supply methyl units for one-carbon metabolism; an intricate network based 
upon the shuttling of carbon units via folate derivatives for the biosynthesis of crucial 
macromolecules such as proteins, lipids and nucleic acids for cellular proliferation as well 




Knockdown of YAP and TAZ was seen to significantly perturb serine metabolism in U343 
cells under normoxic conditions, which is evident by a significant reduction in the 
percentage of 13C incorporation into serine from [U-13C6]-glucose when compared to the 
siNT control (Figure 3.11B, C). Changes in the serine M+3 isotopomer are indicative of 
reduced de novo serine synthesis upon knockdown of YAP/TAZ. M+2 labelled serine on 
the other hand could arise from the conversion of glycine back into serine via SHMT 1/2, 
which again was significantly reduced upon YAP/TAZ knockdown. Interestingly, M+1 
serine – which could potentially be generated through labelled glucose being utilised 
upstream through the oxidative and non-oxidative arms of the PPP – was also 
significantly reduced upon knockdown of YAP/TAZ. The majority of 13C incorporation into 
serine was however unlabelled (M+0) suggesting that the U343 cells rely heavily on 
serine from extracellular sources rather than from de novo synthesis from glucose 
(Figure 3.11C, D). Knockdown of YAP and TAZ appeared to have no additional effect on 
serine metabolism in hypoxia, with a significantly reduced M+3 labelling observed across 
all conditions compared to normoxia suggesting a potential diversion from serine 









Figure 3.11 YAP/TAZ support de novo serine synthesis under normoxic conditions. (A) 
Schematic showing an overview of the de novo SSP and pathways into one-carbon 
metabolism from glycolysis. Red circles denote the carbons in each metabolite which are 
incorporated from uniformly labelled 13C glucose ([U-13C6]-glucose). (B) Successful 
knockdown of YAP, TAZ and YAP/TAZ was confirmed in U343 cells from glucose tracing 
experiments. (C) MIDs of serine following 24 h labelling of U343 cells with [U-13C6]-glucose 
and 72 h knockdown of YAP, TAZ and YAP/TAZ under normoxic conditions. M+0, M+1, M+2 
etc. mass isotopomers correspond to the ion fragments containing 0, 1, 2 etc. 13C atoms 
respectively. It is clear that knockdown of YAP, TAZ and YAP/TAZ significantly reduces the 
percentage of 13C labelling into serine compared to the non-targeting siRNA (siNT). (D) 
Under hypoxic conditions however, the knockdown has no additional effect when compared 
to the siNT. (E) De novo serine synthesis can be denoted by the M+3 isotopomer, which is 
significantly reduced upon knockdown of TAZ and YAP/TAZ suggesting a potential role for 
YAP and TAZ supporting serine synthesis derived from glucose under normoxic conditions. 
Additionally, hypoxia was also seen to significantly reduce the percentage of M+3 serine 
derived from glucose. Abbreviations: 3-PG, 3-phosphoglycerate; 3-PHP, 3-
phosphohydroxypyruvate; 3-PS, 3-phosphoserine; 5,10-CH2-THF, N5,N10-methylene 
tetrahydrofolate; PHGDH, phosphoglycerate dehydrogenase; PSAT1, phosphoserine 
aminotransferase 1; PSPH, phosphoserine phosphatase; SHMT 1/2, serine 
hydroxymethyltransferase 1/2; TCA, tricarboxylic acid; THF, tetrahydrofolate. Data obtained 
was from 5 technical replicates. Error bars represent ± S.D. Significance determined using 
two-way ANOVA with Tukey post-hoc test. * p<0.05, *** p<0.001. 
 
 
Despite a reduction in fully labelled M+3 serine suggesting reduced synthesis, it could 
also indicate that serine usage was increased upon YAP/TAZ knockdown, resulting in 
less detectable 13C incorporation. Therefore, 13C incorporation into glycine from [U-13C6]-
glucose was analysed in both normoxic and hypoxic conditions (Figure 3.12). 
Surprisingly M+2 glycine, which is indicative of conversion from M+3 serine, was not 
detected in both normoxic (Figure 3.12A) or hypoxic conditions (Figure 3.12B) 
suggesting either disrupted de novo glycine production from serine or increased usage 
by the glycine-cleavage system for one-carbon metabolism. As the case for serine, the 
majority of glycine from glucose was unlabelled suggesting that U343 cells rely on 






Figure 3.12 U343 cells exhibit altered serine-glycine metabolism. MIDs of glycine 
following 24 h labelling of U343 cells with [U-13C6]-glucose and 72 h knockdown of YAP, TAZ 
and YAP/TAZ under normoxic (A; 21% O2) and hypoxic (B; 1% O2) conditions. It is clear that 
knockdown of YAP, TAZ and YAP/TAZ results in reduced 13C incorporation into glycine from 
glucose compared to the siNT under normoxic but not hypoxic conditions. Interestingly, no 
M+2 labelled glycine was detected in either condition, which would have been derived from 
M+3 serine. M+1 labelled glycine could be established by upstream processing of glucose 
through the oxidative and non-oxidative PPP resulting in differential labelling 13C patterns of 
3-PG which would then result in M+1 labelled serine. Data obtained was from 5 technical 
replicates. Error bars represent ± S.D. Significance determined using two-way ANOVA with 
Tukey post-hoc test. *** p<0.001. 
 
 
3.2.6.2. Knockdown of YAP/TAZ alters pyruvate metabolism 
At the end point of glycolysis, pyruvate is a critical metabolic node driving several crucial 
biosynthetic pathways as well as being one of the main entry points into the TCA cycle 
(Figure 3.13A). Alterations to 13C incorporation into this important metabolite can 
therefore disclose information with regards to the cell metabolic function. Knockdown of 
YAP/TAZ was seen to significantly increase the percentage 13C incorporation into fully 
labelled M+3 pyruvate from [U-13C6]-glucose when compared to the siNT control under 
both normoxic (Figure 3.13B) and hypoxic (Figure 3.13C) conditions. Under hypoxic 
conditions, 13C incorporation into pyruvate was significantly increased with siYAP/TAZ 
compared to knockdown under normoxic conditions as well as the hypoxic siNT control 
(Figure 3.13D). Interestingly, upon knockdown of YAP/TAZ, unlabelled pyruvate was also 
significantly reduced suggesting increased reliance on pyruvate derived from glucose as 
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opposed to from other sources in these cells, particularly under hypoxic conditions 
(Figure 3.13C). These data thereby suggest that the glycolytic rate could be increased in 





Figure 3.13 Knockdown of YAP and TAZ increases glycolysis in U343 cells. (A) 
Schematic showing an overview of pyruvate metabolism from glycolysis into the TCA cycle. 
Circles denote the incorporation of carbon from uniformly labelled 13C glucose ([U-13C6]-
glucose) through PDH (red) and PC (blue) activity in U343 cells. Upon YAP, TAZ and 
YAP/TAZ knockdown, fully labelled M+3 pyruvate is increased in both normoxic (B; 21% O2) 
and hypoxic (C; 1% O2) conditions. (D) Knockdown of YAP/TAZ is shown to significantly 
increase fully labelled M+3 pyruvate under hypoxia compared to normoxic conditions. 
Additionally, YAP/TAZ knockdown is seen to exacerbate M+3 labelled pyruvate when 
compared to siNT in 1% O2 suggesting increased glycolysis. Abbreviations: 3-PG, 3-
phosphoglycerate; OAA, oxaloacetate; PC, pyruvate carboxylase; PDH, pyruvate 
dehydrogenase, TCA, tricarboxylic acid. Data obtained was from 5 technical replicates. Error 
bars represent ± S.D. Significance determined using two-way ANOVA with Tukey post-hoc 
test.* p<0.05, ** p<0.01, *** p<0.001. 
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A significant proportion of glucose-derived pyruvate is reduced in the cytosol to form 
lactate via LDH; a reaction that is coupled with the oxidation of NADH to generate NAD+ 
that can be subsequently recycled by GAPDH to maintain glycolytic flux179. Under 
hypoxic conditions, lactate production from pyruvate is substantially increased due to the 
decreased NADH oxidation by the mitochondrial ETC, thereby ensuring continued 
glycolytic flux for ATP production179. After knockdown of YAP and TAZ, percentage 13C 
incorporation from [U-13C6]-glucose into lactate was seen to be slightly increased 
compared to the normoxic control (Figure 3.14A). Under hypoxic conditions however, 
knockdown of YAP, TAZ and YAP/TAZ all caused a significant reduction in M+3 lactate 
when compared to the siNT control (Figure 3.14B). Comparing the percentage 
incorporation from glucose into fully labelled (M+3) lactate, a significant increase was 
observed when cells were exposed to hypoxia, indicative of the cell maintaining 
increased glycolytic flux where conditions are limiting for ATP production through 
oxidative phosphorylation (Figure 3.14C). Interestingly, when the ratio of M+3 lactate 
from M+3 pyruvate was calculated (Figure 3.14D), a significant reduction was seen upon 
YAP and TAZ knockdown when compared to the siNT control in both normoxia and 
hypoxia suggesting that YAP and TAZ may influence pyruvate reduction to lactate. This 
would most often be through changes in mitochondrial NADH oxidation, so the fate of 





Figure 3.14 Knockdown of YAP and TAZ alters pyruvate metabolism in U343 cells. The 
percentage 13C incorporation into lactate from [U-13C6]-glucose was increased following 
siYAP and siTAZ in normoxia (A; 21% O2) but was decreased with siYAP, siTAZ and 
siYAP/TAZ under hypoxic conditions (B; 1% O2) when compared to the siNT control. (C) M+3 
lactate can be derived from fully labelled pyruvate and was seen to significantly increase 
under hypoxic conditions, which is indicative of increased aerobic glycolysis (D) The ratio of 
fully labelled lactate from fully labelled pyruvate was calculated and seen to significantly 
decrease upon knockdown with siYAP and siTAZ in normoxic and siTAZ and siYAP/TAZ in 
hypoxia when compared to the siNT for each oxygen tension. Data obtained was from 5 
technical replicates. Error bars represent ± S.D. Significance determined using two-way 
ANOVA with Tukey post-hoc test.* p<0.05, ** p<0.01, *** p<0.001. 
 
Transamination of pyruvate to alanine via ALT is thought to occur in the mitochondria for 
use in amino acid metabolism179. Metabolic analysis of 13C incorporation from [U-13C6]-
glucose into alanine revealed that knockdown of YAP/TAZ significantly reduced 
percentage incorporation in both normoxic (Figure 3.15A) and hypoxic conditions (Figure 
3.15B). Furthermore, upon knockdown, the percentage incorporation which was 
unlabelled was significantly increased suggesting an increased reliance of carbon 
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incorporation into alanine from other sources. Hypoxia was seen to increase fully labelled 
M+3 alanine from glucose in both siNT and siYAP/TAZ cells however, percentage 
incorporation was significantly reduced upon siYAP/TAZ knockdown compared to the 
siNT in both normoxic and hypoxic conditions (Figure 3.15C). Analysis of the ratio of 
M+3 alanine from M+3 pyruvate (Figure 3.15D) showed that YAP/TAZ knockdown 
caused a significant reduction suggesting that pyruvate maybe being diverted elsewhere, 






Figure 3.15 U343 cells showed reduced 13C incorporation into alanine with knockdown 
of YAP/TAZ. The percentage 13C incorporation into alanine from [U-13C6]-glucose was 
significantly decreased following knockdown of siYAP, siTAZ and siYAP/TAZ in normoxic (A; 
21% O2) and hypoxic conditions (B; 1% O2) when compared to the siNT control. (C) Fully 
labelled M+3 alanine can be derived from fully labelled pyruvate and was seen to increase 
under hypoxic conditions in both the control cells and after knockdown of YAP/TAZ. 
However, when compared to the siNT control, YAP/TAZ caused a significant reduction in 
M+3 alanine in both 21% and 1% O2. (D) Calculating the ratio of M+3 alanine derived from 
M+3 pyruvate showed a significant decrease upon knockdown of YAP and TAZ in both 
normoxic and hypoxic conditions. Data obtained was from 5 technical replicates. Error bars 
represent ± S.D. Significance determined using two-way ANOVA with Tukey post-hoc test. ** 
p<0.01, *** p<0.001. 
 
 
Introduction of glucose carbons into the mitochondrial TCA cycle is through two different 
metabolic fates of pyruvate – oxidation to acetyl CoA by PDH, or carboxylation by PC to 
form OAA (Figure 3.13A). Due to a different number of carbons being incorporated from 
pyruvate into both acetyl CoA (M+2 labelled) and OAA (M+3 labelled), the resulting 
downstream TCA metabolites will demonstrate different labelling patterns from [U-13C6]-
glucose depending on the relative enzymatic activity of PDH or PC (Figure 3.13A). 
Analysis of the TCA cycle (and related) metabolites aspartate, malate and fumarate 
showed significantly increased percentage 13C incorporation in the M+3 isotopomer upon 
knockdown of YAP/TAZ in both normoxic and hypoxic conditions (Figure 3.16). 
Interestingly, there were no significant changes in the M+2 isotopomer in any of the 
metabolites upon knockdown compared to the siNT, indicating that upon knockdown of 
YAP/TAZ, downstream oxidative glucose metabolism remains relatively unchanged. On 
the other hand, an increase in M+3 labelled metabolites suggests that activity of PC is 





Figure 3.16 Knockdown of YAP/TAZ results in increased anaplerotic pyruvate 
metabolism. Upon knockdown of YAP, TAZ and YAP/TAZ, an increase in the M+3 labelling 
of metabolites aspartate (A, B), malate (C, D) and fumarate (E, F) was apparent in both 
normoxic (21% O2) and hypoxic (1% O2) conditions when compared to the siNT control. This 
increase in M+3 is indicative of increased pyruvate carboxylation by PC which subsequently 
generates M+3 labelled OAA from pyruvate and can therefore produce M+3 labelled 
aspartate, malate and fumarate. Little to no-change was apparent in the M+2 labelling which 
is a product of pyruvate being oxidatively decarboxylated via PDH to produce M+2 acetyl 
CoA, thus forming downstream M+2 labelled TCA metabolites. Data obtained was from 5 
technical replicates. Error bars represent ± S.D. Significance determined using two-way 




This observation can be further explored by investigating the MID of citrate, where 
carbons can arise both from acetyl CoA as well as OAA (Figure 3.17). Observations 
show that M+2 citrate was significantly reduced upon YAP/TAZ knockdown in both 
normoxic (Figure 3.17A) and hypoxic conditions (Figure 3.17B) which coincided with a 
significant increase in M+3 labelled citrate. Although, M+2 labelled citrate is most 
predominant isotopomer observed, these results suggest that YAP/TAZ knockdown can 
enforce a switch in pyruvate metabolism from oxidising glucose to anaplerotic pyruvate 
carboxylation to replenish TCA metabolites. Relative PC activity was therefore calculated 
through the ratio of M+3 citrate/M+2 citrate (Figure 3.17D) and observed to be 
significantly increased upon knockdown of YAP, TAZ and YAP/TAZ when compared to 
the siNT in both normoxic and hypoxic conditions. PC activity was seen to be 
significantly reduced under hypoxic conditions in the control cells which corresponds to 
an expected reduction in TCA activity, however knockdown of YAP/TAZ was able to 




Figure 3.17 PC activity is increased following YAP/TAZ knockdown and is sustained 
under hypoxia. Knockdown of YAP/TAZ was seen to significantly reduce citrate M+2 
labelling in both 21% (A) which was exacerbated under 1% O2 (B). Additionally, a significant 
increase in citrate M+3 labelling was observed compared to the siNT control in both 
conditions. (C) Schematic showing the metabolic fate of pyruvate derived from [U-13C6]-
glucose into the TCA cycle. Pyruvate oxidation via PDH (red pathway) results in M+2 citrate 
from [U-13C6]-glucose. Under certain conditions such as hypoxia, PDH activity can be 
reduced and an increase in PC activity is (blue pathway) observed which results in the 
carboxylation of pyruvate to OAA subsequently producing M+3 citrate. (D) The difference in 
the production of M+3 over M+2 labelled citrate can therefore imply the differential activity of 
these enzymes. It is clear that despite at a lower level than PDH activity, a switch from PDH 
to PC activity occurs upon knockdown of YAP, TAZ and YAP/TAZ which is significantly 
increased under hypoxic conditions when compared to the siNT control. Abbreviations: PC, 
pyruvate carboxylase; PDH, pyruvate dehydrogenase; OAA, oxaloacetate. Data obtained 
was from 5 technical replicates. Error bars represent ± S.D. Significance determined using 
two-way ANOVA with Tukey post-hoc test. *** p<0.001. 
 
 
3.2.6.3. Knockdown of YAP/TAZ compromises oxidative glutamine metabolism 
Cancer cells, in the absence of adequate glucose oxidation, are known to switch their 
reliance to glutamine as a carbon and nitrogen source to fuel nucleotide biosynthesis as 
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well as supply carbons into the TCA cycle to support the functioning of the ETC in the 
production of ATP224. Glutamine is known to be avidly consumed under hypoxic 
conditions to sustain rapid cell proliferation as well as becoming the major carbon source 
for fatty acid synthesis, as hypoxic cells shift their metabolism away from glucose 
oxidation through the TCA cycle towards increased glycolytic metabolism197,198. 
 
Since glutamine metabolism is crucial for rapidly proliferating cells and the oncogenic 
relationship between YAP/TAZ and malignant cell growth and survival, glutamine 
metabolism was investigated upon knockdown of YAP, TAZ and YAP/TAZ in U343 
glioma cells under both normoxic and hypoxic conditions using [U-13C5]-glutamine. 
Following cellular uptake, glutamine can be deaminated to glutamate via GLS, which can 
subsequently be converted to α-KG by either GLDH or via transamination through 
transaminase activity (Figure 3.18A). Metabolic tracer analysis showed that upon 
knockdown of YAP/TAZ (Figure 3.18B), 13C incorporation from [U-13C5]-glutamine into 
both glutamate and α-KG was significantly reduced under normoxic conditions (Figure 
3.18C, E) and was seen to be amplified in hypoxia (Figure 3.18D, F), where glutamine 
usage is known to be increased. The ratio of fully labelled M+5 glutamate (Figure 3.18G) 
and α-KG (Figure 3.18H) from M+5 glutamine was significantly increased under hypoxic 
conditions as expected, however knockdown of YAP/TAZ caused a significant reduction 
in both normoxic and hypoxic conditions, with levels in hypoxia similar to those observed 
in normoxia upon knockdown (Figure 3.18G, H). These results fit with the increased 
anaplerosis from glucose through PC activity observed after knockdown of YAP and/or 









Figure 3.18 YAP/TAZ supports glutamine metabolism in glioma cells. (A) Schematic 
outlining the metabolic pathways of [U-13C5]-glutamine. Glutamine-derived α-KG can either 
be subjected to oxidative TCA metabolism (purple pathway) producing M+4 labelled TCA 
cycle intermediates or can undergo reductive carboxylation (green pathway) in conditions 
such as hypoxia, to generate M+5 labelled citrate and M+3 labelled TCA intermediates. 
Additionally a second round of the oxidative TCA cycle (light purple) can produce M+3 
labelled α-KG (highlighted in blue) which generates M+2 labelled TCA metabolites and M+2 
labelled citrate (outlined in red). (B) Successful knockdown of YAP, TAZ and YAP/TAZ was 
confirmed in U343 cells from [U-13C5]-glutamine tracing experiments. (C) M+5 labelled 
glutamate and α-KG (E) derived from [U-13C5]-glutamine was significantly reduced upon 
knockdown of YAP, TAZ and YAP/TAZ in 21% O2 and was exacerbated in 1% O2 (D and F). 
The ratio of M+5 glutamate (G) and M+5 α-KG (H) from fully labelled glutamine was 
calculated and seen to significantly decrease upon knockdown of YAP/TAZ in both normoxic 
and hypoxic conditions when compared to the siNT control. Additionally, significantly more 
M+5 labelled glutamate and α-KG from M+5 glutamine was observed under 1% O2 which is 
indicative of metabolic changes seen in hypoxia. Abbreviations: α-KG, alpha-ketoglutarate; 
OAA, oxaloacetate; TCA, tricarboxylic acid. Data obtained was from 5 technical replicates. 
Error bars represent ± S.D. Significance determined using two-way ANOVA with Tukey post-
hoc test. ** p<0.01, *** p<0.001. 
 
Glutamine-derived α-KG is either metabolised oxidatively through glutaminolysis, 
supplying carbons into the TCA cycle for the production of anabolic substrates and 
reducing potential to generate ATP, or through reductive carboxylation to produce citrate 
to support de novo lipogenesis, the latter of which may be a major contributor to the 
anabolic drive in hypoxic conditions198. 13C incorporation into citrate can therefore be 
used as evidence for the prevailing metabolic phenotype in a cancer cell. Upon 
knockdown of YAP/TAZ, a significant reduction in the citrate M+4 isotopomer was 
apparent under normoxic conditions, which is indicative of reduced contribution of 
glutamine oxidation through the TCA cycle to the citrate pool (Figure 3.19A). Under 
hypoxic conditions, an increase in M+5 labelling was seen compared to normoxia, 
however was reduced upon knockdown of YAP/TAZ, indicating that reductive 
carboxylation of glutamine was increased in hypoxia but attenuated in YAP/TAZ deficient 
cells (Figure 3.19B). A significant reduction in citrate M+4 labelling was also apparent in 
hypoxia upon YAP/TAZ deficiency, again suggesting that oxidative glutamine metabolism 
was severely compromised. The relative reductive/oxidative glutamine metabolism was 
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calculated using the ratio of M+5 citrate/M+4 citrate, which showed that despite reductive 
and oxidative glutamine metabolism being overall reduced in hypoxia with YAP/TAZ 
knockdown, the relative contribution of reductive glutamine metabolism was increased 
compared to glutamine oxidation under hypoxia (Figure 3.19C, D). These data suggest, 
in agreement with the literature on breast cancer, that YAP/TAZ activity supports 
glutamine oxidation in glioma – in both normoxia and hypoxia. This increased importance 
of YAP/TAZ to support glutaminolysis in hypoxia could be expected to sustain cell 
proliferation under these hostile conditions. Interestingly, knockdown of YAP/TAZ in U87 
and U343 cells (Figure 3.10), significantly reduced cell proliferation in both normoxic and 
hypoxic conditions, supporting this potential association. 
 
Due to the significant reduction in 13C incorporation into glutamate and α-KG from [U-
13C5]-glutamine coupled with attenuated glutamine oxidative and reductive metabolism, it 
was hypothesised that knockdown of YAP/TAZ could potentially interfere with glutamine 
processing such as through impeding glutaminase activity. Thus, GLS1 expression was 
analysed following knockdown of YAP, TAZ and YAP and TAZ together in both U87 
(Figure 3.19E) and U343 (Figure 3.19F) cells. Despite considerable knockdown of these 
proteins, no differences were observed in GLS1 expression suggesting potentially that 
glutamine uptake could be reduced or that glutamine was being diverted elsewhere in 





Figure 3.19 Knockdown of YAP/TAZ significantly increases reductive glutamine 
metabolism in hypoxia. (A) Knockdown of YAP/TAZ significantly decreased M+4 citrate 
from [U-13C5]-glutamine compared to siNT control. Under 1% O2 (B), M+4 labelling was also 
decreased upon siTAZ and siYAP/TAZ however M+5 labelling was seen to increase, albeit at 
a reduced amount upon knockdown of TAZ and YAP/TAZ when compared to the siNT 
control. (C) The ratio of M+5 citrate to M+4 citrate was calculated to determine relative 
reductive glutamine metabolism and was observed to be significantly increased in hypoxic 
conditions compared to normoxic conditions which was further exacerbated upon knockdown 
of YAP/TAZ. (D) Schematic outlining the oxidative (purple) and reductive (green) glutamine 
metabolism including the relevant enzymes in orange. (E) Knockdown of YAP, TAZ and 
YAP/TAZ did not appear to cause any reduction in GLS1 expression in both the U87 and 
U343 cell lines. Abbreviations: α-KG, alpha-ketoglutarate; ACO1/2, aconitase 1/2; GLDH, 
glutamate dehydrogenase; GLS, glutaminase; IDH1/2, isocitrate dehydrogenase 1/2. Data 
obtained was from 5 technical replicates. Error bars represent ± S.D. Significance 




The synthesis of glutamine-derived aspartate, a metabolite shown to be essential for 
tumour growth, was also observed to be affected upon YAP/TAZ knockdown181,182. 
Metabolic analysis showed that 13C incorporation from [U-13C5]-glutamine was 
significantly reduced in normoxic (Figure 3.20A) and hypoxic conditions (Figure 3.20B). 
The aspartate M+4 and M+2 isotopomer was reduced, which corresponds to one and 
two rounds of oxidative glutamine metabolism respectively and corroborates previous 
data suggesting attenuated glutaminolysis upon YAP/TAZ deficiency. Interestingly, the 
M+3 isotopomer, derived from M+5 citrate through reductive carboxylation was also 
reduced suggesting the potential diversion of citrate and/or OAA – the latter of which 
cannot be detected due to very low steady-state levels being maintained in cells. 
Furthermore, the percentage of unlabelled (M+0) aspartate was significantly enhanced 
upon YAP/TAZ knockdown in both normoxia and hypoxia, suggesting an increased 
reliance on other carbon sources for aspartate production. Interestingly, in addition to 
unlabelled sources, a significantly increased carbon contribution from glucose to 
aspartate was observed upon YAP/TAZ knockdown in both normoxia and hypoxia 
(discussed later in Figure 3.22B). Nevertheless, some glutamine is still ultimately 
required to contribute the nitrogen in the amine group for aspartate synthesis via 
transamination of OAA. These observations may suggest that YAP/TAZ could influence 






Figure 3.20 Knockdown of YAP/TAZ compromises oxidative glutamine metabolism. 
Knockdown of YAP/TAZ was seen to significantly decrease M+4 aspartate from [U-13C5]-
glutamine compared to siNT control. Under 1% O2 (B), M+4 labelling was also decreased 
upon siTAZ and siYAP/TAZ when compared to the siNT control. Data obtained was from 5 
technical replicates. Error bars represent ± S.D. Significance determined using two-way 
ANOVA with Tukey post-hoc test. *** p<0.001. 
 
 
3.2.6.4. YAP/TAZ support glutamine-derived proline biosynthesis  
Glutamine is known to have a number of metabolic fates within the cell. In addition to 
amino acid and nucleotide synthesis, the biosynthesis of one of the many glutamine-
derived NEAAs proline is particularly important for subsequent protein synthesis and cell 
proliferation225 (Figure 3.21A). Metabolic tracing analysis showed a significant reduction 
in the percentage 13C incorporation from [U-13C5]-glutamine into M+5 labelled proline in 
both normoxic (Figure 3.21B) and hypoxic (Figure 3.21C) conditions upon knockdown of 
YAP/TAZ. The relative ratio of fully labelled M+5 proline derived from M+5 glutamine was 
calculated and was seen to be significantly reduced upon YAP/TAZ knockdown when 
compared to the siNT control cells (Figure 3.21D). Hypoxia induced an increase in the 
ratio of M+5 proline from M+5 glutamine as a result of the enhanced hypoxic usage of 
glutamine. However with knockdown of both YAP/TAZ, this ratio was reduced to levels 
comparative to that observed in normoxia. This reduction in glutamine-derived proline 
synthesis could therefore suggest less glutamine uptake or the diversion of glutamine 
into other important biosynthetic processes such as nucleotide synthesis upon YAP/TAZ 
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deficiency in U343 cells. Alternatively, the data suggesting increased use of reductive 
glutamine metabolism could indicate that glutamine uptake remains the same but its use 
is changed. As GLS1 is mainly mitochondrial and did not appear to alter glutamine 
processing in this context upon YAP/TAZ knockdown, it could suggest that there are 
differences in glutamine cellular localisation. 
 
Figure 3.21 YAP/TAZ supports glutamine-derived proline synthesis. (A) Schematic 
outlining fates of glutamine following cellular uptake through glutamine transporter SLC1A5 
including proline biosynthesis (purple pathway). Relevant enzymes are presented in orange. 
(B) siTAZ and siYAP/TAZ significantly reduced M+5 proline in 21% O2 and was exacerbated 
under hypoxic (1% O2) conditions (C). (D) Proline biosynthesis from M+5 glutamine was 
significantly increased in hypoxia in the siNT control cells. Interestingly, YAP/TAZ induced a 
significant reduction in glutamine-derived proline compared to the control. Additionally, 
despite hypoxia-induced increases in proline synthesis, no increase was seen in hypoxia 
upon siYAP/TAZ when compared to normoxia. Abbreviations: GLS, glutaminase; GSH, 
glutathione; P5C, pyrroline-5-carboxylate synthetase; P5CS, Delta-1-pyrroline-5-carboxylate 
synthetase; PYCR1/2, pyrroline-5-carboxylate reductase 1/2; SLC1A5, solute carrier family 1 
member 5. Data obtained was from 5 technical replicates. Error bars represent ± S.D. 
Significance determined using two-way ANOVA with Tukey post-hoc test. *** p<0.001. 
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3.2.6.5. Total carbon contribution from glutamine into TCA metabolites is 
significantly attenuated upon YAP/TAZ knockdown  
The percentage of 13C enrichment from both [U-13C6]-glucose and [U-13C5]-glutamine into 
various TCA metabolites and amino acids was calculated to investigate the overall effect 
of knockdown of YAP/TAZ on central carbon metabolism (Figure 3.22). It is clear, that 
the percentage enrichment of glutamine into each metabolite was significantly reduced 
upon YAP/TAZ knockdown when compared to the siNT in both normoxia and hypoxia. 
Under hypoxia, 13C enrichment from glutamine was increased consistent with the 
knowledge that glutamine is increasingly relied upon as a carbon source in hypoxic 
conditions. Interestingly, this increase was not apparent with YAP/TAZ deficiency and 
percentage enrichment into each metabolite remained similar to that of normoxia. 
 
Glucose utilisation was consequently altered upon YAP/TAZ knockdown, with 13C 
enrichment from glucose being increased in all metabolites except citrate (Figure 3.22). 
This effect was more prominent under hypoxic conditions where glucose contribution 
was reduced in the hypoxic control cells, corroborating reduced glucose oxidation under 
hypoxia. Knockdown of YAP/TAZ however, was able to retain levels of 13C incorporation 
from glucose in hypoxia similar to that of control cells in normoxia. 
 
Finally, it was implied that 13C contribution from other carbon sources was increased 
upon YAP/TAZ knockdown, particularly under hypoxic conditions, which suggests that 
while 13C enrichment from glucose is increased with YAP/TAZ deficiency, it is not enough 
to compensate for the significant loss of 13C contribution from glutamine and so carbon 
must be incorporated from other sources such as lipids, breakdown of other amino acids 






Figure 3.22 Knockdown of YAP/TAZ significantly alters glutamine contribution into 
TCA metabolites. The total contribution of 13C from glucose and glutamine was calculated 
for various metabolites; citrate (A), aspartate (B), malate (C), fumarate (D), α-KG (E), 
glutamate (F) and proline (G). The remaining percentage not derived from glucose or 
glutamine was deemed to be from other contributors such as from lipids or breakdown of 
amino acids. For all metabolites analysed there is a significantly reduced contribution from 
13C glutamine upon knockdown of YAP/TAZ when compared to the siNT control and is 
amplified in hypoxic conditions where the use of glutamine as a carbon source is preferred. 
To account for differences in glutamine use, the percentage 13C contribution from glucose is 
increased upon YAP/TAZ knockdown, which is more apparent under hypoxic conditions. 
Furthermore, carbon contribution from other carbon sources is also increased upon YAP/TAZ 
knockdown to account for the significant reduction in glutamine usage. Data obtained was 
from 5 technical replicates. Error bars represent ± S.D. Significance determined using two-





Hypoxia is a major hallmark of solid tumours stemming from the rapid proliferation of 
malignant cells avidly exhausting nutrients and oxygen from the surrounding 
vasculature71. Pro-angiogenic factors such as VEGF are consequently upregulated, 
stimulating neovascularisation of the tumour. However, these newer vessels are often 
inefficient and ‘leaky’, subsequently leading to large areas of hypoxia throughout the 
tumour mass72,226.The hypoxic tumour areas demonstrate increased treatment resistance 
and overall poorer patient survival due to the increased invasion and metastatic potential 
incurred as a biological response to hypoxia97. It is therefore crucial to investigate the 
underlying mechanisms of how hypoxia can influence tumour growth through aberrant 
regulation of various signalling pathways, as well as how hypoxia and the tumour 
microenvironment can be exploited therapeutically to enhance patient survival. 
 
3.3.1. Glioma lines, U87 and U343, exhibit differential growth sensitivity to 
pathophysiological hypoxic conditions 
Gliomas, as previously discussed, are particularly hypoxic tumours with a median pO2 of 
a 7.4 mmHg (1% O2), with some high-grade tumours shown to contain areas under 2.5 
mmHg (0.3% O2), as opposed to normal brain tissue which has a pO2 of around 35 
mmHg (4.6% O2)96,97. Since in vitro cell culture is generally conducted at the 
supraphysiological oxygen concentration of 21% O2, in vitro glioma cell lines were 
cultured at both 1% and 0.3% O2 to investigate whether cell proliferation and/or survival 
was affected upon exposure to oxygen concentrations similar to that observed in vivo. 
Results showed that glioma cells were still viable and able to proliferate following chronic 
exposure to both 1% and 0.3% O2, although hypoxia induced a significant reduction in 
U87 proliferation rate after 48 hours when compared to normoxia (21% O2; Figure 3.1), 
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which is in agreement with previous studies227. Interestingly, U343 cell proliferation was 
completely unaffected when cells were cultured under 1% and 0.3% O2 over 72 hours, 
highlighting the heterogeneous nature of the different glioma subtypes. According to the 
Verhaak classification system of gliomas, the U343 cell line is believed to be 
representative of the classical subgroup as it exhibits amplified expression of EGFR 
(Figure 2.1A), which is present in 40-50% of GBM24,28. Increased EGFR has been 
previously shown to confer a significant survival advantage under hypoxic conditions in 
many cancers such as breast, pancreas and NSCLC, with amplified EGFR signalling 
enhancing hypoxic induction of pathways promoting cell survival228. Hence, this growth 
advantage exhibited by the U343 cells under hypoxic conditions could be mediated 
through enhanced EGFR signalling and should thereby be investigated in further detail. 
Due to the difference in hypoxic growth between the two cell lines, future experiments 
were thereby normalised to the control for each oxygen tension, unless otherwise stated, 
to account for any reduced growth rate under hypoxia. 
 
3.3.2. Hypoxia upregulates YAP/TAZ expression and transcriptional co-
activator activity in glioma cell lines 
Hypoxia has been previously shown to increase YAP/TAZ signalling in HCC135, 
breast131,133 and ovarian229 cancer however as the activity and possibly control of 
YAP/TAZ is tissue-dependent, it is important to define whether a mechanistic link exists 
in gliomas. Glioma cells were therefore exposed to hypoxia (1% O2) for 8 hours after 
which YAP1, and YAP1-target genes, CYR61, CTGF and BBC3, were assessed via 
qPCR. Hypoxia induced a significant upregulation of YAP1 mRNA expression in U87, 
U343 and HOG IDH1 WT cell lines, which coincided with an increase in YAP1-target 
genes (Figure 3.2 and 3.3). However, not all target genes were significantly upregulated 
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across all the glioma cell lines suggesting that a lower oxygen tension or longer period of 
hypoxia might be necessary to induce a significant difference in gene expression when 
compared to normoxic conditions. Interestingly, hypoxia was seen to induce both pro-
proliferative (CYR61 and CTGF) and pro-apoptotic (BBC3) gene expression highlighting 
the complexity of YAP transcriptional regulation since it can bind with different 
transcription factor binding partners to transcribe different set of genes depending on the 
cell context143. In this circumstance, although BBC3 gene expression is increased 
potentially acting to induce cell death in response to a hostile environment such as 
hypoxia, other pro-survival mechanisms could be activated to counteract this increased 
expression since cell death was not induced under acute hypoxia. Interestingly, HOG 
IDH1 MUT cells were seen to significantly upregulate BBC3 expression in both normoxia 
and hypoxia when compared to HOG IDH1 WT cells (Figure 3.3L), which could 
potentially, despite an initial growth advantage (Figure 4.5), contribute towards the 
reduced cell proliferation observed upon R132H IDH1 mutation as previously reported230. 
 
Since enhanced gene transcription does not always necessitate increased protein 
expression, YAP1, as well as its inactive phosphorylated form (p-YAP), protein 
expression were analysed periodically over 24 hours. Interestingly, 1% O2 induced a 
minimal increase in YAP1 protein levels, with even a slight decrease evident in the HOG 
IDH1 MUT cell line (Figure 3.6 and 3.7). This apparent difference between mRNA and 
protein expression could be due to differential post-transcriptional processing of YAP1 
mRNA, differences in RNA stability or even protein translation. Importantly, there are 
data to show that the 2-HG produced by mutant IDH1 can alter RNA processing and 
translation through the inhibition of the 2-OG-dependent dioxygenases that play a 
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significant role in these processes, suggesting a potential reason for this differential 
protein expression231,232. 
 
Interestingly, protein expression of YAP paralog TAZ, was dramatically increased 
following exposure to 1% O2 (Figure 3.8B), suggesting potential differential regulation 
and sensitivity to hypoxia. This concept has been previously suggested however due to 
limited evidence, further investigation is crucial to understand the complex relationship 
between the two co-activators229. To investigate whether a lower oxygen tension could 
evoke a stronger YAP protein response, p-YAP and YAP1 expression were analysed at 
a lower oxygen tension of 0.3% O2, which is comparable to some in vivo oxygen 
measurements taken from GBM96,97. This more severe oxygen environment was 
observed to elicit a stronger response across the glioma cell lines – with the exception of 
the U343 cells – with YAP expression significantly increased compared to the normoxic 
control. This strongly upregulated YAP1 response under severe hypoxia (≤2.5 mmHg) 
could therefore confer a survival advantage under such extreme environments where 
cells struggle to survive. Hence, it could also explain why the highest YAP1 expression is 
found in grade IV gliomas, which are generally the most hypoxic96. The smaller increase 
in YAP1 expression after hypoxia in the U343 cells may be explained by their 
insensitivity to hypoxia-induced growth restriction (Figure 3.1B) – perhaps through a pre-
existing enhanced basal YAP1 expression. 
 
Increased YAP1 expression does not necessarily indicate increased transcriptional co-
activation activity since YAP nuclear localisation is required for this role, and is controlled 
by its phosphorylation. Therefore, the ratio of cytosolically-retained p-YAP to total YAP 
expression was calculated, as well as analysis of the expression of downstream YAP1-
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target, CTGF (Figures 3.6-3.8). A reduction was apparent in the p-YAP/YAP1 ratio in 
both the U87 and HOG IDH1 WT cell lines indicating that less of the YAP pool was 
inactive, although this alteration was more ambiguous in the U343 and HOG IDH1 MUT 
cell lines. CTGF expression on the other hand, was seen to increase across all glioma 
cell lines when exposed to both 1% and 0.3% O2, implying increased YAP1 
transactivational activity. To investigate whether hypoxia induced YAP1 expression in a 
more physiologically relevant model, p-YAP and YAP1 were also assessed in two novel 
cell lines which were derived from a single GBM patient biopsy. Interestingly, these two 
lines, despite originating from the same tumour specimen, had exhibited differential 
sensitivity to chemoradiation treatment. T1 cells were derived from an area of tumour 
recurrence that had progressed significantly post-treatment, and thus was believed to be 
therapy-resistant, whereas T2 cells were harvested from an area of the tumour which 
had not progressed post-treatment, and was therefore considered therapy-responsive. 
Initial investigations showed T1 cells express a higher level of both p-YAP and YAP1 
protein compared to the T2 cells, suggesting that YAP1 signalling was amplified (Figure 
3.8C). This amplified YAP1 expression could potentially contribute to the therapy-
resistance exhibited by these cells, corroborating previous reports of YAP-induced 
chemoresistance135,233. However, this hypothesis would have to be appropriately tested 
in further experiments in vitro. Immediately following tissue dissociation, cells from the T1 
and T2 tumour regions were transferred to hypoxia where they were subsequently 
cultured. YAP1 expression was characterised under these conditions and was seen to 
increase in both T1 and T2 cell lines, although the largest increase was seen in the T2 
cells (Figure 3.8C-E), most likely due to the higher basal expression already observed in 




Finally, YAP1 expression was characterised in the U87 and U343 cell lines using 
immunocytochemistry to directly visualise whether hypoxia increased YAP1 nuclear 
localisation. Nuclear YAP1 fluorescence was investigated following cell exposure to 1% 
O2 for 4 and 8 hours, and was seen to be significantly increased in U87 cells when 
compared to the normoxic control suggesting potential increased YAP1 co-activator 
activity (Figure 3.9B). Although YAP1 nuclear localisation was seen to be increased 
following 4 hour exposure in the U343 cells, interestingly YAP1 localisation was similar to 
that of normoxic cells after 8 hours (Figure 3.9C). As previously discussed, U343 cells 
have shown a lesser YAP1 response to hypoxia potentially due to their high basal YAP1 
expression, which could be a result of their EGFR amplification. He et al., have 
previously shown that EGFR signalling can interact with the Hippo pathway to upregulate 
the proliferation of cervical cancer cells, specifically through transforming growth factor-α 
(TGF-α) and AREG, acting through EGFR, to increase YAP transcriptional activity234. 
Furthermore, they describe that this signalling is further amplified through an 
autocrine/paracrine feedback loop, in which enhanced YAP transcriptional activity 
causes a subsequent increase in TGF-α, AREG and EGFR, therefore perpetuating 
tumour progression234. This EGFR enhanced YAP signalling could therefore provide 
some explanation as to why hypoxia elicits a weaker YAP response in this glioma cell 
line compared to the others. Together, these data suggest that hypoxia can influence 
YAP1’s activity as a transcriptional co-activator as well increasing its expression in 
glioma cells, supporting previous investigations in other cancers demonstrating hypoxia-
enhanced YAP signalling131,135. To further validate these observations in glioma, 
expression of additional YAP1-targets should be investigated as well showing increased 




3.3.3. Glioma cell proliferation is significantly reduced upon YAP/TAZ 
knockdown 
As YAP amplification and increased transcriptional co-activation have been associated 
with oncogenesis, it could therefore be suggested that suppression of YAP and its 
paralog TAZ expression and/or activity in malignant cells could be an attractive 
therapeutic option, particularly in hypoxia where cells are highly therapy-resistant. 
 
This hypothesis was consequently investigated through knockdown of YAP, TAZ or both 
using siRNA in both the U87 and U343 cell lines (Figure 3.10). When cell proliferation 
was assessed 72 hours post-transfection, it was found to be significantly reduced in both 
cell lines, corroborating previous data demonstrating attenuated cell proliferation of both 
HCC and gastric cancer cell lines upon YAP silencing235,236. Knockdown of YAP 
individually however, did not induce a significant growth reduction in the U343 glioma 
cells, potentially due to its association with EGFR signalling, although it has been 
reported that TAZ can mitigate similar enhanced EGFR signalling237. Knockdown of YAP 
and TAZ together was seen to have the most effect on cell growth in both cell lines, 
suggesting a degree of redundancy between the two proteins. It appears that knockdown 
of YAP could induce TAZ expression resulting in a reduced effect of siYAP. Conversely, 
knockdown of TAZ may not influence YAP expression since knockdown of TAZ induced 
a greater reduction in cell proliferation than when YAP was silenced individually (Figure 
3.10C-E). This hypothesis is supported by previous research which showed that 
silencing of YAP through shRNA resulted in a concomitant increase in TAZ expression 
and that YAP overexpression significantly decreased TAZ abundance238. Furthermore, 
the authors showed that this was specific to YAP with TAZ knockdown or overexpression 
inducing no changes in YAP expression. This further suggests that in addition to the 
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regulatory mechanisms shared by both proteins, TAZ expression is also modulated 
directly through YAP but not the other way around238. These findings could also 
potentially explain why YAP knockdown has an attenuated effect on reducing cell growth 
in the U343 cell lines since increased TAZ expression can also perpetuate EGFR 
signalling. 
 
Hypoxia was found to have a minimal additional effect on the reduced proliferation seen 
upon YAP/TAZ knockdown in the U343 cells but did slightly enhance the effect of the 
knockdown in the U87 cells (Figure 3.10C, D). This again could potentially be due to the 
reduced effect hypoxia has on the growth of U343 cells. Although knockdown 
significantly attenuated glioma cell proliferation, the reduction was moderate suggesting 
that a longer knockdown period is probably required in these cell lines to induce a 
biologically significant effect.  
 
Overall, knockdown of YAP, TAZ and YAP and TAZ reduced the proliferation rate of 
glioma cells, corroborating previous research in other cancers. Knockdown of YAP/TAZ 
expression could therefore represent a therapeutic target to reduce tumour proliferation, 
although these data suggest that targeting of both YAP and TAZ should be considered 
for maximum therapeutic benefit. 
 
3.3.4. YAP/TAZ knockdown induces significant alterations in glucose and 
glutamine metabolism 
It has long been established that cancer cells rewire their metabolism to fuel the 
increased energetic demand and generation of new biomass required to sustain the 
uncontrolled proliferation exhibited by tumours239. A key hallmark of cancer metabolism 
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first described by Otto Warburg in the 1920’s, is the enigma that is aerobic glycolysis; 
where in the presence of oxygen, cells preferentially metabolise glucose through 
glycolysis to lactate, despite being a considerably less efficient pathway at producing 
ATP169,170. To this day, the purpose of this remains unclear however whilst endeavouring 
to understand this phenomenon, researchers have uncovered the full complexity of 
cancer metabolism and focus has now shifted towards cancer-induced metabolism of 
other nutrients and amino acids such as glutamine, serine, glycine and acetate in 
addition to glucose240. 
 
YAP and its paralog TAZ are known to play a central role in the tumorigenesis of various 
cancers, although it remains to be elucidated as to precisely how these signalling factors 
interact with metabolism – whether they directly alter metabolic enzyme expression to 
support a proliferative driver, or whether the changes in metabolism that have been 
previously reported are a downstream effect of the phenotypic changes directed by 
YAP/TAZ. In the last few years, aerobic glycolysis has been identified to regulate 
YAP/TAZ transcriptional activity through PFK1187. PFK1, a crucial enzyme in glycolysis, 
can interact with TEAD transcription factors to stabilise their binding to YAP/TAZ and 
thus, under conditions when cells are actively consuming glucose such as cancer, 
increase transcription of pro-proliferative target genes to support tumour growth. With 
this in mind, it was therefore hypothesised that YAP/TAZ could potentially associate with 
other metabolic and biosynthetic pathways in glioma to support tumour growth, in 
particular under hypoxic conditions, where YAP/TAZ activity is increased and metabolism 




3.3.4.1. YAP/TAZ act to support normoxic de novo serine synthesis in glioma 
Aberrant serine and glycine metabolism is indispensable for tumorigenesis, with hyper-
activated de novo serine synthesis providing increased precursors for protein and nucleic 
acids synthesis, in addition to modulating cellular antioxidant capacity to promote tumour 
survival221. Conversion of serine to glycine is a major aspect of serine metabolism, and 
through the decarboxylation of serine, supplies carbon units for one-carbon metabolism 
which is essential for biosynthesis of proteins, nucleic acids and lipids as well as for DNA 
and histone methylation223,241. The use of metabolic tracers to investigate metabolism 
permit analysis of the changes induced in specific metabolic pathways (such as 13C-
glucose to study glycolysis) in different experimental conditions. After knockdown of 
YAP/TAZ, [U-13C6]-glucose labelling of cellular metabolites indicated that de novo serine 
synthesis was reduced and the large majority of serine was taken up by extracellular 
sources (Figure 3.11C). Interestingly in hypoxic conditions, 13C incorporation into serine 
from glucose was significantly reduced across all conditions, which was unexpected 
since it has been documented that HIF-1 mediates increased flux through the SSP by 
inducing expression of SSP enzymes, PHGDH (phosphoglycerate dehydrogenase), 
PSAT1 (phosphoserine aminotransferase) and PSPH (phosphoserine 
phosphatase)242,243. One of the benefits of shunting 3-PG towards the SSP in hypoxia is 
to ultimately increase anti-oxidant capacity through the production of NADPH and GSH 
to subsequently combat increased hypoxia-induced ROS production243. A DCFDA assay 
could therefore be used to measure ROS levels following knockdown of YAP/TAZ to 
investigate whether ROS are increased as a result of reduced de novo serine synthesis. 
Additionally, the reduced GSH to oxidised glutathione (GSSG) could be biochemically 
quantified to assess any alterations in redox homeostasis and oxidative stress as a result 
of YAP/TAZ knockdown. 
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Intriguingly, the M2 isoform of pyruvate kinase (PKM2) may play a role in the regulation 
of serine synthesis in U343 cells exposed to hypoxia. PKM2, known to be upregulated in 
cancer, catalyses the last step of glycolysis, producing pyruvate and ATP from 
phosphoenolpyruvate (PEP) and ADP (adenine diphosphate)223. Serine is known to 
allosterically activate PKM2, increasing glycolytic glucose consumption in conditions 
when serine is abundant244. However, when serine is depleted PKM2 activity is reduced 
consequently causing accumulation of upstream glycolytic intermediates which are then 
diverted towards use in anabolic pathways such as the SSP, to sustain cell 
proliferation244. Interestingly, EGFR245,246 and HIF-1247 are known interactors of PKM2 
both increasing PKM2 activity to promote aerobic glycolysis which could potentially 
provide an explanation as to why de novo serine synthesis is significantly reduced in 
hypoxia in U343 cells. Further investigations should be therefore be conducted to test 
this hypothesis such as by investigating PKM2 activity as well as conducting metabolic 
tracing analysis following knockdown of YAP/TAZ in other glioma cell lines, such as U87 
and primary GBM lines, to assess whether these metabolic alterations are common to 
glioma or specific to the classical subtype. 
 
Another possible interpretation of the serine/glycine data is that knockdown of YAP/TAZ 
increased serine usage, resulting in less being detected. Analysis showed that serine to 
glycine conversion was undetectable with no serine-derived glycine observed under both 
normoxic and hypoxic conditions (Figure 3.12). Together, these data could suggest 
increased flux through serine and glycine to shuttle more carbons into one-carbon 
metabolism or a diversion from this biosynthetic pathway, particularly under hypoxic 




Nonetheless, it has recently been observed that YAP/TAZ knockdown disrupted de novo 
serine synthesis in breast cancer cells through reducing both the mRNA and protein 
expression of one of the enzymes in the SSP, PSAT1, which converts 3-
phosphohydroxypyruvate (3-PHP) into 3-phosphoserine (3-PS) in a transamination 
reaction that uses glutamate-derived nitrogen and produces α-KG222,248. Attenuated 
PSAT1 activity reduces both production of glutamate-derived α-KG required for 
anaplerosis, as well as decreasing one-carbon metabolism as a consequence of reduced 
serine and glycine synthesis. Together, this overall reduction could therefore contribute 
towards the reduced cell proliferation observed in these cells upon knockdown of 
YAP/TAZ (Figure 3.10). This investigation therefore provides evidence to suggest that 
YAP/TAZ actively support de novo serine synthesis in gliomas and since it has been 
shown that serine is essential for tumour growth249,250, it could provide another benefit of 
attenuating YAP/TAZ activity in these tumours. To further support this hypothesis, 
enzyme expression of the SSP pathway should be checked upon YAP/TAZ knockdown 
in these cells. 
 
3.3.4.2. Pyruvate metabolism is altered in YAP/TAZ deficient cells 
Pyruvate is a critical metabolic node driving several crucial biosynthetic pathways as well 
as being one of the main entry points into the TCA cycle179. Metabolic tracing analysis 
showed that the percentage of 13C incorporation into pyruvate from [U-13C6]-glucose was 
significantly increased upon YAP/TAZ knockdown consistent with increased glycolysis, 
which was further enhanced under hypoxic conditions (Figure 3.13). Unlabelled sources 
of pyruvate were also decreased suggesting that YAP/TAZ knockdown caused the cells 
to increase their reliance on glucose as a source for pyruvate. As previously discussed, 
Enzo et al., showed the ability of aerobic glycolysis to regulate YAP/TAZ transactivational 
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activity, with increased glycolysis amplifying YAP/TAZ pro-tumorigenic function through 
interaction with TEAD and PFK1187. Since labelling into pyruvate was increased upon 
YAP/TAZ knockdown, it therefore suggests that despite glycolysis regulating YAP/TAZ 
activity, glycolysis itself was not attenuated when YAP and TAZ activity was reduced. 
 
Aerobic glycolysis is a hallmark of cancer metabolism, increasing pyruvate conversion to 
lactate through LDH coupled with the oxidation of NADH to NAD+ that can be 
subsequently recycled by GAPDH to maintain cellular glycolytic flux179. Glycolysis can be 
further amplified under hypoxic conditions, substantially increasing lactate production to 
guarantee continued glycolytic flux for ATP production as well as diverting carbon entry 
into the TCA cycle thus reducing ROS production and oxidative damage179,239. As 
expected, metabolic tracer analysis showed an increased percentage 13C incorporation 
into lactate from [U-13C6]-glucose when cells were exposed to hypoxia indicating 
increased aerobic glycolysis (Figure 3.14C). Intriguingly, the ratio of lactate derived from 
pyruvate was significantly reduced upon YAP/TAZ knockdown in hypoxic conditions 
suggesting potential increased lactate export out of the cell through MCTs and therefore 
less incorporation detected (Figure 3.14D). Lactate levels in the cell medium could 
therefore be measured to test this hypothesis. Alternatively, it could suggest that LDH 
activity was impaired upon YAP/TAZ knockdown. YAP/TAZ depletion has previously 
been shown to decrease the lactate/pyruvate ratio by decreasing LDHA expression, 
providing evidence that YAP/TAZ influences lactate production over exportation190. 
Upregulated LDHA expression and increased lactate production has been shown to be 
crucial for tumour growth and survival and therefore promoting LDHA expression and 
activity could be another approach that YAP/TAZ exploit to enhance tumour growth179,251. 
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Knockdown of YAP/TAZ induced a significant decrease in 13C incorporation into lactate 
and alanine from glucose suggesting that pyruvate was being preferentially shunted 
towards the TCA cycle (Figure 3.14 and 3.15). As previously described, once pyruvate is 
transported into the mitochondria, it can either undergo oxidative decarboxylation by 
PDH to acetyl CoA or carboxylation via PC to form OAA. Metabolic tracing analysis 
showed that although PDH activity was predominant, PC activity was significantly 
increased upon YAP/TAZ knockdown (Figure 3.17). As expected, hypoxia significantly 
attenuated PC activity due to hypoxia inducing reduced carbon entry into the TCA cycle 
in order to minimise ROS production. What was intriguing however was that cells were 
able to sustain PC activity in hypoxia to levels comparable to that of normoxia upon 
YAP/TAZ knockdown (Figure 3.17D). This therefore suggests that cells sustained PC 
activity regardless of oxygen presence. Previous research has shown that if LDHA 
activity is reduced, cancer cells revert to oxidative phosphorylation252, which could 
explain the increased dependency on glucose as a carbon source upon YAP/TAZ 
knockdown when analysing the total 13C contribution to TCA intermediates (Figure 3.22). 
Additionally, PDH activity is known to be reduced under hypoxia due to HIF-1-mediated 
upregulation of PDK1, which phosphorylates and inactivates the PDH complex195,243. 
Inactivation of PDH was induced upon YAP/TAZ knockdown in hypoxia, implied through 
significantly decreased citrate M+2 labelling, suggesting the relative increase in PC 
activity could be to continue using pyruvate for anaplerosis. However, this also suggests 
an alternative source of acetyl CoA is required in these conditions – the only sources 





3.3.4.3. YAP/TAZ support oxidative glutamine metabolism 
Increased glycolysis in cancer – either aerobic, or when oxygen availability is limiting – is 
inefficient in terms of both energy production (per carbon used) and generation of 
anabolic precursors. Alternative pathways are therefore relied upon to compensate and 
sustain tumour proliferation. Glutamine is the most abundant amino acid in plasma, and 
tumour cells are known to consume it at much greater rate than any other amino acid, 
with some tumour cells believed to be ‘glutamine-addicted’253. Glutamine is therefore 
used as an alternative carbon source for the TCA cycle and has been shown to be 
essential for de novo lipogenesis in these conditions198. 
 
Metabolic tracer analysis showed knockdown of YAP/TAZ to induce a significant 
reduction in glutamine-derived glutamate and α-KG when cells were labelled with [U-
13C5]-glutamine (Figure 3.18). As expected, hypoxia significantly increased the 
percentage incorporation of 13C into both glutamate and α-KG indicating their increased 
synthesis from glutamine under hypoxic conditions. However, this was not the case upon 
YAP/TAZ knockdown, with a significant reduction observed. Relative carbon 
incorporation from glutamine into glutamate and α-KG was the same in both normoxia 
and hypoxia upon knockdown of both YAP and TAZ suggesting that oxygen availability 
was an independent factor (Figure 3.18G, H). This therefore suggests a potential 
interference in glutamine conversion to glutamate via glutaminases and/or through 
transamination/dehydrogenation of glutamate to α-KG or possibly even differences in the 
cellular localisation of glutamine. 
 
A-KG can be used oxidatively through glutaminolysis, replenishing metabolic 
intermediates through the TCA cycle to ultimately produce ATP. Conversely, α-KG can 
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undergo reductive carboxylation to produce citrate, which has been previously described 
as the major pathway for citrate production in hypoxic cells, to generate acetyl CoA for 
fatty acid synthesis198. Metabolic tracer analysis in this investigation corroborated these 
findings, as cells under hypoxia significantly increased M+5 labelled citrate, which is 
derived through reductive carboxylation (Figure 3.19). The data suggest that glutamine 
metabolism was severely affected upon YAP/TAZ knockdown as glutaminolysis was 
significantly reduced in both normoxia and hypoxia, implied through reduced M+4 citrate 
labelling, as well as reduced reductive carboxylation under hypoxic conditions (Figure 
3.19). Interestingly, despite significant impairment in both pathways upon YAP/TAZ 
knockdown, cells were observed to likely switch to reductive glutamine metabolism as 
reductive carboxylation was significantly increased relative to oxidative glutamine 
metabolism in hypoxia (Figure 3.19C). 
 
Since both oxidative and reductive glutamine metabolism was attenuated upon YAP/TAZ 
knockdown, it led to the idea that the cell’s ability to utilise glutamine efficiently was 
hindered and so expression of GLS1, which mediates glutamine to glutamate conversion 
and is the rate-limiting enzyme for glutamine use, was assessed (Figure 3.19E, F). 
Surprisingly, no discernible differences in GLS1 expression were observed upon 
YAP/TAZ knockdown which was in contrast with two recent studies which both showed 
YAP/TAZ knockdown to suppress GLS1 expression190,191. However, these studies were 
conducted in pulmonary hypertension and liver fibrosis models and so there could be 
additional contributing factors in the context of cancer since GLS1 expression has been 




As previously discussed, Yang et al., showed that YAP/TAZ not only influence glutamine-
utilising transaminase PSAT1, but also the glutamate-oxaloacetate transaminase GOT1 
(also known as aspartate aminotransferase), which transfers nitrogen from glutamate to 
OAA to produce both aspartate and α-KG186,248. This finding could provide evidence to 
support why carbon contribution from glutamine into α-KG was significantly reduced 
upon YAP/TAZ knockdown since Yang et al., also showed a positive association 
between YAP/TAZ and GOT1 and a negative correlation with GLDH, implying that 
YAP/TAZ act to promote transamination as opposed to oxidative deamination of 
glutamate to produce α-KG248. Knockdown of YAP/TAZ suppressing GOT1 expression 
could therefore also suggest why glutamine-derived carbon incorporation into aspartate 
was significantly reduced since the majority of carbon used for de novo aspartate 
synthesis is supplied by anaplerotic glutamine256. Furthermore, Garcia-Bermudez et 
al.,182 and Sullivan et al.,181 have both recently shown aspartate to be a limiting 
metabolite for tumour growth. Aspartate has poor cell membrane permeability and so 
cells generally rely on de novo synthesis from glutamine176,181. This could also explain 
the increasing reliance of U343 cells on carbon from glucose and other unlabelled 
sources to maintain aspartate production when glutamine-derived aspartate was reduced 
(Figure 3.22B). Cell proliferation was significantly reduced upon YAP/TAZ knockdown 
and so absolute aspartate levels could be measured to investigate whether YAP/TAZ 
knockdown influenced total aspartate synthesis, which could hence limit tumour cell 
proliferation. Furthermore, α-KG or aspartate could be supplemented to the cells to see 
whether exogenous α-KG or aspartate would restore oxidative metabolism and rescue 




Like aspartate, proline is an amino acid important for tumour cell proliferation and 
metastasis, which can be derived from glutamine225. Interestingly, YAP/TAZ knockdown 
induced a significant reduction in glutamine-derived proline, which was exacerbated 
under hypoxic conditions suggesting that YAP/TAZ could also influence enzymes which 
mediate proline biosynthesis such as delta-1-pyrroline-5-carboxylate synthetase (P5CS 
encoded by ALDH18A1) or pyrroline-5-carboxylate reductase 1/2 (PYCR1/2; Figure 
3.21D). Conversely, it could also suggest that glutamine may have been diverted 
towards nucleotide and amino acid synthesis in an attempt to compensate for reduced 
oxidative metabolism and therefore incorporating less 13C from glutamine into proline. On 
the other hand, a reduction in carbon incorporation from glutamine into proline, as well as 
glutamate and α-KG, could ultimately suggest that glutamine uptake could be attenuated 
upon YAP/TAZ knockdown. Further experiments such as measuring glutamine 
consumption and excretion rate and the expression of the glutamine transporter SLC1A5 
as well as investigating label incorporation into nucleotides could help to delineate the 
metabolic fate of glutamine upon YAP/TAZ knockdown. 
 
Calculation of the total carbon contribution from both [U-13C6]-glucose and [U-13C5]-
glutamine into various metabolites showed a significant reduction in glutamine-derived 
carbon into every metabolite upon YAP/TAZ knockdown corroborating the previous 
results highlighting a potential role for YAP/TAZ in glutamine metabolism (Figure 3.22). 
This reduction in glutamine contribution was amplified under hypoxia; a condition in 
which reliance on glutamine metabolism for anaplerosis is known to increase. 
Interestingly, 13C enrichment from glutamine into various metabolites in hypoxia was at a 
similar level to that of normoxia with YAP/TAZ knockdown. To compensate for the loss in 
glutamate-derived carbon upon knockdown, 13C enrichment from glucose was seen to 
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increase as well as from unlabelled carbon sources, most likely to be scavenged from 
lipids, breakdown of amino acids, increased rates of autophagy or in the case of proline, 
other precursors such as ornithine257. Interestingly, it has also recently been shown in 
rapidly proliferating mammalian cells, that amino acids are the major contributors of 
carbon to cell mass and surprisingly not glucose or glutamine which demonstrate the 
highest consumption rates176. These data in this study therefore indicate that long-term 
YAP/TAZ inhibition could potentially result in huge metabolic complications for the cell 
and consequently reduced tumour survival as cells would eventually run out of 
alternative carbon sources to sustain this inefficient cellular metabolism. 
 
Together, these data highlight the importance of YAP/TAZ in glioma metabolism mainly 
through supporting oxidative glutamine metabolism for anaplerosis and subsequently 
promoting tumour proliferation and survival in hostile environments such as hypoxia. 
Further investigations are required to extensively delineate this relationship, however 
these data provide preliminary evidence to suggest that disrupting YAP/TAZ expression 
and transcriptional co-activator activity, particularly in hypoxia, could be a key target for 
therapeutic development since both pro-survival signalling and metabolism can be 





The data presented in this chapter established the role of hypoxia-induced regulation of 
YAP/TAZ signalling in gliomas. Hypoxia was seen to amplify YAP/TAZ expression as 
well as increase their activity as transcriptional co-activators across four established 
glioma cell lines and two novel GBM lines. Tumour hypoxia remains incredibly 
challenging in the design of therapeutics since hypoxic cells are generally therapy-
resistant and poorly vascularised, limiting drug perfusion. Hypoxia-induced YAP/TAZ 
signalling may therefore contribute towards to this enhanced chemoresistance and cell 
survival. Thus, targeting YAP/TAZ signalling may be an effective therapeutic opportunity 
to target this highly-resistant hypoxic subset of cells in gliomas. Furthermore, due to the 
central role of YAP/TAZ in aberrant tumour growth, it was questioned whether YAP/TAZ 
signalling could influence glioma metabolism to subsequently support the production of 
biomass required to generate new cells. Interestingly, YAP/TAZ were identified to 
support de novo serine synthesis and potentially one-carbon metabolism which is 
required for nucleotide, lipid and protein synthesis. YAP/TAZ signalling was also seen to 
heavily influence glutamine metabolism, with YAP/TAZ knockdown severely attenuating 
glutaminolysis, which is an interesting finding since glutamine is heavily relied upon in 
hypoxic tumour cells to sustain anabolism for tumour growth. Together, the metabolomic 
data therefore suggest that YAP/TAZ activity plays an important role in sustaining cell 
proliferation both in normoxic, but more importantly hypoxic conditions and is potentially 
critical for supporting the hallmarks of cancer in hypoxia. Further investigations including 
metabolic tracer studies using other labelled carbon sources such as serine, palmitate 
and positionally labelled tracers such as [1,2-13C]-glucose can help fully elucidate this 
complex relationship between cell metabolism and YAP/TAZ in gliomas. Together, these 
data provide an exciting basis highlighting how disrupting YAP/TAZ signalling could be 
 
144 
an attractive therapeutic opportunity for gliomas since targeting this pathway can disrupt 





Assessing the potential of repurposing 





4.1. Introduction  
Gliomas are highly therapy-resistant tumours which have proved extremely challenging 
to treat effectively. Complications in the design of successful therapeutics have arisen 
from a number of hallmarks including their severe hypoxic nature, extensive invasion into 
the surrounding healthy brain as well as widespread genetic heterogeneity101,258,259. 
Despite considerable endeavours, glioma therapies have remained mostly stagnant 
since the development of TMZ in the 1990’s, which remains first-line treatment over 20 
years later260. Surgical and technological advancements have provided a small 
improvement in patient survival, but further significant improvements are desperately 
needed. It is therefore imperative that pathways involved in gliomagenesis, as well as 
those affecting the tumour microenvironment, are identified in the hope to discover 
better, more effective therapies. 
 
As outlined in chapter three, disrupting abnormal YAP activity in malignant cells is of 
significant interest in cancer research and recently Liu-Chittenden et al., identified the 
benzoporphyrin derivative VP to be a potent YAP inhibitor153. VP is a second-generation 
FDA-approved photosensitiser, which in addition to its photochemical properties, has 
shown the ability to inhibit the pro-proliferative YAP-TEAD interaction through selective 
YAP binding153,155. This competitive interaction alters YAP protein confirmation thereby 
abolishing TEAD binding ability and consequently suppresses the oncogenic activity of 
YAP153. As a result, there has been a plethora of studies showing VP to have anti-tumour 
properties by reducing cell proliferation and viability in various cancers such as 
retinoblastoma158, ovarian160, colon165 and pancreatic159. Recent research has also 
demonstrated VP to inhibit proliferation of glioma cell lines LN229 and SNB19 through 
suppression of the YAP-TEAD axis, again highlighting the importance of this signalling 
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pathway in gliomas161. Given the role of hypoxia in GBM and its ability to alter YAP 
activity, the activity of VP in hypoxia is an important aspect that has yet to be examined 
in gliomas. Furthermore, despite being identified to inhibit the YAP-TEAD interaction 
thereby suppressing proliferation, the exact mechanism as to how VP induces a 
reduction in cell viability has yet to be fully elucidated. Previous studies have shown VP 
to induce cell death in the absence of light-activation through various mechanisms 
including apoptosis166,261,262, induction of proteotoxicity through impaired clearance of 
protein oligomers165,263, and as an inhibitor of autophagy264. It has therefore become 
apparent that VP-induced cell death is largely dependent on cellular and 
microenvironmental context and thus should also be examined in the context of glioma. 
 
Repurposing of clinically established drugs has become of significance in cancer 
research due to the incredibly low rate of less than 5% of novel cancer therapeutics 
passing through phase I trials to clinical approval265. Successful examples of drug 
reprofiling for cancer therapy include treatment of MM with derivatives of the anti-nausea 
agent Thalidomide as well as clinical trials proposing treatment of breast cancer patients 
with the type 2 diabetic drug Metformin266,267. VP therefore has significant repurposing 
potential as it is already used clinically in the treatment of neovascular AMD155. With its 
demonstrative ability to reduce cancer growth in vitro, this chapter aims to assess the 
effectiveness of VP to reduce glioma growth, with the hope that VP could be repurposed 





4.2.1. VP reduces proliferation of glioma cells 
VP has been identified as a YAP inhibitor as it disrupts the interaction between YAP and 
the TEAD family of transcription factors. This vital interaction is required to transcribe 
downstream target genes such as CTGF and CYR61 which are subsequently involved in 
cell growth and survival158. Results from chapter three identify YAP to be an attractive 
therapeutic target for glioma and so the effect of VP on malignant cell growth and 
survival was therefore assessed, since if effective, VP could potentially be repurposed to 
treat gliomas and possibly other hypoxic cancers. 
 
To assess growth characteristics, glioma cells were cultured in the presence of a range 
of VP concentrations (1-10 µM) for up to 96 hours. Proliferation was seen to be 
significantly reduced with all VP concentrations in both U87 and U343 cells (Figure 4.1A, 
B) by 96 hours, which is in agreement with previous studies160,161. To check that this VP-
induced decline in cell number was a result of reduced proliferation and not from cell 





Figure 4.1 VP reduces cell proliferation of glioma cell lines. Cell proliferation assay of 
U87 (A) and U343 (B) cells treated with either vehicle (DMSO) or 1-10 µM VP for 24-96 h. 
Cell counts were taken by manual counting at the stated times. All concentrations of VP 
significantly reduced proliferation by 96 h in U87 (* 1 µM; ** 3 and 5 µM; *** 10 µM) and U343 
(* 1 µM; ** 3, 5 µM and 10 µM) cell lines. (C) Representative images showing cell growth 
after 96 h treatment of either vehicle or increasing concentrations of VP. It is clear that the 
reduced cell density upon VP treatment is a result of a reduced proliferation rate and not 
from cell death. Images were taken at 20x objective and the scale bar represents 100 µm. 
Data is of 2 independent experiments. Error bars represent ± S.E.M. Significance is 
determined by one-way ANOVA, Tukey post-hoc analysis. * p<0.05, ** p<0.01, *** p<0.001. 
 
To conduct further experiments investigating the effect of VP on glioma cell viability, the 
optimal dosage and treatment time was assessed. U87 and U343 cells were grown for 
24 hours before being treated with a range of VP concentrations (1-10 µM) for 24-72 
hours after which cell number was assessed via SRB analyses. It is evident that 10 µM 
VP caused a significant reduction in cell number in both U87 and U343 cells after 24 
hours (Figure 4.2A, B). Consequently, 5 µM VP for 24 hours was chosen as the optimal 
dosage and treatment time as this was the highest dose that had the least effect on cell 
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number under normoxic conditions. It should be noted that there was a dose-dependent 
effect on reduction in cell number although this was only evident following 72 hour 
treatment. Cells were imaged 72 hours post-treatment which again confirmed that the 




Figure 4.2 Determining VP dosage and treatment time. U87 (A) and U343 (B) cells were 
treated with either vehicle (DMSO) or 1-10 µM VP for up to 72 h. Cell number was 
determined using the SRB assay and normalised to the control at each time point. It is clear 
that 10 µM VP significantly reduced cell number in both cell lines following 24 and 48 h with 
lower concentrations not significantly reducing cell number until 72 h. (C) Representative 
images of U87 and U343 cells following 72 h treatment of either vehicle or increasing 
concentrations of VP. Cell number is seen to reduce with increasing concentrations of VP. 
Images were taken at 10x objective and the scale bar represents 100 µm. Analysis was 
performed in technical triplicate, in a minimum of 3 (U87) and 4 (U343) independent 
experiments. Error bars represent ± S.E.M. Significance determined using one-way ANOVA 




4.2.2. VP induces cell death under hypoxic conditions 
Hypoxia is an important aspect of glioma biology and is a major determinant of treatment 
failure, as previously discussed. Since YAP expression and its activity has been shown 
to be upregulated under hypoxic conditions and that the YAP inhibitor VP can suppress 
proliferation of glioma cells, the effect of hypoxia on VP treatment was evaluated. U87 
and U343 cells were cultured under either normoxic (21% O2) or hypoxic (1% O2) 
conditions for 24 hours in the presence of 1-10 µM VP before cell viability being 
assessed. As previously shown, only a high concentration of VP (10 µM) was able to 
significantly reduce cell number in normoxic conditions in both U87 and U343 cells 
(Figure 4.3A, B). Strikingly, when the cells were cultured under hypoxic conditions, VP 
significantly reduced cell viability. This was confirmed using brightfield imaging which 
showed that with increasing VP concentration the cells remained viable in normoxia but 





Figure 4.3 VP causes significant cell death under hypoxic conditions. U87 (A) and 
U343 (B) cell viability was measured using the SRB method following treatment with either 
vehicle (0.2% DMSO) or 1-10 µM VP for 24 h in both 21% and 1% O2. Both cell lines 
remained viable with increasing concentrations of VP in normoxia (21% O2) although 10 µM 
caused a significant reduction in cell number in both cells lines. In hypoxia, VP caused a 
significant reduction in cell viability under hypoxia (1% O2) compared to the hypoxic control 
with all VP concentrations. Viability was normalised to the control for each oxygen tension. 
(C) Representative images of U87 and U343 cells showing that under normoxic conditions 
the cells remain viable however with 5 and 10 µM VP in hypoxia, the cells died. Images were 
taken at 10x objective and the scale bar represents 100 µm. Analysis was performed in 
technical duplicate/triplicate, in 4 independent experiments. Error bars represent ± S.E.M. 
Significance determined using one-way ANOVA, Tukey post-hoc analysis.  *** p<0.001. 
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To investigate whether this effect was specific to VP, other porphyrin or porphyrin-related 
molecules – ZnPP and PPIX – were incubated with cells. Importantly, PPIX has also 
been previously identified as a YAP inhibitor153. Despite such similarity in structure 
(Figure 4.4A), when U87 and U343 cells were treated with the porphyrin compounds, 
only VP was observed to induce hypoxic cell death (Figure 4.4B, C). To investigate 
whether this VP-induced hypoxic cell death was unique to glioma, A375 melanoma cells 
were also treated with the different porphyrin compounds and again, only VP could 
significantly induce hypoxic cell death (Figure 4.4D). A pair of primary GBM cell lines 
derived in-house, T1 and T2, were also treated with VP for 24 hours in both normoxia 
and hypoxic conditions. T1 and T2 had been previously described by the pathologist 
upon tumour excision to have been derived from therapy-resistant and therapy-sensitive 
areas of the tumour respectively and therefore may vary in their response to cell death 
stimuli. Interestingly, VP induced hypoxia-specific cell death in both these novel primary 





Figure 4.4 Porphyrin family members do not exhibit the same hypoxic cell-killing 
effect as VP. (A) Structures of porphyrin members VP, ZnPP and PPIX. U87 (B) and U343 
(C) cells were treated with either vehicle (0.1% DMSO), or 5 µM VP, ZnPP or PPIX for 24 h 
in 21% and 1% O2. Cell viability was then measured using the SRB assay. Of the porphyrin 
family members, only VP was seen to have a significant cell killing effect in hypoxia in both 
cell lines. (D) Viability of melanoma cell line A375 was also analysed and VP elicited the 
same hypoxic cell-killing effect as seen in the glioma cell lines. (E) Cell lines T1 and T2, 
which were generated from a GBM patient biopsy, were treated with either vehicle (0.1% 
DMSO) or 5 µM VP for 24 h in 21% and 1% O2 after which the cell viability was analysed by 
SRB. Again, VP is seen to significantly reduce cell viability but only under hypoxic conditions. 
Treatments were normalised to the control for each corresponding oxygen tension. Analysis 
was performed in technical triplicate, in 3-4 independent experiments. Error bars represent ± 





Another important facet of glioma biology is the mutational status of the IDH enzyme, as 
previously mentioned. In order to assess whether there was a relationship between the 
mutational status of IDH and VP treatment, WT and MUT IDH1 and IDH2 cells were 
treated with VP for 24 hours, after which cell viability was assessed. Confirmation that 
the HOG and LN18 cells exhibited the R132H mutation in IDH1 was first achieved via 
western blotting (Figure 4.5A). The mutational status of the IDH2 cells (R172K) was 
previously confirmed as outlined in Hollinshead et al209. 
 
VP was seen to significantly reduce cell viability under hypoxic conditions in all cell lines 
regardless of IDH mutational status (Figure 4.5B-G). Interestingly, there seemed to be a 
little sensitisation to VP treatment in HOG IDH1 MUT cells under normoxic conditions 
(Figure 4.5B) as well as in both LN18 IDH1 WT and MUT cells (Figure 4.5D). When cell 
viability was normalised to the IDH1/2 WT control for both 21% and 1% O2, it was 
evident that the mutation in IDH1 and IDH2 caused a significant increase in cell 







Figure 4.5 VP significantly reduces cell viability in IDH1 and IDH2 WT and MUT cells. 
(A) Representative western blot confirming the presence of the mutant IDH1 (R132H) protein 
in both the HOG and LN18 IDH1 MUT but not WT glioma cell lines. (B) Cell viability was 
measured via SRB in both HOG IDH1 WT and MUT cells following treatment with either 
vehicle (0.1% DMSO) or 5 µM VP for 24 h in 21% and 1% O2. VP was seen to significantly 
reduce cell viability in hypoxia but also in the IDH1 MUT in normoxia. Viability was 
normalised to the control for each cell line in each oxygen tension. (C) Cell viability data was 
also normalised to the HOG IDH1 WT cell line showing that the IDH1 MUT cells proliferated 
considerably more in both oxygen tensions. (D) VP also increased cell death in hypoxia in 
LN18 IDH1 WT and MUT cells with some sensitisation also seen under normoxic conditions. 
(E) Normalisation to the LN18 IDH1 WT control cells in both oxygen tensions again show that 
the IDH1 mutation permitted increased proliferation. (F) LN18 IDH2 WT and MUT cells also 
showed VP-induced cell killing in hypoxic conditions. (G) Normalisation to the LN18 IDH2 WT 
control cells show that IDH2 MUT cells grew significantly more under both normoxia and 
hypoxia. Analysis was performed in technical triplicate, in 3 independent experiments. Error 
bars represent ± S.E.M. Significance was determined by one-way ANOVA, Tukey post-hoc 
analysis. * p<0.05, ** p<0.01 *** p<0.001. 
 
 
4.2.3. VP reduces spheroid volume and causes destabilisation over time 
To assess whether VP kills hypoxic cells in a more physiologically relevant in vitro model, 
U87 and U343 cells were cultured as 3D spheroids. After seeding, cells were cultured in 
the presence of 1-10 µM VP for 24 and 48 hours (Figure 4.6A, B). The average spheroid 
diameter was seen to be significantly reduced in a dose-dependent manner over 24 and 
48 hours (Figure 4.6C, D). It was also clear that higher concentrations of VP (10 µM), 





Figure 4.6 VP reduces proliferation and formation of glioma spheroids. U87 and U343 
cells were grown as spheroids in the presence of either vehicle (0.2% DMSO) or 1-10 µM VP 
for 24 and 48 h after which the spheroid diameter was recorded. Representative images of 
U87 (A) and U343 (B) show a prominent reduction in spheroid size with increasing 
concentrations of VP. Additionally, spheroids formation appears to be altered due to the 
looser, less spherical appearance upon VP treatment. (C) and (D) Spheroid diameter was 
recorded from both U87 and U343 spheroids respectively, and was seen to be significantly 
reduced in all conditions following both 24 and 48 h VP treatment. Between 55-60 and 45-50 
U87 and 50-55 and 35-40 U343 spheroids were analysed for each condition for both 24 and 
48 h respectively. All experiments were conducted in biological triplicate. Scale bar 
represents 100 µm. Data is presented as box-and-whisker (min-max). Significance is 
determined by two-way ANOVA with Tukey post-hoc test. *** p<0.001. 
 
 
When spheroids were incubated for a longer period of one week in the presence of VP, 
spheroids were unable to proliferate which was evident by the drastic reduction in size 
compared to the vehicle control (Figure 4.7A). To assess whether VP interfered with 
spheroid stability, cells were left to form spheroids for one week before the addition of 5 
µM VP to the culture medium for a further 7 days. Spheroids were imaged over the 
course of treatment and it is evident that VP caused destabilisation of U87 and U343 
spheroids due to the loss of spherical appearance and increased detachment of cells 
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which corresponded with a greater number of single cells present within the culture 
medium (Figure 4.7B, C). 
 
 
Figure 4.7 Destabilisation of glioma spheroids occurs following long-term VP 
treatment. (A) U87 and U343 spheroids were incubated for 7 days in the presence of vehicle 
(0.2% DMSO) or 1-10 µM VP. It is clear that compared to the vehicle control, spheroids are 
considerably smaller with significantly less cells comprising the spheroid. With higher 
concentrations (5-10 µM), the spheroids appear to have not properly formed, with a lot 
singular cells present. (B) and (C) U87 and U343 cells were first left to form spheroids over 7 
days before being treated with 5 µM VP for an additional 7 days. Compared to the vehicle 
control spheroids, it is clear that VP causes the spheroids to destabilise and lose the cell-cell 
connections needed to form compact spheroids. Experiments were conducted in biological 
duplicate. Scale bar represents 100 µm. 
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4.2.4. VP rapidly induces changes in cell morphology 
Anti-cancer treatments in the clinic are most often given over a shorter period than the 
VP treatments used above. It was therefore investigated whether VP could induce cell 
death within a more clinically relevant treatment window of 1-8 hours in both normoxic 
and hypoxic conditions, after which cells were processed via ICC and stained for YAP1 
expression (Figure 4.8A, B). Alterations in gross cell morphology were apparent even 
after 1 hour VP treatment in both cell lines and was exacerbated with longer treatment 
time. Visually, the cells appeared to be undergoing cell-death processes even at this 
early time point, with characteristics present such as increased membrane blebbing and 
vacuolisation. In control cells, YAP1 was seen to be ubiquitously expressed in the 
cytoplasm, where the inactive phosphorylated form is understood to reside (Figure 4.8A, 
B). However upon VP addition, YAP1 is seen to progressively re-localise from the 






Figure 4.8 VP induces morphological changes in glioma cells. U87 (A) and U343 (B) 
cells were treated with 5 µM VP for 1-8 h in both 21% and 1% O2. Cells were fixed at each 
stated time-point and processed via ICC and imaged via confocal microscopy. Cells were 
stained with YAP1 and Hoechst to distinguish the cell nucleus. Cellular morphology altered in 
VP treated cells as early as 1 h post-treatment compared to the control (Con). YAP1 
relocalised from the cytoplasm to the plasma membrane with increasing time. Cells also 
appeared to have undergone significant cell death processes by 8 h post-treatment. Images 
are representative of 3 independent experiments. Scale bar represents 10 µm. 
 
 
As previously described, the cellular localisation of YAP1 is critical to its function, with 
active YAP1 believed to residue in the cell nucleus where, as a transcriptional co-
activator, it is free to bind with transcription factor binding partners to synergistically 
transcribe downstream target genes143. Quantitative analysis of YAP1 nuclear staining 
shows that YAP1 fluorescence is significantly increased in both U87 and U343 cells 
following 4 hours of hypoxia suggesting increased YAP1 activity in hypoxia (Figure 4.9A, 
B). This effect was also apparent after 8 hours hypoxia in U87 cells although was not 
observed in U343 cells (Figure 4.9C, D). Upon addition of VP however, YAP1 nuclear 
fluorescence was seen to reduce in all conditions, implying that not only could VP 





Figure 4.9 YAP1 expression is increased in hypoxia and reduced upon VP treatment. 
Nuclear YAP1 fluorescence was quantitatively analysed in both U87 and U343 cells 4 and 8 
h post-treatment with 5 µM VP. YAP1 nuclear expression was seen to significantly increase 
in hypoxia after 4 h in both U87 (A) and U343 (B) cells but only in U87 (C) and not U343 (D) 
cells 8 h post VP treatment. VP was seen to reduce YAP1 nuclear expression compared to 
control cells in all oxygen conditions in both glioma cell lines 4 and 8 h post-treatment. All 
experiments were conducted in biological triplicate (except U343 4 h in biological duplicate). 
2-4 images were analysed per condition, per experiment. Error bars represent ± S.E.M. 
Significance is determined by one-way ANOVA, with Tukey post-hoc analysis. * p<0.05, ** 
p<0.01, *** p<0.001. 
 
 
To further investigate this, U87 and U343 cells were treated with 5 µM VP in both 
normoxic and hypoxic conditions for 4 hours, after which cells were lysed. Protein 
expression of YAP1, and its downstream target CTGF, was subsequently investigated 
via western blotting (Figure 4.10A). Unexpectedly, YAP1 and CTGF expression 
remained unchanged upon exposure to VP in both oxygen conditions indicating that 
despite attenuated YAP1 nuclear fluorescence with VP treatment, overall YAP protein 
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expression remains unaffected. To investigate whether VP could induce changes in YAP 
expression over a longer treatment period, cells were treated for 24 and 48 hours under 
normoxic conditions (Figure 4.10B). Long-term expression under hypoxic conditions 
could not be determined due to rapid VP-induced hypoxic cell death. Again, YAP1 and 
CTGF expression remained unchanged upon VP treatment suggesting VP to potentially 
exhibit YAP-independent effects in glioma cells within this time period. 
 
 
Figure 4.10 YAP1 protein expression is unchanged upon VP treatment. (A) Expression 
of YAP1 and YAP-target CTGF were assessed in both U87 and U343 cells following 
exposure to 5 µM VP for 4 h in both 21% and 1% O2. Successful induction of hypoxia was 
observed through increased stabilisation of HIF-1α. YAP1 and CTGF expression levels 
remained unchanged following VP treatment. CTGF expression is denoted by the lower band 
and was incredibly low in U87 cells. (B) U87 and U343 cells were treated with and without 5 
µM VP for 24 and 48 h under normoxic conditions. Again, VP did not induce any changes in 




4.2.5. Exposure to ambient light during VP treatment increases sensitivity 
Since VP can induce cell death processes almost immediately following exposure, a 
more clinically relevant VP treatment time of 4 hours was chosen. To confirm that 
hypoxic glioma cells were indeed dying with VP treatment within this treatment window, 
cells were treated with VP for 4 hours after which they are incubated in normal medium 
without VP for the remaining 20 hours in both normoxic and hypoxic conditions (Figure 
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4.11A, B). Interestingly, despite the shorter treatment time of 4 hours, hypoxic cell death 
was still apparent in both cell lines indicating that VP induces early cell death 
mechanisms which cannot be prevented upon removal of the drug. Furthermore, due to 
the light-sensitivity of VP, experiments involving VP were conducted in the dark however 
if these cells were exposed to ambient light during the removal of VP, normoxic cells 
were significantly sensitised to VP treatment (Figure 4.11C, D). It should also be noted 
that despite VP being capable of inducing cell death after 4 hours, in hypoxia the killing 
was further increased if the cells had been exposed to VP for the complete treatment 
time of 24 hours thus indicating that to achieve almost complete cell death a longer 





Figure 4.11 VP sensitises cells to death if exposed to ambient light during treatment. 
Cell viability was measured via SRB following treatment with vehicle (0.1% DMSO) or 5 µM 
VP for 4 h after which VP was removed and cells incubated in media for 20 h or 5 µM VP for 
24 h. Cell viability of U87 (A) and U343 (B) cells which had remained obscured from ambient 
light during changing of the media after 4 h VP treatment. VP was still able to significantly 
induce cell death after 4 h treatment to levels similarly achieved with 24 h. Interestingly, if 
cells were exposed to light during changing of the media following 4 h treatment, VP also 
caused a significant reduction in cell viability under normoxic conditions in both U87 (C) and 
U343 (D) cells. Treatment was normalised to the control for each oxygen tension. 
Experiments were conducted in 3-4 biological experiments, in technical 
triplicate/quadruplicate. Error bars represent ± S.E.M. Significance is determined by two-way 
ANOVA, with Tukey post-hoc analysis. * p<0.05, *** p<0.001. 
 
4.2.6. Global expression of tumour suppressor and YAP binding partner, p73 
is increased following VP exposure 
Now defined as a potent oncogene, YAP has been previously identified to exhibit many 
roles in the growth and survival of malignant cells. However its effects are largely reliant 
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on the cellular and microenvironmental context, as previously discussed. Under certain 
situations YAP has been identified to exhibit tumour suppressive qualities such as 
switching its transcription factor binding partners from the favoured TEAD family that 
promote cell survival, to other transcription factors such as p73, which act to transcribe 
genes linked to the induction of cell death. To examine if YAP was exhibiting this role 
during VP-induced cell death, the expression of YAP transcription factor binding partner 
and p53-related protein, p73 was investigated through ICC (Figure 4.12A, B). Evidently, 
a large increase in p73 expression was seen following 4 hour exposure to VP which was 
exacerbated with a longer treatment time of 8 hours. Increased p73 expression was 
apparent in both normoxic and hypoxic conditions, although was more prominently 
increased under hypoxic conditions. Co-localisation of YAP1 and p73 protein was also 
witnessed and seen to be enhanced in hypoxia, suggesting potential increased 





Figure 4.12 Expression of p73 is significantly increased following VP treatment. U87 
(A) and U343 (B) cells were treated with either vehicle (0.1% DMSO; Con) or 5 µM VP for 4 
and 8 h in both 21% (normoxia) and 1% (hypoxia) O2. Cells were then processed via ICC 
and imaged via confocal microscopy. Expression of apoptotic protein p73 is dramatically 
increased upon VP treatment, which is enhanced under hypoxic conditions. Images are 
representative of 3 independent experiments. Scale bar represents 10 µm. 
 
 
For further investigation of this potential interaction, U343 cells were treated with VP for 4 
hours in hypoxia then subjected to co-immunoprecipitation using YAP1 coated agarose 
beads. Western blotting was then used to determine whether p73 could be detected 
through binding to YAP1 protein. Unexpectedly, no binding of p73 to YAP1 was exhibited 
(Figure 4.13A) suggesting that despite the significantly increased p73 expression, this 





Figure 4.13 YAP1 does not bind partner p73 upon VP treatment in hypoxia, despite 
increased expression. (A) U343 cells were treated with either vehicle (DMSO) or 5 µM VP 
for 4 h under 1% O2 after which lysates were subject to co-immunoprecipitation with YAP1-
conjugated agarose beads for 3 h. Protein from the lysate (I) and those bound to the agarose 
beads (B) were subject to western blotting and probed for both YAP1 and p73 expression. It 
is clear that p73 did not bind with YAP1 in hypoxic conditions, with or without VP treatment. 
Experiments were conducted in biological triplicate. 
 
4.2.7. VP-induced hypoxic cell death is YAP-independent 
As VP has been characterised as a YAP inhibitor, we wanted to confirm that the hypoxia-
specific cell death induced by VP treatment was through this mechanism. We therefore 
knocked down expression of YAP1, its paralog TAZ, and both proteins in U87 and U343 
glioma cell lines. Western blot analysis confirmed that successful knockdown of these 
proteins was achieved (Figure 4.14A). Cell viability was then measured following 5 µM 
VP treatment for 24 hours in both normoxic and hypoxic conditions (Figure 4.14B, C). 
Surprisingly, VP was still able to induce significant cell death in hypoxia despite 
knockdown of YAP, TAZ and both YAP and TAZ suggesting that this VP-induced hypoxic 
cell death is YAP1-independent. Additionally, results in chapter three (Figure 3.10) show 
that knockdown of YAP, TAZ and YAP and TAZ was able to reduce cell proliferation but 
was not sufficient to induce hypoxic cell death, therefore unable to phenocopy the 




Figure 4.14 Hypoxic VP-induced cell death is YAP-independent. (A) Western blot 
showing successful knockdown of YAP (siYAP), TAZ (siTAZ) and both YAP and TAZ 
(siYAP/TAZ) 72 h post-transfection with 25 nM siRNA. Non-targeting siRNA (siNT) is used as 
a control. (B) and (C) U87 and U343 cells were treated with 5 µM VP 48 h post-transfection, 
for 24 h in both 21% and 1% O2. VP still caused a significant reduction in cell viability despite 
knockdown of YAP, TAZ and both YAP and TAZ indicating that hypoxic VP-induced cell 
death is likely to be through a YAP-independent mechanism. Viability was determined via 
SRB assay with each condition normalised to each untreated siRNA control for each oxygen 
tension. Experiments were conducted in technical duplicate/triplicate in 3 independent 
experiments. Error bars represent ± S.E.M. Significance is determined by two-way ANOVA, 





It has recently been suggested that VP could act independently of YAP1, inducing cell 
death by forming cross-linked oligomers with p62, also known as sequestosome 1 
(SQSTM1), which acts to recognise toxic cellular aggregates and target them to the 
autophagosome for degradation268. Aggregation of p62 consequently impairs this 
function and so toxic protein aggregates accumulate eventually causing proteotoxicity 
and cell death268. To see whether VP caused an increase in these protein aggregates in 
glioma cells, p62 expression was investigated following 4 hour VP treatment (Figure 
4.15A, B). It is clear that basal expression of p62 was high in normoxic control cells and 
did not increase upon VP exposure. p62 was observed to form more aggregates with VP 
treatment although these results were not clear enough to conclude that this was a major 





Figure 4.15 VP reduces p62 expression. U87(A) and U343 (B) cells were treated with VP 
for 4 h before stained for YAP1 and p62 expression. High p62 expression was observed in 
normoxic control cells in both the U87 and U343 cell lines. VP treatment however attenuated 
p62 expression but potentially induced aggregation. Experiments were conducted in 
biological duplicate. Scale bar represents 10 µm. 
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4.2.8. Stabilisation of HIF-1α only partially sensitises glioma cells to VP in 
normoxia 
Due to VP-induced cell death occurring only under hypoxic conditions, this potential 
selective mechanism was further investigated. As previously described, hypoxia 
inducible transcription factor HIF-1α is considered to a central regulator of the adaptive 
cellular response to hypoxia. Stabilisation of HIF can be pharmacologically induced 
under normoxic conditions through the addition of the α-KG-like molecule DMOG, which 
acts as a PHD and FIH inhibitor269,270. DMOG was therefore used to assess whether 
mimicking hypoxic conditions under normoxia could sensitise normoxic cells to VP-
induced cell death (Figure 4.16A, B). Intriguingly, addition of DMOG was seen to partially 
but significantly sensitise the cells to VP, although the effect was smaller in U343 cells. 
Western blots were used to confirm that DMOG-induced HIF-1α stabilisation under 
normoxia, and was comparable to expression levels seen in hypoxia (Figure 4.16C). 
 
To further implore this concept, U87 cells were transfected with a plasmid to express a 
triple mutant form of HIF-1α (HIF1αTM), which is mutated on every residue that confers 
the sensitivity to oxygen tension through hydroxylation (P402, P564 and N803), and is 
therefore stable under normoxia213. Although stabilisation levels reached were not as 
high as with application of DMOG, overexpression of HIF1αTM caused a small, but 
significant, sensitisation to VP treatment in normoxia (Figure 4.16D, E). Despite the 
increased sensitisation, normoxic HIF-1α stabilisation was not enough to completely 
phenocopy the VP-induced cell death observed under hypoxic conditions, suggesting 





Figure 4.16 Normoxic glioma cells are sensitised to VP upon stabilisation of HIF-1α. 
U87 (A) and U343 (B) cells were treated overnight (14-16 h) with either vehicle or 1 mM 
DMOG prior to treatment with 5 µM VP for 4 h in 21% O2. It is clear that upon stabilisation of 
HIF-1α in normoxia, cells became significantly more sensitive to VP treatment. Cell viability 
was measured via SRB assay and results were normalised to either control or untreated 
DMOG alone. (C) Representative western blots show increased HIF-1α stabilisation and 
hence protein expression in normoxia upon DMOG treatment. Protein extracted under 
hypoxia (1% O2) is shown as a comparison. (D) A mutant form of HIF-1α (HIF1αTM) was 
over-expressed (O/E) in U87 cells to stabilise HIF-1α expression under normoxic conditions. 
Cells were treated 48 h post-transfection with 5 µM VP for 4 h in 21% O2 after which cell 
viability was measured via SRB. Viability was significantly reduced upon HIF-1α 
overexpression, although the effect was not as great as when cells were treated with the 
chemical DMOG. (E) Western blot showing increased expression of HIF-1α with 
overexpression of the mutant form HIF1αTM. Protein extracted from cells treated with 1 mM 
DMOG for 20 h is shown as a comparison. Experiments were conducted in technical 
duplicate/triplicate in 3 independent experiments. Error bars represent ± S.E.M. Significance 







As an alternative approach, siRNA was employed to knockdown HIF-1α in hypoxia to 
assess whether HIF-1α was required for VP to induce cell death. Surprisingly, despite 
dramatic reduction in HIF-1α protein, VP was still able to mediate hypoxic cell death 
(Figure 4.17A-C). This suggests that an additional aspect of hypoxic biology is likely the 
major determinant for hypoxic sensitisation to VP. 
 
 
Figure 4.17 VP-induced hypoxic cell death despite knockdown of HIF-1α. Cells were 
subjected to 48 h siRNA knockdown of HIF-1α before 5 µM VP treatment in both normoxia 
and hypoxia for 24 h. (A) Representative western blot showing knockdown of HIF-1α. (B) 
U87 and U343 (C) cell viability analysis shows that despite successful knockdown of HIF-1α, 
VP could still induce hypoxic cell death. Experiments were conducted in biological triplicate. 
Data is presented as ± S.E.M. Significance is determined by two-way ANOVA, Tukey post-




4.2.9. VP-mediated hypoxic cell death is partially preventable by 
pharmacological inhibitors of cell death 
To better define how exposure to VP caused hypoxic cell death in glioma cells, 
pharmacological inhibitors of different cell death processes were employed in an attempt 
to pinpoint the mechanism of VP-induced hypoxic cell death. Firstly, a few investigations 
had previously suggested that VP could induce apoptosis and so the pan-caspase and 
apoptosis inhibitor, Z-VAD-FMK was used. Cells were treated with 5 µM VP in the 
presence and absence of the caspase-inhibitor for 8 hours before assessing caspase-
mediated cell death using Annexin V/PI staining and flow cytometry. The viable U87 cell 
population was measured and was significantly reduced upon VP addition in hypoxia 
(Figure 4.18A). Furthermore, addition of Z-VAD-FMK alongside VP was unable to 
significantly restore cell viability. Upon closer examination, it was apparent that upon VP 
treatment for 8 hours, the cells exhibited increased PI staining, reminiscent of necrotic 
rather than apoptotic cells (Figure 4.18B, C). To confirm that this necrosis was not as a 
result of a longer treatment time and thus missing early apoptotic mechanisms, cells 
were VP-treated for 4 hours (Figure 4.18D). Again, cells were seen to have pronounced 
staining for PI over Annexin V, implying that they were not passing through earlier 
apoptotic stages before undergoing necrosis. These results were also recapitulated in 





Figure 4.18 VP-induced cell death cannot be inhibited by Z-VAD-FMK in U87 cells. U87 
(A) cells were pre-treated with 20 µM Z-VAD-FMK (Z-VAD) prior to being treated with 5 µM 
VP for 8 h in both 21% and 1% O2. Cells were then dual stained with Annexin V and PI and 
the viable cell population measured via flow cytometry. No significant rescue in cell viability 
upon Z-VAD-FMK treatment was observed suggesting that cell death is not predominately 
through apoptosis. (B) Representative flow plot of H2O2 positive control to increase 
confidence in gating parameters. (C) Representative flow cytometry plots show that upon 8 h 
VP treatment cells have a significantly higher proportion of PI staining to Annexin V, 
indicating that these cells could be necrotic rather than apoptotic. (D) Flow plots of U87 cells 
treated for 4 h with VP and Z-VAD-FMK show that even with a shorter treatment time, these 
cells do not seem to pass through early apoptosis, which is normally indicated by high 
Annexin V, low PI staining. Data is from 4 biological experiments and 1 experiment for 4 h. 
Data is presented as ± S.E.M. Significance is determined by two-way ANOVA, Tukey post-





Figure 4.19 VP-induced cell death cannot be inhibited by Z-VAD-FMK in U343 cells. 
U343 (A) cells were pre-treated with 20 µM Z-VAD-FMK (Z-VAD) prior to being treated with 5 
µM VP for 8 h in both 21% and 1% O2. Cells were then dual stained with Annexin V and PI 
and the viable cell population was measured via flow cytometry. There was no significant 
rescue in cell viability upon Z-VAD-FMK treatment, suggesting that the mechanism of cell 
death is not predominately through apoptosis. (B) Representative flow plot of H2O2 positive 
control to increase confidence in gating parameters (C) Representative flow cytometry plots 
show that upon 8 h VP treatment cells have a significantly higher proportion of PI staining to 
Annexin V, indicating that these cells could be necrotic rather than apoptotic. (D) Flow plots 
of U87 cells treated for 4 h with VP and Z-VAD-FMK show that even with a shorter treatment 
time, these cells do not seem to pass through early apoptosis, which is normally indicated by 
high Annexin V, low PI staining. Data is from 3 biological experiments and 1 experiment for 4 
h. Data is presented as ± S.E.M. Significance is determined by two-way ANOVA, Tukey post-
hoc analysis. *** p<0.001. 
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Cell viability was alternatively measured through SRB analyses 24 hour post-treatment 
with VP and Z-VAD-FMK (Figure 4.20A, B). Cell viability was seen to partially increase 
upon co-treatment with Z-VAD-FMK in the U87 cell line however remained unchanged in 
the U343 cells implying different cell death pathways could potentially be utilised in the 
different cell lines. 
 
 
Figure 4.20 Z-VAD-FMK can partially rescue VP-induced death in U87 cells over 24 
hours. U87 (A) and U343 (B) cells were treated with either vehicle (0.1% DMSO), 5 µM VP, 
5 µM VP and 20 µM Z-VAD-FMK or 20 µM Z-VAD-FMK alone for 24 h in 21% and 1% O2. 
Cell viability was significantly higher in U87 cells co-treated with VP and Z-VAD-FMK in 
hypoxia compared to VP alone. This rescue in viability was not seen in the U343 cells 
however suggesting that VP may affect different pathways in the different cell lines. Cell 
viability was measured via SRB and normalised to the control or Z-VAD-FMK alone for each 
oxygen tension. Experiments were conducted in technical triplicate/quadruplicate in 3 
biological experiments. Data is presented as ± S.E.M. Significance is determined by two-way 
ANOVA, Tukey post-hoc analysis. *** p<0.001. 
 
 
Immunocytochemistry analysis was further conducted to see whether Z-VAD-FMK could 
prevent the gross alterations seen in cell morphology upon VP treatment (Figure 4.21A, 
B). Unsurprisingly from the results obtained from the cell viability data, Z-VAD-FMK was 
unable to prevent the cell death and progressive relocalisation of YAP protein to the 







Figure 4.21 VP-induced changes in glioma cell morphology could not be prevented 
upon addition of Z-VAD-FMK. U87 (A) and U343 (B) cells were treated with either vehicle 
(0.1% DMSO; Con), 5 µM VP, 5 µM VP and 20 µM Z-VAD-FMK or 20 µM Z-VAD-FMK alone 
for 8 h in 21% and 1% O2. It is clear that even upon addition of the caspase inhibitor, the 
cells were under significant stress and were dying following VP treatment again indicating 
that apoptosis was likely not the main mechanism of VP-induced cell death. Images are 
representative of 3 biological experiments. Scale bar represents 10 µm.  
 
Since apoptosis was concluded to not be the main driver of VP-induced hypoxic cell 
death, additional cell death inhibitors inhibiting the activity of calpain and cathepsins 
(ALLN), calcium-mediated cell death occurring through opening of the mitochondrial 
permeability transition pore (mPTP; CsA) and also death domain receptor interacting 
protein kinase (RIPK)-dependent necrosis (Nec-1) were employed (Figure 4.22A, B). All 
of these inhibitors however were unable to prevent VP-induced hypoxic cell death 
although ALLN and CsA did induce a small sensitisation to VP under normoxic 





Figure 4.22 Hypoxic VP-induced cell death of glioma cells could not be prevented by 
alternative inhibitors of cell death. Cell viability of U87 (A) and U343 (B) cells was 
measured via SRB assay following 24 h treatment in 21% and 1% O2 of either vehicle (0.1% 
DMSO) or 5 µM VP with and without the presence of alternative cell death inhibitors; 10 µM 
ALLN (Calpain/Cathepsin inhibitor), 15 µM CsA (mitochondrial cyclophillin D inhibitor) and 50 
µM Nec-1 (inhibitor of RIP-kinase dependent necrosis. It is clear that VP-induced hypoxic cell 
death could not be prevented. Cell viability was normalised to either the control or the 
relevant untreated inhibitor for each oxygen tension. (C) and (D) Data normalised to the 
normoxic control for each inhibitor showed that ALLN in the U87 cells and CsA in both the 
U87 and U343s partially sensitised glioma cells to 5 µM VP treatment over 24h in 21% O2. 
Experiments were conducted in technical quadruplicate in 5 (U87) and 6 (U343) biological 
experiments. Nec-1 data was conducted in 3 (U87) and 4 (U343) independent experiments. 
Data is presented as ± S.E.M. Significance is determined by two-way ANOVA, Tukey post-
hoc analysis. *** p<0.001. 
 
 
Next, cells were co-treated with VP and inhibitors against p53-mediated cell death (PFT-
α) and autophagy (CQ) in order to elucidate the mechanism of cell death. Again, these 
inhibitors provided no protection against VP-induced hypoxic cell death in either of the 
glioma cell lines indicating that perhaps a non-traditional or regulated mechanism of cell 




Figure 4.23 Inhibiting p53-mediated cell death and autophagy did not prevent VP-
induced cell death in hypoxia. Cells were treated with p53/p73 inhibitor PFT- (30 µM) 
alongside 5 µM VP for 24 h in both 21% and 1% O2. SRB analysis shows that VP was still 
able to induce significant cell death in hypoxia in both U87 (A) and U343 (B) cells. Cells were 
also treated with autophagy inhibitor, CQ (10 µM) in combination with 5 µM VP for 24 h and 
was seen to not prevent hypoxic VP-induced cell death in either U87 (C) or U343 (D) cells. 
Data is normalised to the control or inhibitor alone for each oxygen tension. Experiments 
were conducted in technical triplicate in 3-4 independent experiments. Data is presented as ± 




4.2.10. Cellular vacuolisation is a prominent characteristic of VP-induced cell 
death 
Cytoplasmic vacuolisation has recently become of interest in the mechanism of cell 
death, although has yet to be attributed to any one particular form. Evidence does 
suggest however that presence of the vacuoles could be associated with increased 
cellular stress from a range of stress inducers, affecting intracellular organelles such as 
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the ER271,272. It was noted that upon VP exposure, cytoplasmic vacuolisation was 
induced and was particularly amplified in both vacuole number and size under hypoxic 
conditions. These large vacuoles were apparent by both bright-field (Figure 4.24A) and 
confocal microscopy (Figure 4.24B) in both of the cell lines. 
 
Figure 4.24 VP induces cytoplasmic vacuolisation. (A) Large vacuoles can be seen in 
cells treated with 3 µM VP for 24 h but only in 1% O2. Images were taken at 20x objective. 
Scale bar represents 25 µm. (B) Cells imaged using confocal microscopy also show 
presence of cytoplasmic vacuoles upon 5 µM VP for 8 h. Vacuolisation is enhanced under 
hypoxic (1% O2) conditions compared to normoxia (21% O2). Scale bar represents 5 µm. 
 
 
To further investigate whether VP was indeed increasing cellular stress, in particular ER 
stress, cells were stained with an ER stress marker CRT following 4 hour VP treatment 
(Figure 4.25A, B). Exposure to VP was seen to cause an increase in ER stress, which 





Figure 4.25 ER stress is significantly increased upon VP treatment and is enhanced in 
hypoxia. U87 (A) and U343 (B) cells were treated with 5 µM VP for 2 h in both 21% and 1% 
O2 after which cells were fixed and stained with Hoechst, YAP1 and ER stress marker, CRT. 
CRT expression was seen to dramatically increase upon VP treatment compared to the 
control and was enhanced under hypoxic conditions. Images are representative of 3 
biological experiments. Scale bar 10 µm.  
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Since this suggested that ER stress may play a role in VP-mediated cell death, cells 
were treated with an inhibitor of the ER-associated protein degradation pathway (ERAD), 
Eer1, to see whether this inhibition could rescue hypoxic cell viability post VP exposure. 
Immunocytochemistry showed that Eer1 unfortunately could not rescue cell death or 
vacuolisation of the cell in hypoxia (Figure 4.26A) although at a higher concentration, 
Eer1 was able to partially increase cell viability when co-incubated alongside VP (Figure 
4.26B, C). This rescue in viability was again not complete, suggesting that there could 





Figure 4.26 ERAD inhibitor Eer1 causes partial rescue of cell viability following VP 
treatment in hypoxia. (A) U87 cells were treated with 1 µM Eer1 alongside 5 µM VP for 4 h 
in both 21% and 1% O2, after which cells were fixed and stained with Hoechst and YAP1 for 
confocal microscopy. Eer1 did not appear to inhibit the cells from dying in hypoxia compared 
to VP treated cells. Images are from 1 independent experiment. Cell viability of U87 (B) and 
U343 (C) cells was also measured via SRB analyses following co-treatment of 1 µM and 3 
µM Eer1 with 5 µM VP for 24 h in both 21% and 1% O2. Co-treatment with 3 µM Eer1 and 
VP caused a significant increase in cell viability in hypoxia in U343 cells and a small increase 
but non-significant in the U87 cells compared to VP-treated cells. Data is normalised to the 
control or inhibitor alone for each oxygen tension. Experiments were conducted in technical 
triplicate in 3-4 independent experiments. Data is presented as ± S.E.M. Significance is 





4.2.11. Increased ROS production and DNA oxidation suggests VP 
significantly increases cellular oxidative stress 
Cells are known to undergo oxidative stress when perturbations in the normal redox 
homeostasis are induced through the increased generation of ROS such as superoxide 
anions, hydrogen peroxide and the highly reactive hydroxyl radicals. These radicals can 
attack many biological molecules such as DNA, lipids and proteins, eventually leading to 
destruction of the cell and ultimately cell death. Since VP is a known photosensitiser and 
can generate ROS after photoactivation, the question was raised as to whether VP can 
exert the same mechanism and induce oxidative stress in the absence of light. 
 
Cells were therefore treated with VP and the presence, or increase in 8-
hydroxydeoxyguanosine (8-OHdG), a marker of ROS-induced DNA oxidation, was 
assessed. We observed that 8-OHdG staining was dramatically increased in both 
normoxia and hypoxia (Figure 4.27A, B), but that it was more pronounced under hypoxic 
conditions in U87 cells compared to normoxia. Conversely, ROS-induced damage as a 
result of VP treatment in the U343 cells was lower in hypoxia. Basal levels of DNA 
oxidation under 1% O2 however was already higher in this cell line implying some 
differences between cell lines in the sensitivity to oxidative stress under hypoxic 
conditions. This is also highlighted by the differential sensitivity to the positive control, 





Figure 4.27 VP causes a significant increase in DNA oxidation. U87 (A) and U343 (B) 
were treated with 5 µM VP for 2 h in 21% and 1% O2 after which cells were fixed and stained 
with DNA oxidation marker, 8-OHdG. DNA oxidation was seen to be markedly increased 
after VP treatment compared to control in both normoxic and hypoxic conditions. H2O2 (100 
µM) was used as a positive control. Images are representative of 4 independent 
experiments. Scale bar 10 µm. 
 
 
Production of ROS was measured using a DCFDA assay and was seen to be 
significantly increased upon VP exposure in the immortalised U87 and U343 cell lines as 
well as in the primary GBM cells, T1 and T2 (Figure 4.28A-D). Interestingly, when cells 
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were first pre-treated and then co-treated alongside VP with the free radical scavenger 
TEMPOL, this increase in ROS production could be reversed to levels lower than the 
control. H2O2 treatment, which was used as a positive control, confirmed that TEMPOL 
could indeed inhibit ROS production. Furthermore, it should be noted that in the T1 GBM 
cells, H2O2 did not generate a significant increase in ROS production suggesting that this 
therapy-resistant GBM line required a higher concentration of H2O2 to generate a 
response. ROS levels were also measured in the U343 cells under hypoxic conditions 
and again the same trend was observed with VP significantly increasing ROS production 
(Figure 4.28E). When levels were normalised to the normoxic control, it is clear that ROS 
levels were significantly elevated under hypoxia and were further exacerbated upon VP 
exposure (Figure 4.28F). Interestingly, treatment with related porphyrin PPIX did not 






Figure 4.28 VP increases ROS which can be prevented upon treatment with TEMPOL. 
Cells were treated with 5 µM VP for 2 h in 21% O2 followed by overlay of 2x DCFDA (20 µM 
final concentration) 45 min before treatment endpoint after which fluorescence was 
measured at 520 nm. DCFDA fluorescence was significantly increased upon VP treatment in 
U87 (A), U343 (B) and GBM lines T1 (C) and T2 (D). This increase could be prevented if 
cells were co-treated with 3 mM TEMPOL (TPL; 2 h pre-treatment). H2O2 (50 µM, 2 h) was 
used as a positive control for ROS production. (E) U343 cells were treated with VP in 
hypoxia for 2 h. ROS levels were also significantly increased following VP treatment, which 
could be reduced when co-treated with TEMPOL. (F) DCFDA fluorescence values from both 
U343 normoxia and hypoxia were normalised to the normoxic control and were increased in 
hypoxia, which is significantly increased upon the addition of VP. (G) PPIX however did not 
induce ROS production in normoxia or hypoxia. Experiments were conducted in technical 
quadruplicate in 3 independent experiments. Data is presented as ± S.E.M. Significance is 
determined by one-way ANOVA, Tukey post-hoc analysis. * p<0.05, ** p<0.01, *** p<0.001. 
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Cell viability following 24 hour VP treatment in the presence of anti-oxidant TEMPOL was 
also measured (Figure 4.29A, B). TEMPOL treatment was seen to significantly increase 
hypoxic cell viability after VP exposure, which was most pronounced in the U343 cells. 
Although the viability was improved, the VP-mediated hypoxic cell death could not be 
completely reversed in either cell line suggesting again that the mode of cell death 
induced by VP is multifactorial. 
 
 
Figure 4.29 VP- induced cell death in hypoxia can be significantly reduced upon co-
treatment with TEMPOL. Cell viability of U87 (A) and U343 (B) cells determined by SRB 
analyses following treatment with either vehicle (0.1% DMSO), 5 µM VP, 5 µM VP+ 3mM 
TEMPOL (TPL) or 3 mM TEMPOL alone for 24 h in both 21% and 1% O2. Cell viability was 
significantly increased when cells were co-treated with TEMPOL. Experiments were 
conducted in technical quadruplicate in 3 independent experiments. Data is presented as ± 
S.E.M. Significance is determined by two-way ANOVA, Tukey post-hoc analysis. * p<0.05, 
*** p<0.001. 
 
4.2.12. VP avidly binds ferric iron 
Noting that VP is structurally similar to porphyrins, such as PPIX (Figure 4.4A), which are 
capable of metal complexation, the mode of action of VP was hypothesised to be 
through binding of free iron resulting in a Fenton-like mechanism to generate hydroxyl 




Firstly, the absorbance spectrum of VP was measured in the UV/visible spectrum after 
being diluted in either distilled H2O or methanol. The absorbance spectrum was seen to 
be most prominent when diluted in methanol and so this was then chosen as the diluent 
for further experiments (Figure 4.30A). To keep the absorbance values in a suitable 
range of 0-1 (arbitrary units), the concentration of VP most appropriate for experiments 
was found to be 30 µM (Figure 4.30B). 
 
 
Figure 4.30 VP absorption spectra profile. (A) VP was diluted in either dH2O or MeOH to a 
concentration of 75 µM and its absorption spectra measured in the UV/Vis range (300-800 
nm). It is clear that using methanol as a diluent produces a cleaner absorption spectra for 
VP. (B) Absorption spectra of 30 µM VP in the UV/visible range diluted in MeOH. 
 
Next, 30 µM VP was incubated in the presence or absence of ferric iron (Fe3+; 3-500 µM) 
and the absorbance spectra measured immediately. Upon increasing concentrations of 
ferric iron, the absorbance spectra was seen to shift; evident by an increase absorption 
around 430 nm as well as shifts in the peaks around 600 and 700 nm indicating potential 
iron binding (Figure 4.31). As previously mentioned, VP is currently used clinically in the 
treatment of AMD as a photosensitiser during PDT. The PDT laser activation point of VP 
is around 685-690 nm and so closer inspection of the spectra around this activation point 
shows that addition of ferric iron caused a dramatic shift in the spectra (Figure 4.31B). 
Upon increasing ferric iron concentrations of 30 µM and above, the absorbance peak 
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shifts from 686 nm towards 670 nm, and is accompanied with a decrease in absorbance, 
strongly suggesting that VP is indeed binding iron resulting in a change of structure and 
hence alterations in absorbance profile. 
 
 
Figure 4.31 VP rapidly binds ferric chloride. (A) Increasing concentrations of ferric 
chloride (FeCl3/Fe3+; 3-500 µM) was added to 30 µM VP diluted in MeOH. Absorption spectra 
were then measured being 300-800 nm, 1 min following combination. There is a distinctive 
shift in VP absorption spectra as well as a dramatic increase in absorbance around 430 nm 
with increasing concentrations of iron indicating binding. (B) A closer look around the VP 
photodynamic therapy activation point at 686 nm shows a progressive shift towards 670 nm 
and a reduction in absorbance with increasing concentrations of ferric chloride. Graphs are 
representative of experiments conducted in biological triplicate. 
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Further investigations into whether the iron oxidation state was important for VP binding 
employed the same approach as above, but in the presence or absence of ferrous iron 
(Fe2+; 3-500 µM). The absorbance profiles generated did not show the same alterations 
as was seen upon ferric iron addition (Figure 4.32) – while ferrous iron induced a slight 
increase in absorption around 430 nm, few differences were seen around the PDT 
activation peak (Figure 4.32B). Higher concentrations of ferrous iron appeared to cause 
a small shift in the spectra with a decrease in absorbance around 686 nm, although this 





Figure 4.32 VP does not bind ferrous chloride as rapidly as ferric chloride. (A) 
Increasing concentrations of ferrous chloride (FeCl2/Fe2+; 3-500 µM) was added to 30 µM VP 
diluted in MeOH. Absorption spectra were then measured being 300-800 nm, 1 min following 
combination. A slight change in absorbance is seen around 430 and 686 nm however only at 
higher concentrations. (B) A closer look at the absorbance peak at 686 nm shows a lack of 
shift towards 670 nm which was apparent with FeCl3. There is a slight change however but 
only with higher concentrations (300 and 500 µM). Graphs are representative of experiments 
conducted in biological triplicate. 
 
Absorbance spectra profiles were also generated for the addition of other metal ions, 
zinc (ZnCl2; Zn2+) and magnesium (MgCl2; Mg2+), to VP. As with ferrous iron, these metal 
ions did not induce the significant alterations in the VP absorbance spectra (Figure 
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4.33A-D). Furthermore, spectral analysis of ferric iron and VP showed that binding was 
capable in both normoxic and hypoxic conditions (Figure 4.33E). 
 
 
Figure 4.33 VP does not immediately bind metal chlorides, magnesium and zinc. 
Absorption was measured in the UV/Vis range 1 min after 30 µM VP was added to 100 µM 
ferric chloride (FeCl3; A), ferrous chloride (FeCl2; B), magnesium chloride (MgCl2; C) and zinc 
chloride (ZnCl2; D). Only addition of ferric chloride was able to alter the absorption spectra of 
VP. (E) Binding of FeCl3 was similar in hypoxia to that of normoxia. Graphs are 
representative of experiments conducted in biological triplicate. 
 
 
It was still possible however that other ions would bind over a longer time period. To 
investigate this, first-order binding kinetics curves were generated from calculating the 
ratio in absorbance at 670 and 686 nm, demonstrative of the largest spectral shift (Figure 
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4.34A-C). VP was added to a range of concentrations of FeCl3, FeCl2, ZnCl2 and MgCl2 
and absorbance values were taken immediately and after 8 and 24 hours. Corroborating 
previous data, ferric iron showed immediate complexation to VP. Additionally, both 
ferrous iron and zinc also showed complexation to VP, albeit over a slower timescale, 
with no apparent immediate spectral alterations however significant changes observed 
after 8 and 24 hours. On the contrary, magnesium did not induce any spectral changes 
even after 24 hour incubation, indicating no VP complex formation. 
 
These observations were then validated by MS, which again shows VP able to complex 
with ferric iron, ferrous iron and zinc but not magnesium (Figure 4.34D). These data also 
indicate 1:1 binding stoichiometry for the three complexes, with two pyrrole units 
deprotonated in each case which is consistent with the macrocycle acting as a 
tetradentate chelating ligand (as interpreted from raw spectra in Appendix 2). Together 






Figure 4.34 VP can bind ferrous and zinc chloride but only over time. Increasing 
concentrations of ferric, ferrous, magnesium and zinc chloride (3-500 µM) were added to VP 
(30 µM) diluted in methanol. VP absorption spectra was then measured 1 min (A), 8 (B) and 
24 h (C) following combination. First order binding kinetic graphs were then generated by 
calculating the ratio of absorbance at 670/686 nm. It is clear that VP can immediately and 
avidly bind ferric chloride. VP can also bind ferrous and zinc chloride but only after 8 h which 
was increased after 24 h. VP did not bind magnesium chloride at all as there is no change 
across all time points. (D) Mass spectrometry was conducted in collaboration with Prof. J. 
Tucker’s research group in the School of Chemistry, UoB. Data showed that VP bound Fe3+, 





4.3. Discussion  
Despite some small improvements in patient survival over the past two decades, gliomas 
remain incurable. The standard treatment for these patients has remained the same 
regardless of tumour mutational status, heterogeneity or therapy-resistance. Current 
treatments do not or are unable to take into account some of the most significant aspects 
of glioma biology such as widespread hypoxia, which is a major determinant for 
treatment failure. Identifying therapies that address the tumour microenvironment could 
be a way of universally targeting the tumour as a whole rather than designing individual 
treatments around the stratification of patients based on mutational status. 
 
As previously reported, the transcriptional co-activator YAP may play an important role in 
hypoxic biology. Results presented in chapter three, demonstrate hypoxia to be an 
upstream regulator of YAP in glioma, increasing its gene expression as well as 
downstream activity. Abnormal YAP activation has been linked to tumorigenesis in many 
cancers, inducing chemoresistance and promoting tumour invasion, migration and 
progression. Therefore, investigations were conducted into whether the YAP inhibitor, VP 
could be repurposed as a novel treatment for suppressing glioma growth and 
progression. 
 
4.3.1. VP suppresses glioma cell proliferation 
VP has been previously reported to supress YAP oncogenic ability through interference 
of the YAP-TEAD interaction thereby downregulating transcription of proliferative target 
genes such as CTGF, CYR61 and axl, causing suppression of cell proliferation153,158. In 
corroboration with previous investigations in other cancer types, initial experiments 
showed VP to inhibit glioma cell growth in a dose-dependent manner (Figure 4.2)158-160. 
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These results are also in agreement with a recent study by Al-Moujahed et al., who 
showed VP to selectively inhibit growth of LN-229 and SNB-19 glioma cell lines through 
downregulation of YAP-TEAD target genes under normoxic conditions161. This paper 
also suggests VP to reduce cell viability, measured through a MTT assay, when cells 
were treated with increasing concentrations of VP (2 and 10 µg/ml) over 3 and 6 days. 
However, it is not made clear whether this reduction in viability is a result of cell death or 
a result of suppression of proliferation since this assay cannot easily distinguish between 
the two. In this present study, images were taken of VP treated cells after 72 and 96 
hours, clearly showing that under these conditions, glioma cells remain viable following 
VP exposure, and that a reduction in cell number (analysed through SRB assay which 
measures cell protein content) is a result of a reduced proliferation rate (Figure 4.1C and 
4.2C). 
 
4.3.2. VP induces cell death under hypoxic conditions 
Hypoxia, as previously described, has been shown to enhance YAP’s role as a 
transcriptional coactivator and thus has been closely linked to increased proliferation and 
survival of malignant cells. Since YAP inhibitor VP demonstrated significantly reduced 
cell proliferation capacity under normoxic conditions, the question was raised as to 
whether VP could induce enhanced growth suppression under conditions that mimicked 
the hypoxic glioma microenvironment. This study provides evidence for the first time, that 
VP can selectively kill hypoxic glioma cells – which was confirmed through cell imaging – 
rather than suppressing hypoxic cell proliferation (Figure 4.3). Despite previous research 
demonstrating VP to induce a reduction in cell viability under normoxic conditions in 
other cancers, normoxic glioma cells in this study remained viable at a VP concentration 
which could induce death under hypoxic conditions. These results suggest however that 
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this discrepancy may well lie in the careful exclusion of light from experiments, which 
increases normoxic cell death. 
 
Adherent monolayer cell culture has undoubtedly been invaluable in the process of drug 
discovery and elucidation of both physiological and pathophysiological cellular 
mechanisms. However, it has come under some scrutiny as to whether these 2D cultures 
can accurately represent the complexity of in vivo biology. Culturing cells in 3D as 
cellular aggregates, commonly known as spheroids, provides a more biologically relevant 
model as it allows spatial and temporal organisation of cell growth as well as generation 
of a nutrient, metabolite and oxygen gradient across the spheroid which is reminiscent of 
in vivo tumours273. 
 
U87 and U343 cells were subsequently grown as spheroids to assess the relationship of 
VP and cell proliferation and death in a more physiologically relevant model. VP 
treatment significantly attenuated spheroid size and growth in a dose-dependent manner 
if cells were exposed during spheroid formation (Figure 4.6). Furthermore, VP exposure 
destabilised the integrity of the surface layer of fully formed spheroids, leading to 
detachment of cells and spheroid destabilisation. Proliferating cells are known to 
preferentially locate on the outermost layers of spheroids and therefore are easily 
accessible for VP to potentially suppress YAP activity and lead to decreased growth274. 
These observations are supported by Fisher et al., who showed that VP was capable of 
suppressing formation of melanoma spheroids and through prolonged treatment, caused 





In addition to VP, the structurally-related porphyrin PPIX was also previously shown to 
disrupt the physical interaction between YAP and TEAD153. In this investigation, glioma 
cells were treated with PPIX and an additional derivative ZnPP, to uncover whether it 
was a characteristic of porphyrins in general that could elicit this hypoxia-selective cell 
killing (Figure 4.4). Surprisingly, VP was the only porphyrin member to induce glioma cell 
death, which was corroborated in the melanoma cell line, A375. This selectivity could be 
a result of VP displaying a stronger inhibitory phenotype since PPIX has been previously 
reported to exhibit weaker inhibitory properties compared to VP153. In support of this, 
Wang et al., also reported that VP treatment of endometrial cancer cell lines induced a 
dose and time-dependent decrease in YAP protein expression that upon PPIX treatment 
remained unchanged275. Additionally, although a structural derivative of PPIX, VP has 
distinctive structural modifications such as the addition of a propionic acid methyl ester 
and a cyclohexadiene ring bearing two methanoic acid methyl esters264 (Figure 4.35). 
Due to the difference in ability of inducing cell death between the compounds, a number 
of chemical analogs of VP could be therefore generated to identify what specific 





Figure 4.35 Chemical additions to VP.. Structurally derived from PPIX, VP has two main 
chemical modifications – addition of a cyclohexadiene ring bearing two methanoic acid 
methyl esters (orange) and a propionic acid methyl ester (green). 
 
Novel GBM cell lines derived from a patient biopsy were generated in order to test 
whether VP sensitivity could be observed in a cell system more closely linked to ‘real’ 
tumours. After treatment with VP in vitro, it was observed that both T1 and T2 GBM lines 
were sensitive to VP in hypoxia (Figure 4.4). This is a key result, as the area of the 
original tumour from which the T1 cell line was derived had been resistant to 
conventional therapy (TMZ + fractionated 54 Gy radiation), while T2 cells had 
demonstrated therapy responsiveness. The results presented in this chapter therefore 
suggest that VP-mediated cell killing is independent of normal resistance mechanisms 
observed in GBM, and may reduce the rate of relapse and progression. Previous 
research has shown that YAP-inhibition through VP (in normoxia) can re-sensitise 
resistant cells to drugs such as cisplatin, erlotinib and paclitaxel as well as improving 
effectiveness of radiation treatments162,163. VP therefore has the potential to not only be 
employed as a mono-therapy in the selective killing of hypoxic cells in cancer but could 
be introduced as part of a combination therapy to enhance treatment sensitivity in 
therapy-resistant tumours. Unfortunately, at least 50% of TMZ-treated patients exhibit 
resistance so future experiments should investigate whether there is a synergistic 
 
205 
relationship between VP and TMZ and whether this provides any improvement in TMZ-
resistant patient survival276. 
 
4.3.3. VP induces rapid changes in cell morphology and is sensitive to 
ambient light 
We also investigated whether VP could be used at a more clinically relevant treatment 
period, showing that hypoxic-induced cell death was a rapid process that was initiated 
within the first hour of exposure (Figure 4.8). These observations were also supported by 
cell viability assays showing that 4 hour VP exposure followed by removal of the drug for 
the remaining 20 hours was adequate to induce significant cell death under hypoxic 
conditions (Figure 4.11A, B). This data additionally supports evidence by Zhang et al., 
showing that washout of VP following treatment did not restore cell proliferation in colon 
cancer cells165. Normoxic sensitivity was also apparent in this study if cells were exposed 
to ambient light during the media replacement following 4 hour treatment, showing that 
photo-activation of VP can also increase the sensitivity of glioma cells to cell death under 
normoxic conditions (Figure 4.11C, D). 
 
Hypoxic induction of nuclear YAP expression was apparent after 4 hours hypoxia (Figure 
4.9A, B); again supporting evidence presented in chapter three showing hypoxic 
upregulation of YAP in glioma cells. However, U343 cells failed to recapitulate this 
observation following 8 hours hypoxia suggesting that despite increased gene 
expression (Figure 3.2), these cells have differential protein expression. This is also 
supported by the minimal increase in YAP1 protein expression observed following 8 
hours hypoxia (Figure 3.6), possibly due to an increased basal level of YAP1. VP 
attenuated YAP1 nuclear expression and localisation (immunofluorescence) in this study, 
 
206 
which was enhanced under hypoxic conditions, suggesting VP not only as an inhibitor of 
YAP activity but also of its expression. This observation is supported by previous 
research showing VP to dramatically reduce YAP protein expression164,275 as well as its 
downstream targets CTGF, CYR61, axl, survivin and OCT4158,161. Although ICC showed 
a reduction in YAP1 nuclear fluorescence in this study, analysis of protein expression by 
western blot provides contradictory evidence as YAP1 and CTGF expression remained 
unchanged upon 4-48 hour VP exposure (Figure 4.10). The disparity in results could be 
due to protein being extracted from the whole cell for western blotting compared to 
selective analysis of just nuclear fluorescence in ICC. This would therefore suggest that 
global YAP expression may not alter within that time period however YAP could undergo 
relocation from the nucleus upon VP exposure. Cellular fractionation techniques could 
therefore be employed to determine YAP expression in the different subcellular fractions 
upon VP treatment to see if this supports the ICC data. Furthermore, VP concentrations 
used in the literature can range from 3 µM for 24 hours to 1 µM for 6 days, with some 
studies even using concentrations of 20 and 40 µM162,164,277. Therefore, alterations in 
YAP expression appear to be cell line specific and also dependent on dose and 
treatment time and so for VP to influence YAP expression in these glioma cells, a higher 
concentration or longer exposure time could be required. Conversely, due to the rapid 
induction of hypoxic cytotoxicity and unchanged YAP activity with this concentration of 
VP (5 µM), it is likely that VP is acting either in a YAP-independent fashion or 
independent of YAP-TEAD suppression to induce cell death. It should be noted however 
that the peak concentration of VP found in AMD patient plasma after a 10 minute infusion 
of 6-12 mg/m2 body surface area is approximately between 2-5 µM and so within the 




4.3.4. Expression of YAP-binding partner p73 is increased upon VP exposure 
but does not lead to increased YAP-p73 interaction  
p73, identified to be a structural and functional homolog of p53, is involved in tumour 
suppression and through direct association with YAP can enhance co-activation and 
transcription of target genes such as BBC3 to induce apoptosis143,279. As it has been 
previously discussed, YAP is known to exhibit differential selectivity in transcription factor 
binding partner dependent on cellular and microenvironmental context. Since VP has 
been described to suppress the pro-proliferative YAP-TEAD interaction, the question was 
asked whether this interference could encourage YAP to switch its binding partner to 
favour p73, therefore inducing cell death. Results showed VP to dramatically increase 
p73 expression upon exposure, which was enhanced under hypoxic conditions (Figure 
4.12). Increased p73 expression however does not correlate to increased activity and 
consequently YAP1 did not appear to interact with p73 in co-immunoprecipitation 
analysis (Figure 4.13). As previously discussed, this investigation showed VP to reduce 
YAP1 nuclear fluorescence but not total YAP1 protein implying potential protein 
relocalisation. Previous research has shown that 14-3-3 binding proteins are significantly 
upregulated following VP treatment, consequently sequestering YAP in the cytoplasm275. 
Cellular localisation is critically important for p73 and YAP as sequestered cytoplasmic 
YAP is inactive as it can no longer co-activate gene transcription in the nucleus. 
Intriguingly, VP induced a widespread cytoplasmic expression of p73 which is 
contradictory for it to function as a nuclear co-activator in the induction of apoptosis. 
Cytoplasmic localisation of p73 has however previously been observed although its 
importance remains to be elucidated280,281. Nuclear exclusion of p73 could be a potential 
negative regulatory mechanism to limit its transcriptional activity since its nuclear import 
and export has previously been shown to be tightly controlled 282. However, cytoplasmic 
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localisation could enable a novel function for this protein, as it has been proposed that 
p73 may have a cytoplasmic function which can occur independently to its transcriptional 
regulation of apoptosis. The WW-domain-containing oxidoreductase (Wwox) protein has 
been identified as a tumour suppressor and has been shown to potently sequester and 
co-localise with p73 in the cytoplasm283. This resulting interaction competitively inhibits 
co-activation of p73 by YAP as YAP and Wwox compete for binding to the proline-rich 
PPxY motif of p73279,284,285. Subsequent sequestration and binding of cytoplasmic p73 
has shown to markedly enhance the pro-apoptotic function of Wwox, enabling a pro-
apoptotic function of p73 which is independent of its transcriptional activity283,284,286. Due 
to the dramatic VP-induced p73 expression and decreased nuclear localisation of YAP1 
in this study, this cytoplasmic function of p73 could be of importance in VP-induced cell 
death. To investigate whether VP-mediated cell death could be suppressed through 
reduction in p73 expression, siRNA targeting p73 was used however successful 
knockdown could not be achieved (data not shown). Further investigations into the 
relationship between YAP, p73 and Wwox upon VP treatment are therefore imperative. 
Furthermore, the distinct splice variants of p73, TA-p73 and N-p73, have also been 
proposed as a regulatory mechanism, allowing p73 to exhibit both pro- and anti-apoptotic 
activity respectively287,288. Therefore, a closer look is required as to whether VP can 
influence which p73 isoform is expressed and whether this significant VP-induced 
increase in p73 expression is directly associated with the VP-induced cell death 
observed in these glioma cells. 
 
4.3.5. VP-induced hypoxic cell death is YAP-independent 
The data in this study suggest that VP can induce cell death very rapidly in glioma cells – 
within 1 hour of exposure. These results therefore raised the question as to whether it 
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was possible for YAP to orchestrate this process, given that changes in YAP-mediated 
gene expression would be expected to act over a longer period. To investigate this, YAP, 
its paralog TAZ, and both proteins were silenced in glioma cells before exposure to VP 
(Figure 4.14). Despite significant knockdown of these proteins, VP was still able to 
induce hypoxic cell death indicating, along with the unchanged YAP target gene 
expression levels, that this process was YAP-independent. A question was raised 
however that potentially other YAP isoforms, such as YAP1-2, could still be present and 
inhibited upon VP treatment however the YAP1 siRNA used specifically targets the YAP1 
gene and was therefore, based on the siRNA target sequences (Appendix 1), expected 
to silence all nine YAP1 protein coding isoforms. 
 
Despite numerous studies highlighting VP to inhibit YAP oncogenic activity through YAP-
TEAD suppression, it has emerged in recent years that VP also exhibits significant ‘off-
target’ effects. Research conducted by both Zhang et al., and Konstantinou et al., have 
shown VP to induce proteotoxicity through formation of high-molecular weight protein 
oligomers, such as that of p62 protein, which cannot be successfully cleared through 
proteasomal and autophagic pathways, thereby resulting in cellular toxicity165,289. The 
function of p62 ensures proper turnover of potentially harmful proteins by targeting these 
toxic aggregates for autophagy, consequently promoting cell survival268. However, 
abnormal aggregation and increased sequestration of p62 and other cross-linked 
proteins leads to proteotoxicity-induced apoptosis. VP has been previously identified to 
significantly increase p62 aggregation in colorectal cancer lines and tumours, with p62 
becoming increasing localised to the perinuclear region of the cell165. Expression of p62 
was therefore investigated in this study, but was observed to decrease as opposed to 
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increase upon VP treatment suggesting that this mechanism might not be relevant in 
glioma (Figure 4.15). 
 
Originally proposed as a light-independent effect of VP, Konstantinou et al., have 
suggested that VP does indeed need to be light activated to induce these high-molecular 
weight protein complexes, and that although most studies involving VP are conducted in 
the dark, often post-treatment processes such as cell lysis and western blotting are 
conducted in the light. The authors show that this ambient light exposure post-lysis is 
sufficient to activate VP, inducing its photochemical properties and formation of these 
protein oligomers through increased cross-linking as a result of increased free radical 
generation289. It should be noted that in this study, cells were shielded from ambient light 
during treatment although when harvested for western blotting, cells were lysed and run 
in the light. That being the case, VP was unable to induce changes in protein expression 
of YAP or its downstream targets suggesting that in this investigation, VP exhibited YAP-
independent effects despite potential post-lysis light-activation of VP. It should be noted 
that more consideration should be taken when reporting light-dependent and 
independent effects of VP, with studies being more explicit in stating the light conditions 
of experiments; something which is not currently done. Additionally, when studying light-
independent effects, samples should not only be shielded from light during the treatment 
period but during all downstream processing. 
 
4.3.6. VP-mediated hypoxic cell death is HIF-1α independent 
This study has demonstrated that VP can selectively induce cell death under hypoxic but 
not normoxic conditions. These results therefore raised the question as to what hypoxia-
responsive mechanism was responsible for influencing this selective sensitivity. Hypoxia 
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results in numerous alterations in cell phenotype some of which are mediated through 
hypoxia-induced activity of the HIF-1 transcription factor, often entitled the master 
regulator of hypoxia135,290. Other phenotypic changes however can be directly triggered 
through the reduced oxygen availability such as disturbances in mitochondrial activity 
and increased generation of ROS. Results from chapter three support the few 
investigations which show hypoxia-mediated upregulation of YAP expression and activity 
through increased nuclear localisation, thereby promoting tumour survival131,134,135,229. 
Previous attempts to elucidate this relationship uncovered the presence of a nuclear 
YAP-HIF-1α or TAZ-HIF-1α complex that stimulated TEAD transcriptional activity and 
whose activity was enhanced under hypoxic conditions134. VP has been recently 
identified to inhibit formation of this YAP-HIF-1α complex, independent of TEAD 
activity277. HIF-1-dependent effects on VP-induced cell death were therefore investigated 
via pharmacological stabilisation of HIF-1α in normoxia as well as over-expression of a 
HIF-1α mutant resistant to normoxic degradation213 (Figure 4.16). Induction of HIF-1α 
partially sensitised cells to VP, although the effect did not approach the level observed 
under 1% O2. Since it had also been shown that VP was capable of inducing cell death 
independent of YAP function, it could explain why only partial sensitivity was seen with 
HIF-1α stabilisation in normoxic conditions as there are other participating hypoxia-
responsive mechanisms independent of the putative YAP-HIF-1α relationship. 
Knockdown of HIF-1α confirmed that the VP-induced cell death observed in this study 
appears to be YAP- and HIF-1-independent, as VP was still able to induce cell death in 
hypoxia even in the absence of HIF-1α (Figure 4.17). Although HIF-1α stabilisation was 
capable of partially sensitising cells to VP-cell death in this study, the greatest effect was 
observed with DMOG treatment suggesting that DMOG could potentially exhibit other off-
target effects, contributing to cell death. This partial sensitivity also suggests that there 
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are clearly additional mechanisms which have a greater precedence in VP-induced cell 
death and are exacerbated under low oxygen conditions. 
 
4.3.7. Traditional cell death inhibitors only partially prevent VP-mediated 
hypoxic cell death  
To further elucidate the mode of VP-induced hypoxic cell death in glioma cells, a number 
of pharmacological inhibitors of cell death were employed. Previous papers have 
suggested in various cancer models that VP induces cell death through apoptosis both in 
vivo and in vitro, although it is unclear whether this induction is light-dependent or 
independent159,166,291. Glioma cell lines were therefore treated with VP in the presence 
and absence of a cell-permeable pan-caspase inhibitor, Z-VAD-FMK. Despite previous 
research demonstrating that VP induces apoptosis, it was found here to not be the 
predominant mode of cell death, assessed through incapability of Z-VAD-FMK in 
preventing VP-induced cell death (Figure 4.18-4.21). Although a small rescue in cell 
viability was observed in the U87 cells upon Z-VAD-FMK addition, Annexin V-PI cell 
viability assays demonstrated cells to have minimal Annexin V staining but increased PI 
uptake, which is indicative of a disrupted plasma membrane therefore suggesting an 
alternative form of cell death, such as necrosis292,293. Since apoptosis can be executed 
as rapidly as 4 hours, a shorter VP-treatment time was investigated in case the cells 
exhibited early-apoptotic mechanisms before necrosis. However, even at these 
timepoints, increased uptake of PI was still predominant over Annexin V staining. This 
was also corroborated by the fact that traditional morphological hallmarks of apoptosis 
such as nuclear fragmentation or shrinkage were not apparent in these cells (Figure 
4.21). From the use of Z-VAD-FMK, the data suggests VP cell death is not predominately 
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through caspase-dependent apoptosis however it does not rule out other caspase-
independent apoptotic and alternative mechanisms of cell death. 
 
Once regarded to be a chaotic, unprogrammed mode of cell death, research has 
uncovered necrosis to be an alternative and often tightly-regulated mechanism of death; 
also known as necroptosis. Nec-1 is a potent allosteric inhibitor of RIPK1, inhibiting the 
formation of the necrosome and subsequent activation of necroptosis294,295. Surprisingly, 
contrary to research showing VP and PDT to induce tissue necrosis156, VP-induced 
hypoxic cell death could not be prevented in the presence of Nec-1, indicating that other 
mechanisms are at play (Figure 4.22). Apoptosis, necrosis and autophagy were once 
believed to be distinct individual death mechanisms, with apoptosis being the most 
favoured by the cell; however it is now understood that there is considerable cross-talk 
between these modes of cell death. Research has uncovered evidence that these 
pathways are often regulated by the same stimuli and can even share downstream 
initiator and effector molecules296. With this in mind, cells were also treated with the 
inhibitor ALLN, which prevents activation of calpains – known to play a role in caspase-
independent apoptosis and necrosis – and cathepsins – believed to be a part of 
autophagic cell death296,297 (Figure 4.22). Again, VP-induced cell death could not be 
prevented upon addition of this inhibitor. A number of modes of cell death induce, as part 
of their process, opening of the mPTP, mitochondrial swelling, dissipation of the 
mitochondrial inner transmembrane potential and release of apoptogenic molecules into 
the cytosol261,298. Cyclophillin D, (CyP-D) is an essential component of this membrane 
pore playing a vital role in channel opening and can be potently inhibited by the 
compound CsA299,300. Interestingly, Belzacq et al., have also shown VP to act on the 
mPTP inducing cell death, although light-activation was required261. Glioma cells were 
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therefore treated with VP in the presence of CsA to investigate whether inhibiting mPTP 
opening could prevent VP-induced cell death (Figure 4.22). In this system however, 
hypoxia-specific cell death could not be inhibited upon VP exposure. Finally, inhibitors 
against p53/p73 mediated and autophagic cell death, PFT-α301 and CQ302, were 
employed although neither could prevent VP cell death under hypoxic conditions (Figure 
4.23). From use of these various inhibitors, the data suggest that VP-induced cell death 
is multifactorial and likely based on a biochemical, rather than a signalling, response. It 
should be noted however, as previously mentioned, that there is convergence of these 
cell death mechanisms and evidence to suggest that treating cells with one cell death 
inhibitor can often push cells towards utilising an alternative mode of cell death. Nec-1 
has recently been identified to also inhibit apoptosis in addition to necroptosis and 
conversely Z-VAD-FMK can also induce expression of the necroptosis effector RIPK1298. 
To increase confidence in confirming the mode of VP-induced cell death in glioma cells, 
a combination of inhibitors should be employed upon VP exposure and a further look at 
molecular initiators and effectors such as BCL2 proteins and cytochrome c release could 
confirm that these regulated mechanisms of cell death are not involved. 
 
4.3.8. Hypoxia exacerbates VP-induced cellular vacuolisation and ER stress 
A significant phenotype observed as a result of VP exposure was cellular vacuolisation, 
which was exacerbated under hypoxic conditions (Figure 4.24). Vacuolisation is a 
hallmark of non-apoptotic or caspase-independent cell death pathways such as 
autophagy, methuosis, oncosis, paraptosis and also necroptosis271. It is believed that 
irreversible vacuolisation can arise in cytopathological conditions as a result of cytotoxic 
stimuli, significantly affecting the Golgi apparatus, the endosomal-lysosomal 
compartment as well as the ER272. However, it remains undetermined whether these 
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vacuoles play a role in cell survival under stress conditions or whether they are 
connected to cell death. The ER was therefore investigated to determine whether VP-
induced vacuolisation could be a result of increased stress to this organelle. VP 
exposure significantly increased ER stress, which was determined through expression of 
CRT; an ER-residing molecular chaperone involved in the correct folding of glycosylated 
proteins and regulation of calcium homeostasis and is subsequently known to be 
significantly upregulated under conditions of ER stress303. ER stress was additionally 
observed to be amplified under hypoxic conditions (Figure 4.25). Previous studies have 
suggested that increased ER stress can increase cell vacuolisation leading to a 
disruption in the ERAD pathway272. Under normal conditions, the ERAD pathway is part 
of a quality control network ensuring correct folding and processing of proteins to prevent 
toxic aggregates of misfolded proteins from accumulating in the cell304; pathologies that 
are observed in neurodegeneration diseases such as Parkinson’s and Alzheimer’s 
disease304,305. When this pathway is disrupted, misfolded proteins can amass in the ER, 
increasing ER stress and inducing the UPR which quickly acts to restore the 
physiological balance by halting protein translation, degrading misfolded proteins as well 
as increasing expression of chaperones for increased protein folding306,307. However, if 
UPR is not completed either rapidly or successfully, then the cell is targeted for cell 
death306,307. Eer1 is a known inhibitor of the p97/VCP cytosolic AAA+ ATPase which 
retrotranslocates misfolded substrates from the ER to the cytoplasm for subsequent 
proteasomal degradation308,309. Eer1-mediated ERAD inhibition has therefore shown to 
increase ER stress due to the accumulation of protein aggregates, driving the cells to 
die307,309,310. This is contrary to the response observed in this investigation, as Eer1 
treatment partially rescued cell viability following VP exposure (Figure 4.26). This 
differing response to Eer1 inhibition could be due to a dose- and time-dependent effect 
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as Wang et al., have shown that by disrupting ERAD, it increases the time for the cell to 
correct misfolded proteins before targeted degradation, allowing the cell to survive longer 
before potential induction of UPR and cell death311. Additionally, the observations in this 
study are also supported by Shah et al., who showed Eer1 to induce EMT and increase 
cell migration and invasion for a period before induction of cell death, which was 
eventually induced through prolonged inhibition of p97/VCP312. Mild activation of the 
UPR has also been shown to promote cancer progression as it can improve ER 
function309. It therefore appears that there is a fine balance in the regulation of this 
pathway in that brief inhibition of ERAD can actually alleviate ER stress promoting cell 
survival however sustained ERAD inhibition over a matter of days causes excessive ER 
stress, resulting in cell death. Furthermore, the concentration of Eer1 used should be 
further investigated as it could have opposing effects with lower doses causing partial 
ERAD inhibition and mild UPR response allowing cell survival, whereas higher doses 
could induce full ERAD inhibition exacerbating ER stress, and thereby forcing the 
decision of cell to die. With respect to VP treatment, it suggests that mild UPR activation 
during VP treatment was able to partially prevent VP-induced cell death indicating that 
VP does indeed trigger ER stress and potential protein aggregation which could 
therefore instigate cell death mechanisms. 
 
4.3.9. VP induces significant cellular stress through increased production of 
ROS 
Tight regulation of redox homeostasis is crucial for maintaining both healthy and 
malignant cell survival and as previously discussed, there is a close relationship between 
ER stress and oxidative stress. During excessive ROS production, these highly reactive 
oxygenated molecules, particularly the hydroxyl radical OH, can attack and cause 
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oxidation of DNA, protein and lipids202. VP, as previously discussed, is a photosensitiser 
and when activated by light has been shown to generate cytotoxic free radicals, 
predominately singlet oxygen – much like other physiological porphyrin molecules – 
exerting damage to the surrounding tissue154,155. To investigate whether VP could induce 
oxidative stress, in addition to ER stress in the absence of light-activation, markers of 
oxidative stress were analysed. VP was seen to induce a significant increase in DNA 
oxidation, observed through increased presence of 8-OHdG and significantly increased 
DCF fluorescence (Figure 4.27-4.28). ROS production upon VP exposure was also 
observed in this investigation to be significantly exacerbated under hypoxic conditions; a 
known stimulator of ROS production313. Although VP induces ROS in normoxic 
conditions, it appears that cell death could be selectively induced in hypoxia since these 
cells already exhibit a higher basal level of ROS production. Therefore, amplifying ROS 
generation under these sensitive conditions is sufficient to tip the balance towards 
causing excessive cellular damage consequently driving the cells to initiate cell death 
driven by apoptotic or necrotic mechanisms. Furthermore, related-porphyrin PPIX did not 
significantly increase ROS production in both normoxia and hypoxia, again providing 
evidence that VP-induced death in hypoxia is explicit to this porphyrin and potentially 
through exacerbated ROS production (Figure 4.28). 
 
Attenuation of ROS production was observed upon the addition of general redox-cycling 
TEMPOL, which is capable of catalysing O2- to H2O2, facilitate detoxification of H2O2 to 
H2O as well as inhibiting Fenton chemistry and subsequent generation of OH radicals 
from H2O2314(Figure 4.28). TEMPOL was also capable of partially inhibiting VP-induced 
hypoxic cell death indicating, as previously mentioned, that there are other mechanisms 
contributing to VP-induced cell death and inhibition of one mechanism is not enough to 
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fully rescue cell viability (Figure 4.29). Further experiments could involve using a 
combination of ROS and cell death inhibitors and over-expressing endogenous 
antioxidant mechanisms such as catalase to see if this can increase cell viability over 
exogenously applied antioxidants. 
 
4.3.10. VP can bind intracellular iron for use in potential Fenton-like chemistry 
to exacerbate ROS production 
Iron is vital for cellular metabolism as in addition to playing a central role in oxygen 
transport, cellular respiration and DNA synthesis, it forms the active site of numerous 
redox-active enzymes enabling these reactions to occur315,316. Under physiological 
conditions, iron homeostasis is tightly-regulated in its uptake, storage and release. Iron 
metabolism is known to be disrupted in cancer with tumours exhibiting enhanced iron 
dependence resulting in increased iron uptake which contributes to increased tumour 
survival316,317. GBM, along with other cancers, has shown in addition to increased iron 
uptake, to increase expression of iron-storage protein ferritin which subsequently allows 
higher sequestration and storage of intracellular iron317,318. Paradoxically, iron 
dysregulation resulting in the excess of free iron can be toxic to the cell due to its role in 
the generation of highly reactive hydroxyl radicals from H2O2 in the Fenton reaction319. 
This increased ROS, as previously mentioned, could be at first beneficial for cancer 
progression as low levels can amplify various survival pathways, such as the Akt/mTOR 
pathway, however once ROS accumulate in excessive amounts it can instigate cell 
death316. 
 
Porphyrins are known to bind to metals to form complexes, with the metal ion usually 
possessing a charge of 2+ or 3+. Due to the similarity in structure of VP with other 
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porphyrins, it was hypothesised that VP would also be capable of binding transition 
metals. The precise mechanism of how VP generates ROS, particularly in the absence of 
light-activation, is not known and so it was further hypothesised that the mode of action 
could be through iron catalysing the Fenton reaction. Results show that VP is indeed 
capable of complexing with ferric (Fe3+), ferrous (Fe2+) and zinc (Zn2+) ions however not 
magnesium (Mg2+) (Figure 4.31-4.34). It was found that VP did not bind magnesium – 
considering that Mg2+ is a biologically relevant ion and porphyrins are capable of binding 
magnesium, this is a significant result320. Instead, ferric iron was the predominant metal 
species which bound to VP, with ferrous and zinc only binding over a longer period of 24 
hours (Figure 4.34). Mass spectrometry data indicated that VP was acting as a 
tetradentate chelating ligand forming a coordination complex with the metal ions. It could 
be hypothesised that VP is predominately chelating ferric iron, which can then elicit 
Fenton-like redox cycling, which would therefore exacerbate ROS production. The 
toxicity of H2O2 is dependent on its reaction with ferrous iron to generate the highly 
reactive OH through the Fenton reaction, as previously discussed. It is now accepted 
that the ferrous iron needed for this reaction can be generated from the reduction of ferric 
iron by superoxide anions, in the iron-catalysed Haber-Weiss reaction (now referred to 
as Fenton-like chemistry)321,322: 
 
𝐹𝑒𝑛𝑡𝑜𝑛 − 𝐿𝑖𝑘𝑒 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 ∶  𝐹𝑒3+ + 𝑂2
  − → 𝐹𝑒2+ + 𝐻2𝑂2 
 
Starke and Farber have shown that both ferric iron and superoxide ions were required for 
the H2O2-induced cell death of hepatocytes in vitro323. Theoretically, VP could bind ferric 
iron to initiate increased redox cycling as reduction of Fe3+ upon the presence of 
superoxide anions generates Fe2+ which consequently produces reactive OH and Fe3+ 
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which could again bind VP therefore perpetuating the ROS pool. Due to the nature of the 
tetradentate complex, the planar structure could also lead to exposure of the iron centre 
making it easily accessible for reduction by superoxide anions. Haem is another iron-
coordinated porphyrin and ROS have been shown to randomly attack the carbon 
methene bridges situated in the tetrapyrrole rings subsequently generating pyrrole 
products and the release of iron, supporting this theory of iron cycling324. Furthermore, 
hypoxia is a known reducing environment and so could exacerbate the reduction of the 
Fe3+-VP complex to produce ferrous ions thereby amplifying ROS production which could 
contribute to the VP-induced hypoxic cell death observed in glioma cells325. Ascorbate is 
another reducing agent known to reduce ferric compounds to ferrous and interestingly 
has been shown to enhance the toxicity of VP326. 
 
This observation could therefore shed some light on the potential mechanism of VP-
induced ROS generation. Further experiments are required to elucidate the chemistry of 
this reaction to fully understand the mechanism of VP preferentially binding ferric iron. 
Cyclic voltammetry experiments could therefore be applied to investigate this potential 
iron redox cycling. Furthermore, it is important to investigate the effect of iron chelation 
on the activity of VP, since it could be hypothesised that upon diminished presence of 
iron, VP would potentially lose its activity. The structural modifications of VP should also 
be further investigated as addition of the cyclohexadiene ring and additional propionic 
acid methyl ester are likely affecting the reactivity of VP within the cells as PPIX and 
ZnPP were not capable of inducing cell death at the same concentration. Iron stores are 
known to be elevated in highly metabolic areas such as the brain and consequently 
gliomas are known to have increased ferritin expression315,318. VP therapy could 
therefore be beneficial for targeting these malignant cells as high levels of iron could 
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therefore increase cell death through increased activity of VP. Thus, iron content and 





The data presented in this chapter clearly outline VP as an attractive target for further 
clinical investigation as a novel treatment for glioma. Results show that VP is capable of 
not only reducing glioma cell proliferation but is capable of inducing cell death in the most 
highly therapy-resistant hypoxic subset of tumour cells. Hypoxic cells represent a 
significant clinical challenge and therapies that can modulate this resistance or directly 
kill hypoxic cells may significantly improve patient outcomes in a number of tumours 
types, not just glioma. Investigations into the mechanism of VP uncovered YAP-
independent effects which were likely induced through increased ER and oxidative 
stress, exacerbating the production of ROS. Although VP was capable of inducing these 
processes under normoxic conditions, ROS was significantly amplified in cells already 
stressed under hypoxia therefore pushing the cells ‘over the edge’ towards cell death. 
Additionally, VP was discovered to bind transition metals, in particular ferric iron; an 
unprecedented finding that sheds some light on the potential mechanism of VP 
generated ROS production. Further investigations are therefore warranted to accurately 
identify how this drug can be used clinically such as identifying the appropriate 
therapeutic dose and treatment window as well as potential methods of drug delivery. In 
summary, these data propose the enormous potential of this clinically available and FDA-
approved therapeutic, VP to be repurposed to target a significant hypoxic population of 









5.1. Significance and aims of investigation 
Advancements in prevention, detection and treatment over the last 40 years have 
significantly transformed cancer healthcare327 – at least 78% of melanoma, prostate and 
breast cancer patients now survive 10-years or more post-diagnosis328. However there 
are a few cancers that are consistently lagging behind, with little improvement in survival 
seen over the past decade328. Lung, pancreatic, oesophageal and brain cancers share a 
significantly poor 10-year survival rate of between 1-14% and as such are considered as 
cancers of a substantial unmet need327,328. 
 
Gliomas, an aggressive type of brain tumour, invade deep into the surrounding healthy 
brain consequently making successful treatment incredibly challenging259. The severe 
hypoxic nature of glioma adds further complications to therapeutic efficacy as hypoxia 
limits efficient drug delivery as well as increasing resistance to both chemo and 
radiotherapy97. As such, these patients cannot be successively cured by existing 
therapies and prognosis remains unrelentingly poor. Therapies that target both the 
hypoxic tumour microenvironment and pathways that regulate glioma growth and 
progression in this environment have significant potential to improve patient survival. 
This thesis therefore aimed to characterise the potential hypoxic and metabolic 
relationship with YAP/TAZ signalling in glioma; a pathway strongly associated with 
induction of the cancer phenotype. Furthermore, this research highlights the significant 
repurposing potential of an inhibitor of this signalling pathway, identifying a possible 




5.2. Hypoxia influences YAP/TAZ signalling in glioma 
The Hippo pathway has become of interest in cancer research due to its strong 
association with tumorigenesis, with increased activity of its downstream effectors 
YAP/TAZ leading to enhanced tumour growth, invasion, metastasis and therapy 
resistance in many cancers136. Regulation of YAP/TAZ signalling is incredibly complex 
however has recently been associated with hypoxia in a model of breast cancer131. This 
research demonstrates for the first time that hypoxia also influences YAP/TAZ signalling 
in glioma. Results confirm that hypoxia (1% O2) induces a significant upregulation of 
YAP1 mRNA, concomitant with an increase in expression of YAP-target genes, CTGF, 
CYR61 and BBC3 across four glioma cell lines. A hypoxia-induced increase in CTGF 
protein expression was also observed alongside enhanced nuclear YAP1 localisation, 
both of which imply that YAP1 transcriptional co-activation activity is increased as a 
result of hypoxia. Together, these data suggest that hypoxic induction of YAP/TAZ 
signalling in glioma could be to confer a survival advantage through increased 
transcription of pro-proliferative genes, such as CTGF, to sustain tumour cell proliferation 
in a hostile microenvironment. 
 
YAP/TAZ signalling was also amplified under hypoxia in two novel GBM lines. 
Interestingly, these two lines, despite originating from the same tumour specimen, had 
exhibited differential sensitivity to chemoradiation treatment. T1 cells were derived from 
an area of tumour recurrence that had progressed significantly post-treatment, and was 
thus believed to be therapy-resistant, whereas T2 cells were harvested from an area of 
the tumour which had not progressed post-treatment, and was therefore considered 
therapy-responsive. Both p-YAP and YAP1 expression were observed to be considerably 
higher in T1 cells compared to T2 cells, indicating amplified YAP signalling in the 
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therapy-resistant cells. Since increased YAP expression and activity has been previously 
associated with chemoresistance in other cancers, it suggests a potential reason for this 
upregulation in the tumour cells. However, further experimentation will be required to test 
whether this increased YAP signalling does in fact confer resistance to current 
chemotherapeutic agents in vitro. 
 
This investigation provides a solid basis to suggest that suppressing YAP/TAZ signalling 
could potentially be a valuable therapeutic opportunity, particularly in hypoxic tumours as 
well as for patients with limited treatment options as a result of high therapy resistance. 
There are however, a few limitations to this study which should be addressed in future 
research. For instance, while established cell lines have been invaluable to cancer 
research and drug discovery, it should be acknowledged that there are potential 
limitations to their use in this investigation. For example, genomic instability and serial 
passage and culture of cell lines can induce both genotypic and phenotypic variation 
over time329. Therefore, these cell lines may not adequately represent the primary tumour 
from which they originated and could therefore lead to potential differences in 
experimental results. Furthermore, the in vitro cell culture environment is dissimilar to the 
original tumour, omitting potential crucial interactions with surrounding cell types as well 
as altering cell morphology, gene expression and behaviour of signalling pathways329. 
These established cell lines do however provide an in vitro model which can be used 
easily and rapidly in a controlled and reproducible fashion, and alongside adequate 
measures such as cell line authentication and low passage cultures, allow detailed pre-





This investigation demonstrated that hypoxia induced YAP/TAZ signalling, however it 
was assessed in established 2D cultures in vitro. Although this provides a good initial 
understanding of this relationship, as previously mentioned, a more meaningful pre-
clinical assessment may be achieved through investigation of the hypoxic regulation of 
YAP/TAZ signalling using a GBM spheroid model or in vivo using patient-derived 
xenografts; both of which more faithfully recapitulate the key features and 
microenvironment of the tumour331. Nevertheless, hypoxia was observed to enhance 
YAP expression in primary cells derived from a GBM tumour, which were cultured long-
term under hypoxic conditions. Upregulation of YAP/TAZ expression and signalling 
should therefore be further examined using more primary cell lines as well in those 
derived from both LGG and HGG patients to establish whether there are any differences 
between malignancy grades and whether this hypoxic upregulation of YAP/TAZ 
signalling could be a contributing factor to this progression. 
 
5.3. YAP/TAZ support glucose and glutamine metabolism in 
glioma 
It has long been established that cancer cells rewire their metabolism to fuel the 
increased energetic demand and generation of new biomass required to sustain 
uncontrolled tumour proliferation239. Hypoxia-induced signalling further remodels these 
metabolic pathways to increase tumour survival within a hostile microenvironment, 
promoting a malignant phenotype192. Since aberrant YAP/TAZ signalling often plays a 
significant role in these tumour phenotypes and as this study showed hypoxia to induce 
YAP/TAZ signalling in glioma, it was investigated whether YAP/TAZ could directly 
influence aspects of hypoxic metabolism in this system. Using metabolic-tracing and 
siRNA approaches, the preliminary research presented in this thesis establishes for the 
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first time an important role for YAP/TAZ in both glucose and glutamine metabolism in 
glioma. 
 
Metabolic tracing analysis identified knockdown of YAP/TAZ to significantly reduce de 
novo serine synthesis and alter the metabolism of pyruvate by the cell; sustaining PC 
activity under hypoxia to support anaplerosis. Continued mitochondrial pyruvate 
oxidation in hypoxia, along with reduced activity of the SSP attenuating anti-oxidant 
capacity, could potentially lead to enhanced ROS accumulation, which could theoretically 
culminate in reduced cell survival. Furthermore, the results demonstrate that YAP/TAZ 
depletion significantly affected oxidative glutamine metabolism, decreasing both the 
anaplerotic metabolism and potentially ATP-generation fuelled by glutamine. The total 
carbon contribution from both glucose and glutamine were calculated for various 
metabolites, with results illustrating that reductions in YAP/TAZ expression clearly 
reduced the cell’s ability to utilise glutamine in the generation of metabolites crucial for 
cellular growth such as aspartate, independently of oxygen tension. These data correlate 
with a significant reduction in cell proliferation observed upon YAP/TAZ knockdown, 
suggesting the possibility that YAP/TAZ are required to support various biosynthetic 
pathways that generate precursors for protein and nucleic acids synthesis as well as 
modulating cellular antioxidant capacity to promote tumour growth and survival221. 
 
The data presented provides a clear picture of the metabolic processes influenced by 
YAP/TAZ, although it is restricted in that these data only illustrate the percentage carbon 
contribution from glucose and glutamine and do not take into account absolute 
metabolite concentrations, which could vary significantly. For future improvement of this 
study, these values should be incorporated as well as measuring metabolite uptake and 
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excretion rates to investigate metabolic flux. Furthermore, this relationship would need to 
be characterised in other established and primary glioma cell lines. Glioma cells form 
only part of the tumour mass, which is also made up of other cell types such as microglia 
and endothelial cells. The role of YAP/TAZ in determining the metabolic relationship 
between these multiple cell types would be key to defining the nature of this signalling 
pathway in glioma aetiology71. Finally, more in-depth metabolic tracing needs to be 
conducted using other relevant nutrient tracers such as acetate and fatty acids as well as 
investigation into the expression of the various biosynthetic enzymes to gain a fuller 
understanding of the relationship between YAP/TAZ and hypoxic glioma metabolism. 
 
These data do however provide preliminary evidence to suggest that disrupting YAP/TAZ 
expression and transcriptional co-activator activity, particularly in hypoxia, could be a 
valuable target for therapeutic development since both pro-survival signalling and 
metabolism can be targeted in combination to reduce glioma growth and progression. 
 
5.4. VP induces hypoxia specific cell death showing potential as a 
novel therapeutic for glioma 
As suppression of YAP/TAZ signalling in hypoxic glioma cells was identified to be a 
potentially valuable therapeutic opportunity, the effect of VP – a previously identified YAP 
inhibitor – on malignant cell growth and survival was investigated. VP is a particularly 
attractive agent as, if effective, it has the potential to be rapidly repurposed to treat 
gliomas, as well as other hypoxic tumours. The results presented in this thesis 
demonstrated VP to be a potent suppressor of glioma cell proliferation, corroborating 
previous research determining VP to attenuate tumour growth through suppression of 
YAP-TEAD activity158,159,161. Strikingly, when glioma cells were treated with VP under 
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hypoxic conditions, VP was observed to induce significant cell death. This observation 
was also recapitulated in a more biologically relevant spheroid model. A significant 
finding was the ability of VP to induce cell death in both the therapy-resistant (T1) and 
therapy-sensitive (T2) primary GBM cells, suggesting that hypoxia-specific VP-mediated 
cell killing is independent of normal resistance mechanisms observed in GBM, and 
therefore may also reduce the rate of relapse and progression. VP has the potential 
therefore to not only be employed as a mono-therapy in the selective killing of hypoxic 
cells in cancer but could also be introduced as part of a combination therapy to enhance 
treatment sensitivity in therapy-resistant tumours, given that the radiotherapy element of 
the current therapeutic regime is highly sensitive to oxygen tension. As previously 
discussed, higher doses of radiation are required in hypoxic areas of tumours to instigate 
significant ROS- induced damage. Since VP significantly increased ROS levels and 
selectively killed hypoxic glioma cells in this investigation, it could be suggested that 
combined radiotherapy and VP treatment could therefore reduce the dosage of radiation 
required in hypoxic cells to initiate the same cell death effect and potentially improve time 
to recurrence by eliminating more of the hypoxic, therapy-resistant cells that instigate 
tumour relapse. Promising results have been recently demonstrated in clinical trials 
investigating the combination of poly (ADP-ribose) polymerase (PARP) inhibitors such as 
olaparib and chemotherapy in the treatment of glioma. It therefore may also be beneficial 
to incorporate VP given its specificity with hypoxia, and its mode of action (ROS 
generation), which would be expected to increase the rate of DNA damage in hypoxia 
and make the cells more susceptible to PARP inhibition332,333. 
 
In this investigation, the activity of VP in inducing hypoxic cell death was interestingly 
discovered to be YAP-independent and instead through significant exacerbation of 
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oxidative and ER stress under hypoxia. The precise mechanism of VP-induced cell death 
remains to be fully elucidated, although this thesis presents evidence to suggest that this 
increased ROS production is generated through the ability of VP to bind to iron – a 
surprisingly novel finding given the well-known iron binding characteristics of the 
porphyrin family of molecules. This investigation provides a promising pre-clinical 
assessment for repurposing VP that could also be extended to the treatment of hypoxic 
tumours. It should be noted, however, that the hypoxia-activated prodrug tirapazamine, 
which similarly elicits release of cytotoxic radicals, while demonstrating excellent clinical 
efficacy in vitro, in phase III trials demonstrated no clinical benefit97,334. Importantly 
though, retrospective analysis of the data showed that no measurement of hypoxia was 
undertaken before or during the trial and thus the patients that would most benefit were 
not identified prospectively97. Further research and appropriately designed trials are 
clearly required in an in vivo setting to determine whether VP will exhibit clinical efficacy. 
 
A promising characteristic of VP is that it has been shown to be selectively taken up by 
malignant cells through LDLs, providing further treatment specificity155. Furthermore, 
LDLs are known to be increased in hypoxia, suggesting potential increased VP uptake 
by hypoxic cells which may contribute towards this selective cell death observed under 
these conditions335. Theoretically, it could also suggest that if VP cellular uptake is 
indeed increased in hypoxia, then possibly a significantly lower concentration of VP is 
required to induce cell death compared with normoxia – although it should be noted that 
cell death was not observed in normoxic conditions in this investigation (up to 10 µM 
VP). Future experiments could therefore quantitatively measure VP uptake by normoxic 
and hypoxic cells to investigate this hypothesis. It also should be noted that VP is a 
benzoporphyrin derivative, derived from the structure of PPIX155. As previously 
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mentioned, oral administration of exogenous 5-ALA to aid surgical resection of HGG 
tumours, results in subsequent conversion and tumour-specific accumulation of PPIX, 
which is known to be well tolerated by patients44,45,336. This therefore suggests that VP, 
being so structurally similar to PPIX, could be predicted to exhibit the same selective 
uptake, and potentially tolerability, in HGG. 
 
Promisingly, VP has shown to induce minimal side-effects in patients during its use in 
PDT, as well as sparing normoxic cells from death, despite being given through an 
intravenous route rather than topically155. With respect to further studies here, the effect 
of VP would have to be investigated at physiological oxygen concentrations (~4.6% O2) 
as well as in healthy brain cells to determine any potential adverse side-effects when 
treating glioma. Despite this, the additional benefit of using VP proposed in this 
investigation is that not only does VP induce cell death in hypoxia, it also suppresses cell 
proliferation in normoxic conditions, and so could be used to target this population of 
tumour cells as well. 
 
A difficulty in using VP as a glioma therapeutic could arise however in establishing how 
and when to employ VP as a treatment. One of the frequently encountered problems 
when treating gliomas – accessibility through the BBB – is unlikely to be an issue with 
VP, given that it is lipophilic. However, delivery of VP to the hypoxic tumour areas may 
still prove challenging. Theoretically, VP could be injected or delivered in slow-release 
coated beads when the patient undergoes tumour biopsy or resection. This could also 
benefit the hypoxic tumour cells which are inevitably left behind and are known to cause 
tumour recurrence and relapse. The effect of VP combined with the current standard 
treatment for glioma (TMZ + ionising radiation) should also be investigated due to VP’s 
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ability to significant induce ROS, particularly under hypoxic conditions where these 
current treatments exhibit limited efficacy. It could be predicted that VP would improve 
sensitivity and response to both TMZ and radiation in hypoxia since they are themselves 
ROS inducing treatments, as previously discussed, and addition of VP would therefore 
significantly amplify this ROS-induced damage and subsequent cell death. Supporting 
evidence in PC9 lung cancer cells has shown that VP synergises with both cisplatin and 
radiation treatment, significantly improving both treatment sensitivity and increasing cell 
death162. This therefore provides promising evidence that VP could also exhibit a similar 
effect alongside standard TMZ and radiation treatment for glioma and could also 
significantly improve their efficacy in hypoxia. Further studies are therefore inevitably 
required to determine the most effective treatment modality and regime. 
 
Together, the data in this thesis establishes the importance of hypoxic and metabolic 
regulation of YAP/TAZ signalling in glioma to support tumour growth and proliferation. 
Furthermore, this research also highlights the significant potential for the clinically 
available and FDA-approved therapeutic VP, to be repurposed to treat glioma, as it 
targets hypoxic glioma cells specifically, which may significantly improve patient survival.
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